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Abstract 
 
Tetanus neurotoxin (TeNT) is among the most poisonous substances on 
Earth and a major cause of neonatal death in non-vaccinated areas. There are 
approximately 300,000 cases reported worldwide each year, and the mortality rate 
is between 10-20%.  
In this work, I identified an extracellular matrix protein receptor for TeNT at 
the neuromuscular junction (NMJ) and developed a peptide inhibitor, which 
prevents tetanic paralysis in vivo in mice. TeNT binds to the NMJ with an extremely 
high affinity, yet the nature of its receptor complex was poorly understood. I 
showed that the presence of nidogens (also known as entactins) at the NMJ is the 
main determinant for TeNT binding. Nidogens are extracellular matrix (ECM) 
proteins, which are taken up into the endosomal carriers containing tetanus toxin 
binding fragment (HCT) in motor neurons. Inhibition of the HCT-nidogen interaction 
using a peptide originating from nidogen-1 abolishes HCT binding on these cells.  
TeNT causes slowly progressing local tetanus when it is injected 
intramuscularly into the triceps surae muscle in a low dose. When preincubated 
with the peptide originating from nidogen-1, TeNT injection does not alter the 
coordination of mice and the muscle force remains largely unchanged. Genetic 
ablation of nidogens prevented the binding of TeNT to neurons and the intact NMJ 
and protected mice from TeNT induced spastic paralysis.  
In my thesis I demonstrated for the first time, that an ECM protein 
accumulates and presents a neurotropic pathogen to the presynapse. This study 
follows recent studies showing that growth factors trigger downstream signalling 
more efficiently if they bind to certain ECM components – a new and rising concept 
in neuroscience. 
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GST gluthatione-S-transferase 
GT1b NAcNeuα3Galβ3GalNAcβ4(NAcNeuα8NAcNeuα3)Galβ4GlcβCer 
HA hemagglutinine 
HBSS Hank's balanced salt solution 
HCA botulinum toxin A binding fragment 
HCT tetanus toxin binding fragment 
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HPLC high-performance liquid chromatography 
HRP horse radish peroxidase 
HSPG heparane sulphate proteoglycans 
IF immunofluorescence 
IgG immunoglobulin G 
IHC immunohistochemistry 
IP immunoprecipitation 
ITC isothermal calorimetry 
Ka association constant 
Kd dissociation constant 
KO knock out 
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LAR leukocyte antigen-related protein phosphatase 
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LB Luria-Bertani medium 
LRP4 
MAPK 
Low-density lipoprotein receptor-related protein 
mitogen- activated protein kinase 
MF microfluidic chamber 
MG myashenia gravis 
MSC congenital myasthenic syndromes 
MT microtubules 
MuSK transmembrane muscle-specific kinase 
NMJ neuromuscular junction 
NRG-1 neuregulin-1 
OPD ortho-phenylenediamine 
P150 p150 Glued subunit 
p75NTR p75 neurotrophin receptor 
PAGE polyacrylamid gel electrophoresis 
PBS phosphate buffered saline 
PC12 pheochromocytoma 12 cell line 
PCR polymerase chain reaction 
PDMS polydimethylsiloxane 
PFA paraformaldehyde 
PI3K phosphoinositide 3-kinase 
PIP2 phosphatidylinositol(4,5)bisphosphate 
PKC protein kinase C 
PLCγ1 phospholipase Cγ1 
PM plasma membrane 
PMD proximal transmembrane domain 
PNS peripheral nervous system 
PTK Src family protein tyrosine kinases 
PTP3 C. elegans LAR homologue 
PVDF polyvinylidene fluoride 
RA retinoic acid 
Rab rat sarcoma proteins in brain 
Ras rat sarcoma proteins 
RIM regulating synaptic membrane exocytosis protein 
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SNAP-25 synaptosome associated protein of 25 kDa 
SNARE soluble NSF attachment protein receptors 
SV synaptic vesicle 
SV2 synaptic vesicle protein 2 
TA tibialis anterior muscle 
TBE Tris-borate-EDTA buffer 
TBS Tris-buffered saline 
TCEP 
TIG 
tris(2-carboxyethyl)phosphine hydrochloride 
tetanus toxin immunoglobulin 
TeNT tetanus toxin 
tPA tissue plasmin activator 
TRIO triple functional domain protein 
Tris 2-amino-2-(hydroxymethyl)-1,3-propandiol 
TrkB tropomyosin-like kinase B 
TS triceps surae muscle 
VSVG vesicular stomatitis virus glycoprotein 
WB western blot 
WHO 
Wnt 
World Health Organisation 
Wingless-related integration site protein family 
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Chapter 1. Introduction 
1.1 The pathomechanism of tetanus 
Tetanus is an acute disease characterised by muscle spasms. It is caused 
by tetanus toxin (TeNT), which is released upon infection with an anaerobic, gram-
positive bacterium, Clostridium tetani. The endospores of C. tetani are ubiquitously 
present in the soil and in the feces of livestock, such as cattle and sheep. Minor 
injury sites can get contaminated with the spores and if the wound is deep, 
anaerobic conditions allow the spores to germinate. TeNT is then released into the 
circulation and targets skeletal muscles (Wells and Wilkins, 1996). The incubation 
period ranges from 8 days to up to 4 months. The main form of tetanic intoxication 
is generalised tetanus (80% of the cases), which presents in a descending pattern, 
first affecting the mandibular muscles and causing trismus, or ‘lockjaw’. This is 
usually followed by stiffness in the neck muscles, difficulty in swallowing and 
spasms of the abdominal muscles (Centers for Disease, 2012). Tetanus is most 
common in newborn babies (‘neonatal tetanus’), the infection occurs in those who 
do not have passive immunity against TeNT, due to the lack of maternal 
vaccination (Vandelaer et al., 2003). The chances of contracting tetanus are 
highest if the umbilical stump is cut with non-sterile instrument (UNICEF, 2000). If 
medical care is available, the wound is cleaned and the patients receive tetanus 
toxin immunoglobulin (TIG) to eliminate TeNT from the cardiovascular system. 
Mechanical ventilation is required for up to 3-4 weeks, while complete recovery 
takes months. The most common cause of death is respiratory failure (Centers for 
Disease, 2012). There are approximately 300,000 tetanus cases each year, and 
the mortality rate is around 20%. Tetanus is common in countries where the 
vaccine is not readily available and despite the decrease in the number of these 
countries, tetanus still claims the lives of 59,000 people per year. Due to the high 
number of tetanus related fatalities, the World Health Organisation (WHO) named 
maternal-neonatal tetanus as the ‘silent killer’ (WHO, 2014). 
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1.2 Clostridial neurotoxins (CNT) 
The CNT family comprises of TeNT and several related botulinum 
neurotoxins (BoNTs, serotypes A to H) (Swaminathan, 2011, Bercsenyi et al., 
2013). BoNT/H has recently been described, but it is currently unclear whether it is 
a new form of BoNT, or a variation of the already existing serotypes (Dover et al., 
2014). 
CNT display similar structural organisation, they have the same intracellular 
targets and primarily bind to motor neurons (Schiavo et al., 2000). However, once 
internalised, BoNTs and TeNT are sorted to fundamentally different intracellular 
pathways (Figure 1-1). BoNTs mostly stay in the neuromuscular junction (NMJ), 
with only a minor fraction of toxin transported back to the motor neuron cell body 
(Restani et al., 2012a). In contrast, TeNT is efficiently transported in a retrograde 
fashion within the motor neuron and it is synaptically transferred to inhibitory 
interneurons in the spinal cord (Figure 1-1) (Schwab and Thoenen, 1976, Lalli et al., 
2003a, Bercsenyi et al., 2013). Since CNT cleave SNARE (soluble NSF attachment 
protein receptor) proteins, which are essential for synaptic vesicle release, the 
direct consequence of their biological activity is the complete silencing of their 
target neuron (Binz, 2013). 
Due to their fundamentally different intracellular targeting, BoNTs and TeNT 
lead to pathologies characterised by opposing symptoms. Botulism, which is 
caused by BoNTs, leads to flaccid paralysis (silencing the motor neuron), whilst 
tetanus, caused by TeNT, leads to spastic paralysis (silencing the inhibitory 
interneuron resulting in constant activity of the motor neuron).  
BoNTs are extensively used as cosmetic agents and as therapeutics against 
pathologies caused by synaptic hyper-activity (Davletov et al., 2005, Sanford, 2014, 
Carod-Artal, 2014). With the improvement of food safety standards, botulism 
became rare disease. However, in 2006 there was a botulism outbreak due to the 
consumption of contaminated home-canned bamboo shoots. A total of 209 people 
were affected, of whom 42 required mechanical ventilation (Thailand, 2006). The 
WHO identified the outbreak as a public health emergency, and later concluded 
that the international response and the availability of anti-toxin agents were 
insufficient.  
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The study of CNT is very important, both to decrease the mortality rate of 
tetanus and to overcome the side effects of BoNT treatment. 
 
 
 
Figure 1-1. TeNT and BoNTs are sorted to different intracellular routes 
TeNT and BoNTs bind to the motor neuron end plate (blue cell) at the NMJ, using 
polysialogangliosides (dots) and protein receptors (sticks). However, TeNT (blue 
sphere) is sorted into signalling endosomes (grey vesicles) and is retrogradely 
transported back to the cell body (blue arrows), while BoNTs (red sphere) enter 
recycling synaptic vesicles (pink vesicles) and mostly stay at the synapse. BoNT/A and 
BoNT/E were reported to undergo long-range axonal transport (dashed red arrow) 
(Restani et al., 2012a). Once transcytosed and synaptically transferred into inhibitory 
interneurons (pink cell), TeNT is likely to enter the synaptic vesicle recycling pathway 
and cleave synaptobrevin in these cells, leading to the loss of inhibition on the motor 
neuron. Reprinted with permission from John Wiley and Sons (Bercsenyi et al., 2013). 
 
1.2.1 The structure of CNT 
TeNT and BoNTs are synthesised as single chain proteins (150 kDa), which 
are cleaved by bacterial and extracellular matrix proteases when they are released 
during bacterial autolysis. This results in a 50 kDa light chain (L) and a 100 kDa 
heavy chain (H), which are linked via a disulphide bridge and non-covalent 
interactions (Figure 1-2 B). The carboxyl-terminus of H mediates neuronal binding 
(HC), while the amino-terminus (HN) is required for the pore formation and 
cytoplasmic dynein
tetanus toxin (TeNT)
botulinum neurotoxin (BoNT)
polysialogangliosides
clostridial neurotoxin receptors
microtubules
inhibitory
interneuron
lysosomal
fusion
nuclear
transfer
TeNT
BoNT
NMJ/
synapse
axon
Chapter 1 Introduction 
 24 
subsequent translocation of the L chain through the endosomal membrane into the 
cytosol (Montal, 2010). The L chain is a metalloprotease (Schiavo et al., 2000) and 
contains the active site of the toxin. All three domains were investigated in detail by 
crystallisation and biochemical studies. The structure of L chain and HC of TeNT 
(Breidenbach and Brunger, 2005a, Chen et al., 2008) (Figure 1-2 A) and full-length 
BoNT/A (Stevens et al., 1991, Lacy et al., 1998, Garcia-Rodriguez et al., 2007) 
(PDB ID: 3BTA, Figure 1-2 C), as well as other BoNTs were determined in high 
resolution. BoNT/A is an elongated molecule, which suggests that the different 
domains are unlikely to cause any interference to each other’s actions. However, 
not all BoNTs are hypothesised to have the same 3D structure as BoNT/A. The 3D 
structure of BoNT/E was calculated by random conical tilt reconstruction. Based on 
this model, the HN and the L chain are tightly coupled and a conformation change is 
required to separate these two domains prior to pore formation and translocation 
through the endosomal membrane (Fischer et al., 2008). 
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Figure 1-2. The structure of CNT show high similarity 
(A) The crystal structure of the L chain and HC of TeNT were solved at a resolution of 
2.3 Å (1Z7H) and 2.0 Å (3HMY), respectively (Breidenbach and Brunger, 2005a) 
(Chen et al., 2009) (B) The two polypeptide chains (L and HC) are connected via a 
disulphide bridge. (C) The crystal structure of full-length BoNT/A was determined at a 
resolution of 2.6 Å (2NYY) (Garcia-Rodriguez et al., 2007). The arrows point at the 
known receptor binding sites. Reprinted with permission from Elsevier (Schmieg, 2015). 
HCN HCC
translocation binding
H2N COOH
HNS-S
L
metalloprotease
HC
Zn
TeNT
BoNT/A
A
C
B
Zn
Chapter 1 Introduction 
 26 
  
1.2.1.1 The binding fragment (HC) 
The HC domain of CNT mediates their neuron-specific binding (Bizzini et al., 
1977, Halpern and Neale, 1995, Herreros et al., 2000b). It contains two 
subdomains, the amino-terminal subdomain (HCN) and the carboxy-terminal 
subdomain (HCC). The structure of the HCN is similar to the structure of the 
carbohydrate-binding domain of oligosaccharide-binding proteins (Chen et al., 
2008). The HCC is a β-trefoil domain, which is present in proteins, which are 
required for binding and cell recognition, such as trypsin inhibitors (Molnar et al., 
2013).  
The HC domain is relatively isolated from the rest of the molecule, and this 
leaves all of the potential binding sites easily accessible (Chen et al., 2008). There 
are two main binding loops within the HC domain of TeNT (HCT), a lactose site (‘L’) 
and a sialic acid site (‘R’). The sequence is less conserved in these regions 
between different CNT, suggesting that they have different affinities to certain 
binding partners (Figueiredo et al., 1997, Lacy and Stevens, 1999, Rummel et al., 
2003). Both sites can be occupied simultaneously, suggesting that two receptors 
might be required for CNT binding and uptake (dual receptor hypothesis) 
(Montecucco, 1986, Rummel et al., 2007). The deletion of a number of residues 
within the HCC domain significantly decreases binding, indicating the importance of 
this fragment in cell recognition (Halpern and Loftus, 1993, Rummel et al., 2003). 
1.2.1.2 The translocation domain (HN) 
The pH-dependent membrane-penetration and translocation of the catalytic 
domain of CNT requires the translocation fragment (HN). In BoNT/A, it is composed 
of two long α-helices and a β-strand as the main structural units. The β-strand lies 
against the two main α-helices and upon acidification it changes its conformation, 
exposing hydrophobic residues (Donovan and Middlebrook, 1986, Shone et al., 
1987, Oblatt-Montal et al., 1995, Puhar et al., 2004). This change enables the HN 
domain to insert into the membrane and form a pore. The L chain gets unfolded 
and migrates through the newly formed pore (Fischer et al., 2009, Montal, 2009). 
The disulphide bridge between a loop of HN and L chain is reduced in the cytosol 
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(Fischer and Montal, 2007, Pirazzini et al., 2013a, Pirazzini et al., 2013b) and the L 
chain is released (Oblatt-Montal et al., 1995). 
1.2.1.3 The metalloprotease domain 
The catalytic domain of CNT is a metalloprotease, targeting proteins 
essential for synaptic vesicle release (Penner et al., 1986, Poulain et al., 1988, 
Ahnert-Hilger et al., 1989, Bittner et al., 1989, Mochida et al., 1989, Weller et al., 
1991). The catalytic zinc atom is essential for the endopeptidase activity, there is 
one in the L chain of TeNT, BoNT/A, B and F (Schiavo et al., 1992a, Schiavo et al., 
1992b, Schiavo et al., 1993a, Stura et al., 2012), whilst BoNT/C binds two zinc 
atoms with different affinities (Schiavo et al., 1995, Breidenbach and Brunger, 
2005b, Garcia-Rodriguez et al., 2007). If the zinc atom is removed with heavy 
metal chelators, the toxins lose their activity (Bhattacharyya and Sugiyama, 1989, 
Schiavo et al., 1992a). CNT cleave SNARE proteins, which are essential for the 
fusion of synaptic vesicles with the plasma membrane (PM) (Montecucco et al., 
2005, Binz, 2013). These include synaptobrevin, syntaxin and SNAP-25 (Table 1) 
(Schiavo et al., 1992, Schiavo et al., 1993, Schiavo et al., 1993a, Blasi et al., 1993a, 
Blasi et al., 1993b, Rickman et al., 2004, Breidenbach and Brunger, 2004). 
 
Table 1. Intracellular targets of CNT 
Synaptobrevin Syntaxin SNAP-25 
BoNT/B, D, F, G; TeNT BoNT/C BoNT/A, C, E 
 
1.2.2 Neuron-specific binding of CNTs 
CNT binding has been examined in many different cell lines, including 
primary motor neurons, as well as in various membrane preparations (Halpern and 
Neale, 1995, Schiavo et al., 2000). In vitro, CNT bind to a large variety of non-
neuronal cells, but only at very high concentrations (Montesano et al., 1982). In 
contrast, in vivo binding of CNT is absolutely neuron specific and only requires 
concentrations in the sub-nanomolar range (Halpern and Neale, 1995, Simpson, 
2000). Addition of the HC fragment alone is sufficient for the entry into neurons, and 
preincubation with recombinant HC fragments can inhibit the uptake of the parental 
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neurotoxin, indicating that this fragment is absolutely essential for neuron-specific 
binding (Lalli et al., 1999). 
 
1.2.2.1 Polysialogangliosides, as cell surface receptors for CNT 
CNT bind the G1b series of polysialogangliosides (GD1b, GT1b and GQ1b) 
(Montecucco, 1986, Halpern and Neale, 1995). The interaction between 
polysialogangliosides and CNT is crucial during intoxication; when residues within 
the carbohydrate-binding pocket of CNT are mutated, the toxicity of the mutant 
neurotoxins is significantly impaired (Louch et al., 2002, Rummel et al., 2003, 
Rummel et al., 2004b, Rummel et al., 2009, Strotmeier et al., 2010). However, 
these sites might participate in protein binding and the drop in toxicity might also be 
due to the inhibition of this process. Accordingly, lack of polysialoganglioside 
biosynthesis only partially protects mice from tetanus (Kitamura et al., 1999, 
Williamson et al., 1999, Kitamura et al., 2005). Also, neuraminidase treatment and 
the reduction of polysialogangliosides on the PM decreases but does not abolish 
CNT activity (Bigalke et al., 1986). In addition, CNT binding is sensitive to prior 
protease treatment (Dolly et al., 1982, Pierce et al., 1986). These results combined 
with the abundance of polysialogangliosides on all cell types and their low binding 
affinity to CNT suggest that there are additional protein receptors for CNT. A high-
affinity interaction is required to account for the extremely low doses of CNT 
causing clinical symptoms in vivo. Although BoNT/E was shown to partially 
compete with TeNT for binding to neurons (Herreros et al., 2001) there is no robust 
competition between TeNT and BoNTs for neuronal binding, which would be 
expected if they shared their receptors on the PM.  
1.2.2.2 Presynaptic receptor arrays for CNT binding 
Based on the structural properties of HCT, both ‘L’ and ‘R’ receptor-binding 
sites can be occupied simultaneously. Both sites were shown to bind 
polysialogangliosides, but the binding of a glycoprotein to the ‘R’ site was 
previously hypothesised (Montecucco, 1986, Rummel et al., 2003, Jayaraman et al., 
2005).  
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Arrays of presynaptic receptors (APRs) could form to bind CNT on the neuronal PM 
(Montecucco et al., 2004). APRs are very similar to lipid rafts; they are dynamic, 
and highly concentrated at the NMJ. In this model, polysialogangliosides would 
serve as the first line of capture, acting as ‘antennas’ on the presynaptic membrane 
and allowing CNT to bind to other membrane components. The second binding 
complex is likely to contain proteins (Dual Receptor Hypothesis), since protease 
treatment inhibits CNT binding to neurons (Montecucco, 1986, Montecucco et al., 
2004, Rummel et al., 2007). Accordingly, specific protein co-receptors have been 
identified for most CNT. 
Most probably, BoNTs bind to APRs, which are different in their composition 
from those serving as a binding platform for TeNT (Figure 1-1). One or more key 
components might be responsible for the subsequent differences in the sorting of 
these toxins.  
1.2.2.3 Protein receptors of BoNTs 
Both binding and uptake of BoNTs is dependent on synaptic activity (Keller 
et al., 2004, Baldwin and Barbieri, 2007). Generally, a high rate of neuroexocytosis 
correlates with a high rate of synaptic vesicle (SV) recycling via endocytosis 
(Murthy and De Camilli, 2003). Since BoNTs enter the lumen of SV, it is not 
surprising that they are taken up faster and in higher quantities upon neural 
stimulation (Matteoli et al., 1992, Kraszewski et al., 1995). Since the intraluminal 
leaflet of SV gets exposed during neuroexocytosis and a significant proportion of 
SV proteins are localised on the PM transiently, they can serve as protein receptors 
for BoNTs. 
Accordingly, most of the protein receptors found for BoNTs are SV proteins. 
BoNT/A, /B, /E and /G interact with synaptotagmins I and II (Nishiki et al., 1994, 
Nishiki et al., 1996, Yowler et al., 2002, Dong et al., 2003, Rummel et al., 2004a). 
In addition, synaptic vesicle protein 2 (SV2) serves as a protein receptor for 
BoNT/A, /C and /F (Mahrhold et al., 2006, Dong et al., 2006, Dong et al., 2007, 
Peng et al., 2011).  
However, our laboratory recently demonstrated that BoNT/A is able to bind 
to neurons in absence of any synaptic activity (due to previous BoNT/D treatment) 
(Restani et al., 2012a). In lack of neuroexocytosis, SV proteins are not readily 
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accessible on the PM, therefore in these conditions BoNT/A must utilise an 
alternative entry route. If it can enter similar intracellular compartments as TeNT, it 
should be retrogradely transported within neurons. Accordingly, several research 
groups have demonstrated that BoNT/A is retrogradely transported in different 
neuronal types, such as hippocampal, tectal and motor neurons (Restani et al., 
2012a, Antonucci et al., 2008). BoNT/A retains its activity during transport and 
undergoes transcytosis in the visual system (Restani et al., 2011, Restani et al., 
2012b).  
Recently, FGFR3 was identified as a new protein receptor for BoNT/A in 
resting conditions (Jacky et al., 2013). FGFR3 undergoes ligand-mediated 
endocytosis followed by retrograde transport (Haugsten et al., 2011, Garay, 2013), 
so it is able to mediate the uptake, sorting and transport of BoNT/A along this 
trafficking route. However, BoNT/A could also exploit the protein receptor of TeNT 
on motor neurons and get transported in shared organelles. 
1.2.2.4 Protein receptors of TeNT 
TeNT binds to two different types of neurons: first it binds to peripheral 
motor neurons and after synaptic transfer, it binds to inhibitory interneurons within 
the spinal cord. Since it is sorted to different intracellular pathways after 
internalisation in these cells, it probably associates with distinct receptors. TeNT 
possesses two polysialoganglioside-binding sites, so it might only need 
polysialogangliosides for its cell specific entry (Niemann, 1991, Binz and Rummel, 
2009, Chen et al., 2009). A strong argument supporting this hypothesis came from 
the observation that immobilised polysialogangliosides have a high affinity towards 
TeNT, due to the cis-interactions occurring in this assay (Rinaldi et al., 2009). 
However, polysialogangliosides are not uniquely localised to the motor neuron end 
terminals and GD1b is not internalised when bound to HCT (Deinhardt et al., 2006a), 
indicating that TeNT definitely requires additional factors to aid its uptake into 
neurons. 
TeNT is unlikely to exploit the SV-recycling pathway in motor neurons, since 
it does not block synaptic transmission at the NMJ at physiological concentrations 
causing tetanus. However, when used at extremely high doses, it causes botulism-
like symptoms (Matsuda et al., 1982), suggesting that TeNT might be able to 
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exploit a similar entry path to BoNTs at the NMJ when its preferred route of 
internalisation is overloaded.  
SV2 emerged as a receptor for TeNT in central neurons (Yeh et al., 2010), 
but these findings were not confirmed by independent experiments (Blum et al., 
2012).  
There are several considerations suggesting that TeNT preferentially follows 
an alternative entry route to that of BoNTs in motor neurons: 
 
1. If the TeNT receptor is exposed during neuroexocytosis to allow TeNT to 
bind and then be endocytosed, an increase in synaptic activity should also 
increase the accessible binding sites at the NMJ. However, high frequency 
stimulation does not enhance the binding of TeNT to the NMJ (Schmitt et al., 
1981).  
2. TeNT is taken up in NMJs where neurotransmitter release is completely 
blocked by the addition of BoNT/A (Schiavo et al., 2000, Koriazova and 
Montal, 2003, Deinhardt et al., 2006a). 
3. Our laboratory has previously shown that HCT is transported away from the 
site of injection in vivo (Bilsland et al., 2010). I also observed that the vast 
majority of HCT is retrogradely transported; only a minor fraction is retained 
at the NMJ after 2 hours of incubation. 
 
A potential membrane receptor was identified for TeNT in differentiated 
pheochromocytoma (PC12) cells. Thy-1, an abundant GPI-anchored protein 
(Herreros et al., 2000a, Herreros et al., 2000b) was shown to bind HCT. However, 
Thy-1 knockout mice do not show a decreased sensitivity to TeNT (Herreros et al., 
2001) and this result excludes the possibility of Thy-1 acting as a primary protein 
receptor on motor neurons.  
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1.2.3 Internalisation of CNT 
BoNT and TeNT bind to distinct receptors on the PM of motor neurons, and 
this leads to two distinct internalisation pathways: BoNTs are taken up via synaptic 
vesicle recycling, whereas TeNT undergoes clathrin-dependent endocytosis into 
signalling endosomes (Deinhardt et al., 2006a, Montal, 2010, Blum et al., 2012).  
1.2.3.1 Internalisation of TeNT 
The first step of clathrin dependent endocytosis is the recruitment of specific 
clathrin adaptors to the PM. These proteins recruit bin–amphiphysin-rvs (BAR) 
domain proteins, which promote the initial curvature of the membrane at the 
internalisation site (Qualmann et al., 2011). Specific lipids accumulate in the PM, 
such as phosphatidylinositol(4,5)bisphosphate (PIP2), which in turn recruits AP2, a 
major clathrin adaptor complex (Haucke, 2005). TeNT uptake requires AP2, but the 
overexpression of a mutant form of epsin-1, which is unable to bind to PIP2, does 
not affect TeNT binding (Deinhardt et al., 2006a). Epsins lack the BAR domain, 
they insert an amphipathic helix into the inner leaflet of the membrane and this 
further curves the membrane (Ford et al., 2002, Hinrichsen et al., 2006). These 
proteins are involved in the targeting of ubiquitinated receptors for lysosomal 
degradation (Le Roy and Wrana, 2005). By taking an entry route independent of 
epsin, TeNT may avoid the carriers destined for acidification, which is crucial to 
prevent the premature release of the L chain into the cytosol within the motor 
neuron. 
When the recruitment of clathrin scaffold is complete, dynamin binds to the 
neck of the curved pit and mediates the fission of the clathrin-coated vesicle (CCV) 
from the PM. Inhibition of dynamin, or overexpression of dynamin mutants inhibits 
the uptake of both TeNT and BoNTs (Deinhardt et al., 2006a, Harper et al., 2011). 
 
1.2.4 Axonal retrograde transport of CNT 
The longest axons in the human body might reach 1 m in length. A very 
efficient and tightly regulated axonal transport system has evolved to maintain 
precise and timely communication between the neuronal cell bodies and axon 
terminals in the periphery (Goldstein and Yang, 2000). Three classes of molecular 
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motors are required for efficient long-range transport: myosins, kinesins and 
cytoplasmic dynein. Kinesins are plus-end motors, carrying their cargo towards the 
growing end of microtubules (MT), which are found at the distal terminal in axons. 
In contrast, cytoplasmic dynein moves its cargo retrogradely towards the minus 
ends of microtubules in the cell body (Vale, 2003, Hirokawa et al., 2010). Myosin is 
an actin-based motor (Vale, 2003) and despite the fact that neuronal traffic is 
mainly MT-based (Goldstein and Yang, 2000), actin-dependent motors also play a 
role in neuronal transport. 
1.2.4.1 Axonal transport of TeNT 
TeNT is retrogradely transported from the motor neuron endplate to the cell 
body (Stöckel et al., 1975). Cytoplasmic dynein is essential in the axonal retrograde 
transport of TeNT, as was demonstrated both in vitro and in vivo (Lalli et al., 2003b, 
Hafezparast et al., 2003). Interestingly, myosin Va loss of function mutation and a 
potent kinesin inhibitor also reduced the speed of retrograde transport of HCT 
carriers (Lalli et al., 2003b). Interfering with the normal function of these motors 
disturbs the balance and tight regulation of the axonal transport system, and this 
might explain why they indirectly affect the retrograde transport of TeNT. 
Numerous motor protein adaptors are recruited to the signalling endosomes, 
such as Bicaudal D homologue 1 (BICD1). The reduction of the expression of  
BICD1 affects both TeNT and p75NTR trafficking, but does not alter the speed of 
retrograde transport in general (Terenzio et al., 2014b, Schmieg et al., 2014). 
Two small GTPases are required for the axonal transport and sorting of 
HCT: Rab5 and Rab7 (Deinhardt et al., 2006b). The former is required for the early 
steps after internalisation, while the latter is essential for sustained axonal 
retrograde transport (Deinhardt et al., 2006b, Salinas et al., 2009).  
HCT transport is considerably slower in primary motor neuron cultures than 
in vivo (Herreros et al., 2000b, Hafezparast et al., 2003, Bilsland et al., 2010). This 
difference might be due to the myelination of motor neuron axons within the sciatic 
nerve. Alternatively, the different developmental state of the observed neurons 
might be the reason for the slower transport observed in primary motor neuron 
cultures; these are derived from embryos, while the in vivo experiments were 
performed on adult mice (Bohnert and Schiavo, 2005, Bilsland et al., 2010). 
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The moving transport organelles have a neutral pH, which is essential to 
prevent pore formation and the release of the L chain into the cytosol (Montecucco 
et al., 1994, Williamson and Neale, 1994). However, the stationary organelles 
containing HCT are more acidic, which is dependent on the presence of the 
vacuolar (H+) ATPase. By targeting organelles, which do not contain this enzyme, 
HCT avoids its premature release from axonal transport carriers (Bohnert and 
Schiavo, 2005).  
1.2.4.2 Axonal transport of BoNTs 
BoNTs are preferentially sorted into synaptic vesicles, which stay in close 
vicinity to the presynaptic membrane (Colasante et al., 2013, Holtje et al., 2013). 
However, BoNT/A was shown to have central effects after injection, which can only 
occur if it undergoes long range axonal transport within neurons (Antonucci et al., 
2008, Caleo and Schiavo, 2009). Recent studies conducted in our laboratory have 
shown that both BoNT/A and /E undergo retrograde transport in motor neurons 
(Restani et al., 2012a). The speed profile of BoNT/A positive organelles is similar to 
the ones containing HCT, while BoNT/E-positive carriers displayed slower 
retrograde transport with more pauses and a higher incidence of reversals (Restani 
et al., 2012a). This result suggests that BoNT/E exploits a less efficient axonal 
transport pathway, while BoNT/A targets a common or very similar pathway to the 
one used by TeNT. This finding may explain why BoNT/E does not display any 
central nervous system effects, in spite of having the same intracellular target as 
BoNT/A.  
 
1.2.5 Synaptic transfer of TeNT 
TeNT is transcytosed in the motor neuron and stays hidden within vesicles 
characterised by neutral pH (Lalli et al., 2003a). It is retrogradely transported 
together with neurotrophin receptors (i.e. p75NTR) and reaches the cell body (Figure 
1-3 A-C), where it is sorted to the trans-synaptic transfer route. The molecular 
mechanism of the targeting is unclear, but it is re-exposed on the PM of motor 
neuron cell bodies and gets selectively taken up by inhibitory interneurons (Figure 
1-3 D) (Schwab and Thoenen, 1976). 
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Figure 1-3. TeNT is taken up, transported and synaptically transferred by motor 
neurons 
(A) TeNT is taken up by motor neurons the NMJ, as shown by the red labelling of the 
presynaptic membrane (AlexaFluor555-HCT was injected intramuscularly). It then 
enters the motor nerve (red puncta within the motor neuron axon). (B) AlexaFluor555-
HCT (red) is retrogradely transported together with neurotrophin receptors, such as 
p75NTR (green). The white arrowheads track the journey of a single signalling 
endosome towards the cell body. (C) AlexaFluor555-HCT (red) accumulates in the cell 
body (βIII tubulin, white) before its targeting to the PM. (D) AlexaFluor555-HCT 
(pseudocolored white) is synaptically transferred between motor neurons and inhibitory 
interneurons in microfluidic chambers (Chapter 5). 
 
1.2.6 Pore formation and translocation into the cytosol 
In recent years, the molecular mechanism of pore formation and subsequent 
translocation of the L chain has been studied in detail and led to the proposal of a 
new model (Montal, 2010, Fischer, 2013, Burns and Baldwin, 2014). During 
synaptic vesicle (SV) recycling the vesicular ATPase (vATPase) proton pump 
accumulates H+ ions in the SV lumen, resulting in the drop of the intraluminal pH. 
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This is required for the re-loading of neurotransmitters into the SV after 
neuroexocytosis (Ahnert-Hilger et al., 2003). When the vATPase is blocked with 
chemical inhibitors, BoNTs still enter neurons but loose their ability to block SV 
release, indicating that the activity of this enzyme plays a crucial role in the 
translocation of the L chain (Simpson et al., 1994, Williamson and Neale, 1994, 
Sun et al., 2011, Sun et al., 2012, Colasante et al., 2013). Patch clamp 
experiments were carried out on Neuro2A and PC12 cells, and it became evident, 
that when the pH drops on the cis side of the membrane (the luminal leaflet), the L 
chain of BoNT/A and /E1 cross the pore formed by the HN domain (15-20 Å in 
diameter) (Sheridan, 1998). There are several amino acids, which change 
protonation state when the pH drops, since the substitution of three different 
carboxylate residues to the corresponding amides in BoNT/B1 bypassed the need 
for the pH drop for membrane translocation (Pirazzini et al., 2013b).  
This channel is not big enough for the fully folded L chain to cross; it must 
unfold prior to translocation (Bade et al., 2004, Fischer et al., 2008). Once the L 
chain has reached the cytosol, the disulphide bridge linking the L chain and H chain 
is reduced and the metalloprotease is released into the cytosol. It is crucial that the 
disulphide bridge remains intact during translocation, since BoNTs with a reduced 
disulphide bridge do not form channels and display reduced toxicity (Schiavo et al., 
1990a, Fischer and Montal, 2007).  
According to a study, where the translocation of TeNT, BoNT/C and /D was 
forced through the PM, the translocation process takes only minutes and requires a 
pH range of 4.5-6 (Pirazzini et al., 2013c).  
 
1.2.7 Substrate recognition and cleavage 
To date, the synaptic SNARE proteins: syntaxin-1, SNAP25 (synaptosomal 
associated protein of 25 kDa) and VAMP/synaptobrevin are the only identified 
substrates of CNT. Cleavage of the cytosolic fragments of synaptic SNARE 
proteins yields the persistent blockade of neurotransmitter release (Schiavo et al., 
1992, Schiavo et al., 1993, Schiavo et al., 1993a, Blasi et al., 1993a, Blasi et al., 
1993b, Yamasaki et al., 1994, Rickman et al., 2004, Breidenbach and Brunger, 
2004). A peptide belt occupies the long channel of the active site, which is removed 
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upon the unfolding event prior to translocation (Rossetto et al., 2014). The 
substrate recognition site binds to the substrate with high specificity, but the 
efficiency of the metalloprotease cleavage varies between subtypes and this is 
likely to cause the different onset, duration and toxicity (Whitemarsh et al., 2013, 
Wang et al., 2013). 
 
1.3 TeNT uptake and neurotrophin signalling  
Since large distances separate the motor neuron end terminal and the soma, 
efficient neurotrophin trafficking and signalling is essential to maintain the 
communication with the distal synapses. Signalling endosomes carry receptor-
ligand complexes from the periphery towards the soma within the spinal cord 
through long-range axonal transport (Hoeller et al., 2005, Howe, 2005). These 
carriers are unidirectional and undergo fast retrograde transport, presenting a more 
efficient alternative to signalling pathways relying on diffusion. One of the best-
known complexes within signalling endosomes are neurotrophins and their 
receptors (Schecterson and Bothwell, 2010).  
1.3.1 Neurotrophin signalling in motor neurons 
1.3.1.1 Tropomyosin-receptor-kinase B (TrkB) and brain derived 
neurotrophic factor (BDNF)  
Motor neurons mainly express TrkB and p75NTR. Trks were initially 
described as oncogenic proteins (Barbacid et al., 1991). They are receptor tyrosine 
kinases; possess a ligand binding extracellular domain (EC), a single 
transmembrane domain and a tyrosine kinase intracellular domain (Figure 1-4). 
The EC domain contains three N-terminal leucine-rich motifs and two IgG-like 
domains. Neurotrophins bind to two sites: the third leucine-rich domain and the 
second cysteine cluster form one binding site, and the second IgG domain is the 
second binding site. Ligand binding triggers the dimerisation and auto-
phosphorylation of the receptors at specific tyrosine residues in the intracellular 
domain. The phosphorylated tyrosine residues bind to a variety of effector proteins, 
and activate several pro-survival and growth signalling cascades, such as the 
phospholipase Cγ1 (PLCγ1), phosphoinositide 3-kinase (PI3K) and the mitogen- 
Chapter 1 Introduction 
 38 
activated protein kinase (MAPK) pathways. The primary ligand of TrkB is BDNF 
(Klein et al., 1991, Garcia et al., 2010), which is essential for motor neuron survival. 
 
 
Figure 1-4. The domain structure of TrkB 
The two neurotrophin binding sites are indicated with arrows (amino acid residues 103-
181 and amino acid residues 342-394). Both of these sites are able to bind BDNF 
independently (Haniu et al., 1997). There are 10 important Y residues within the 
intracellular domain, which can be modified by the addition of a phosphate group. Upon 
ligand binding, the receptor dimerises and autophosphorylates the Y residues; this step 
is crucial for the opening of the activation loop and the subsequent activation of the 
tyrosine kinase domain (Minichiello, 2009). 
 
BDNF is secreted in its precursor form (proBDNF) and this molecule has an 
opposing function compared to the mature form. It preferentially binds to p75NTR 
and sortilin and activates a pro-apoptotic signalling pathway (Teng et al., 2005). 
However, a group of extracellular matrix proteases, tPA matrix metalloproteases 
(tissue plasmin activator), including plasmin, cleave the pro-domain and produce 
the mature form of the neurotrophin (Lu et al., 2005, Gray and Ellis, 2008, Teng et 
COOH
NH2
Signal peptide
Tyr residue
Tyrosine kinase domain
Immunoglubulin-like motif C2-type I and II
Leucine-rich motif
Cysteine cluster I, II
Plasma membrane
Extracellular space
Intracellular space
Chapter 1 Introduction 
 39 
al., 2010). Once cleaved, BDNF forms dimers and binds to heterodimers of TrkB 
and p75NTR, and activates survival and growth promoting downstream signalling 
pathways described above.  
Our laboratory previously demonstrated that TeNT shares its transport 
compartment with BDNF, p75NTR and TrkB both in dorsal root ganglia and primary 
motor neurons (Figure 1-1-5) (Deinhardt et al., 2006b, Terenzio et al., 2014b). This 
pathway has a functional relevance to tetanus intoxication, since mature BDNF 
increases the efficiency and speed of HCT internalisation at the NMJ in a dose 
dependent manner (Roux et al., 2006). Moreover, HCT promotes TrkB signalling in 
the absence of BDNF; both extracellular signal-regulated kinase 1/2 (ERK1/2), 
protein kinase B (Akt), protein kinase C (PKC) and PLCγ1 are activated upon the 
addition of HCT to neurons (Gil et al., 1998, Gil et al., 2000, Gil et al., 2001, Gil et 
al., 2003). 
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Figure 1-1-5. HCT accumulates in signalling endosomes with TrkB and p75NTR 
Primary motor neurons were incubated with colloidal gold-labelled HCT (10nm, empty 
arrowheads), α-TrkB (20 nm, white arrowheads) and α-p75NTR (5nm, black 
arrowheads) for 2 h at 37 °C to allow internalisation. The probes were taken up into 
endosomes, which were pseudocoloured according to the number of probes that they 
contain: yellow (a), pink (b) and green (c) representing single, double and triple labelled 
compartments, respectively. Scale bars: 200 nm (main panels), 50 nm (insets).  
Reprinted with permission from John Wiley and Sons (Terenzio et al., 2014a). 
 
1.3.1.2 Leukocyte common antigen-related (LAR) phosphatase 
A co-regulator of the neurotrophin-signalling pathway, the leukocyte 
common antigen-related (LAR) phosphatase binds to TrkB in a BNDF dependent 
manner (Yang et al., 2006) and it promotes neurite outgrowth (Yang et al., 2005). 
In LAR KO cells, phosphorylation of Y515 in TrkB is decreased, and this leads to a 
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decrease in the activity of the downstream signalling pathway. These results 
suggest that LAR facilitates pro-survival and growth signalling through TrkB. There 
are two possible mechanisms to serve as a molecular background for this 
hypothesis: 
 
1. By recruiting and dephosphorylating and activating a tyrosine kinase, which 
then phosphorylates Y515 on TrkB. Src family protein tyrosine kinases 
(PTK) are excellent candidates for this, as LAR directly binds to them and 
dephosphorylates their negative regulatory C-terminal domain (Tsujikawa et 
al., 2002). Fyn, a PTK associates with the intracellular domain of TrkB in a 
BDNF dependent manner (Iwasaki et al., 1998). Furthermore, adenosine 
activation of Fyn causes direct phosphorylation and activation of Trks in 
PC12 cells (Rajagopal and Chao, 2006). 
2. By dephosphorylating and thus inactivating a phosphatase, which in turn 
cannot dephosphorylate Y515 on TrkB. Shp-2 (Src homology 2 
phosphatase) would be good candidate, as it was shown to 
dephosphorylate Y515 (Minichiello, 2009, Gupta et al., 2012), but it is 
currently unknown whether it is a substrate for LAR. 
 
LAR has three extracellular IgG domains and eight fibronectin domains (Pot 
et al., 1991, Cho et al., 1992, Streuli et al., 1992). It has two phosphatase domains, 
one is active, while the other is inactive and it binds to various intracellular effector 
proteins, such as TRIO (triple functional domain protein), β-catenin, liprin-α and 
enabled (Figure 1-6) (Debant et al., 1996, Kypta et al., 1996, Serra-Pages et al., 
1998, Wills et al., 1999, Haapasalo et al., 2007). Its expression is restricted to the 
presynaptic membrane, where it binds to the laminin-nidogen complex among other 
extracellular matrix proteins, such as syndecan and dallylike (heparane sulphate 
proteoglycans, HSPG) (O'Grady et al., 1998, Johnson et al., 2006).  
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Figure 1-6. The domain structure of LAR 
There are 3 IgG and 8 fibronectin domains in the extracellular part of LAR, while it 
contains two tyrosine phosphatase domains in its intracellular part. The first tyrosine 
phosphatase domain is inactive and serves as a binding site for intracellular effectors, 
such as liprin-α. The other tyrosine phosphatase domain dephosphorylates the 
substrates of LAR, such as ephrin A2 (Lee and Bennett, 2013) and Src-PTK, such as 
Fyn (Tsujikawa et al., 2001). 
 
The loss of function mutation of PTP3 and DLAR, the Caenorhabditis 
elegans and Drosophila melanogaster isoforms of LAR, respectively, resulted in the 
impairment of presynaptic terminal size regulation; the active zones are enlarged 
within the NMJs of knock out animals. 
There are two PTP3 isoforms; PTP3A is the full-length isoform, while 
PTP3B lacks the extracellular IgG domains and the first four fibronectin domains. 
The former regulates synapse formation, while the latter plays a role in axonal 
guidance. PTP3A binds to nidogen-1 (a heavily glycosylated extracellular matrix 
protein) and this interaction is crucial for its accumulation around the perimeter of 
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the presynaptic terminal and the recruitment of the synapse size regulator, RIM 
(regulating synaptic membrane exocytosis protein). If either of the two proteins is 
lost, active zones in the en-passant NMJs become enlarged, indicating that these 
proteins act as synaptic gatekeepers (Ackley et al., 2003, Ackley et al., 2005). 
In D. melanogaster, when the expression of DLAR, or its downstream 
effector, Dliprin-α is reduced, NMJs are enlarged by three fold and there is a 
dramatic reduction in the quantal content of each terminal. This result suggests that 
the disruption of the regulation of the presynaptic terminal boundaries lead to the 
increased size of the active zone and with the SV content remaining the same, but 
spread to a larger area, the quantal content is decreased (Kaufmann et al., 2002).  
The observation that both mutations lead to similar phenotypes and that the 
function of PTP3 depends on the presence of nidogen-1 suggests that nidogens 
and LAR are components of a signalling pathway, which is crucial for presynapse 
specification and maintenance. The role of this protein complex in the mammalian 
nervous system was not investigated, it would be very interesting to test whether 
the complex is conserved through evolution and how it affects the downstream 
signalling of BDNF and TrkB. 
1.3.2 Nidogens are specialised extracellular matrix (ECM) proteins 
Nidogens (entactins) are heavily glycosylated ECM proteins and their main 
function is believed to be formation of a bridge between collagen IV and laminin 
(Ho et al., 2008). Both isoforms have a similar secondary structure; they consist of 
three globular domains with a rod-like and link-like connecting region (Kohfeldt et 
al., 1998, Fox et al., 1991). They are present in epithelial basal lamina (BL) in high 
quantities. The bridge between collagen IV and laminin is predicted to be crucial for 
ECM stability; however, genetic ablation of single nidogens does not cause any 
major disruption in the BL of epithelial cells (Murshed et al., 2000, Schymeinsky et 
al., 2002, Gersdorff et al., 2007). These results combined with the observed 
increase in nidogen-2 expression in nidogen-1 KO mice (Miosge et al., 2002) lead 
to the suggestion that the two isoforms have overlapping functions. The loss of 
nidogen-1 causes neurological phenotypes, such epilepsy and progressive 
hindlimb paralysis, while nidogen-2 knockout mice are healthy (Dong et al., 2002). 
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Mice lacking both nidogen isoforms die shortly after birth, have abnormal BL 
in both the lung and the heart, and present with syndactyly (due to the lack of finger 
separation) (Bader et al., 2005, Bose et al., 2006).  
Nidogens are subject to metalloprotease cleavage, but are largely protected 
when bound to laminin (Mayer et al., 1995). There are numerous target sites within 
the proteins, including a site for plasmin, which was also implicated in the cleavage 
of the pro-domain of BDNF (Mayer et al., 1993, Mayer et al., 1995, Lu et al., 2005, 
Gray and Ellis, 2008). Plasmin cleaves nidogen in the link domain (Lys203-Ser204), 
separating the G1 domain from the rest of the molecule. This is predicted to 
release nidogens from the extracellular matrix and make them more accessible to 
bind to soluble ligands. 
1.3.3 Signalling endosomes as HCT carriers 
Several lines of evidence indicate that TeNT and HCT enter axonal signalling 
endosomes in motor neurons (Bercsenyi et al., 2013, Schmieg et al., 2014), 
therefore suggesting that the TeNT receptor complex is a constituent of these 
axonal organelles (Figure 1-7). The Molecular Neuropathobiology Laboratory was 
in a unique position to identify this complex based on the available protocols for the 
isolation of axonal signalling endosomes, which allowed their proteomic mapping 
(Deinhardt et al., 2006b, Wade et al., 2012). Finding the protein receptor of TeNT 
might not only shed light on tetanus intoxication, but also increase our 
understanding on the targeting of extracellular ligands for retrograde transport. 
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Figure 1-7. Proposed model of TeNT transport in signalling endosomes 
Signalling endosomes containing neurotrophin receptors (TrkB, p75NTR and their 
binding partners, sortilin and LAR) and extracellular matrix components, such as 
nidogens are formed after ligand-mediated endocytosis (BDNF and pro-BDNF). After 
binding to the motor neuron membrane, TeNT enters these endosomes. Following 
initial sorting, Rab5, and then Rab7 is recruited and the endosome is transported 
towards the minus end of the MT, which is located in the cell body. Created based on 
the scheme in (Schmieg et al., 2014). 
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Chapter 2. Materials and Methods 
2.1 Ethics statement 
All experiments were carried out following the guidelines of the Cancer 
Research UK and UCL-Institute of Neurology genetic manipulation and Ethic 
Committees and in accordance with the European Community Council Directive of 
November 24th, 1986 (86/609/EEC). Animal work was carried out under license 
from the UK Home Office in accordance with the Animals (Scientific Procedures) 
Act 1986 (Amended Regulations 2012). 
 
2.2 Materials 
2.2.1 Reagents and media 
Standard reagents were obtained from Sigma-Aldrich, unless stated 
otherwise. Recombinant nidogens were purchased from R&D Systems. Phosphate 
buffered saline (PBS), 0.5 M EDTA pH 8.0, glutamine Luria Bertani (LB) medium, 
and SOC medium and penicillin/streptomycin were provided by Cancer Research 
UK Laboratory Services. 
2.2.2 Animals 
All animals were kept on the C57/Bl6 background. Wild type pregnant 
females were purchased from Charles River. Nidogen-1 and -2 knock out (KO) 
lines were provided by R. Nischt (University of Cologne). 
2.2.3 Bacterial Strains 
E.coli strain XL1Blue was used for DNA amplification, and the TG1 strain 
was used for protein expression.  
2.2.4 Antibodies 
AlexaFluor-maleimide and AlexaFluor-conjugated secondary antibodies 
were purchased from Life Technologies and used at 1:500. HRP (horse radish 
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peroxidase)-conjugated secondary antibodies were obtained from Amersham 
Bioscience and used at 1:2000. The source and dilution of primary antibodies are 
shown in Table 2. 
 
Table 2. Primary Antibodies 
Antigen Host Provider Dilution/Application 
VSVG Mouse CRUK (P5D4) 1:500 (IP,WB) 
βIII tubulin Mouse Covance (MMS-435P) 1:1000 (WB, IF) 
βIII tubulin Rabbit Covance (PRB-435P) 1:1000 (IF) 
HA Mouse CRUK (12CA5) 2 µg/10 µl beads (IP) 
HA Rat Roche (3F10) 1:1000 (WB, IF) 
nidogen-1 Rabbit Abcam (ab14511) 1:500 (WB) 
nidogen-2 Rabbit Abcam (ab14513) 1:500 (WB, IF) 
His Mouse Qiagen (34698) 1:300 (IF) 
LAR PMD Mouse F.M. Longo 1:500 (WB, IF) 
TrKB Rabbit Millipore (07-225) 1:500 (WB, IF) 
SV2C Rabbit T. Sudhof 1:100 (IF) 
SV2A Rabbit Synaptic System (SYSY119002) 1:500 (IF) 
ChAT Goat Millipore (AB144P) 1:100 (IF) 
GST Rabbit Abcam (ab9085) 1:100 (IF) 
SMI31 Mouse Covance 1:1000 (IF) 
IHC: immunohistochemistry, IF: immunofluorescence, WB: western blot, IP: 
immunoprecipitation 
 
The following probes were used in addition to the antibodies described above: 
 
Name Provider Dilution 
α-Bungarotoxin, Alexa Fluor® 555 
conjugate 
Molecular Probes 
(B35451) 
1:1000 
(IHC) 
AlexaFluor488-Cholera Toxin Subunit B 
Molecular Probes  
(C-347775) 
1:500 
(IF) 
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2.2.5 Primers 
2.2.5.1 List of primers for genotyping 
The primers used for genotyping nidogen-1 and -2 KO mice are shown in 
Table 3. The genotyping primer sequences for nidogen-1 were kindly provided by I. 
Koxholt (University of Cologne). I designed the genotyping primers for the detection 
of nidogen-2 wt gene using the Sigma-Aldrich online tool, while the primers 
detecting the Neo cassette were kindly provided by M. Golding (Molecular 
Neuropathobiology laboratory, Cancer Research UK).  
 
Table 3. Genotyping primers 
PCR Sequence 5´-3´ Product (bp) 
Nidogen-1 
FW-CCTCATTTGACCTACATGTAGC 
RW-CTTCAAACTCAGAGGACACAG 
RW-GAGAAAGAGTGGGACGATAG 
900-wt 
350-mu 
Nidogen-2 wt FW-GGCAGATGCAGCTCTCCTAA RP-GTCAGGAGGCTCCAAGAAGAAC 1000 
Nidogen-2 
(Neo casette) 
FW-CGCCAAGCTCTTCAGCAATATCACGGGTAG 
RW-TGCTCCTGCCGAGAAAGTATCCATCATGGC 380 
 
 
2.2.5.2 List of primers for site directed mutagenesis of HCT  
The primers for site directed mutagenesis were designed by M. Wallace 
(Molecular Neuropathobiology laboratory, Cancer Research UK and UCL-Institute 
of Neurology). The target sites on HCT and primer sequences are shown in Table 4. 
  
Chapter 2 Materials and Methods 
 
 49 
Table 4. Primers used for site directed mutagenesis 
Mutant Direction Sequence 
Y1229A Forward 5’-CTAAGAGTAGGTGCTAATGCCCCAGGTATCCC-‘3 
Y1229A Reverse 5’-GGGATACCTGGGGATTAGCACCTACTCTTAG-3’ 
T1146A Forward 5’-GTTCAATTGAAAAATATAGCAGATTATATGTATTTGAC-3’ 
T1146A Reverse 5’-GTCAAATACATATAATCTGCTATATTTTTCAAATTGAAC-3’ 
P1212W Forward 5’-GAGCACATTGTAGGTTATTGGAAAGATGGAAATGCC-3’ 
P1212W Reverse 5’-GGCATTTCCATCTTTCCAATAACCTACAATGTGCTC-3’ 
G1215F Forward 5’-GCACATTGTAGGTTATCCGAAAGATTTCAATGCCTTTAATAATC-3’ 
G1215F Reverse 5’-GATTATTAAAGGCATTGAAATCTTTCGGATAACCTACAATGTGC-3’ 
R1226F Forward 5’-CTTGATAGAATTCTATTCGTAGGTTATAATGCCCCAGG-3’ 
R1226F Reverse 5’-CCTGGGGCATTATAACCTACGAATAGAATTCTATCAAG-3’ 
 
 
2.2.6 Preparation of AlexaFluor555-HCT  
HCT (441 residues) with an improved cysteine-rich tag was prepared by F. 
Giribaldi (Molecular Neuropathobiology laboratory, Cancer Research UK) as 
previously described (Restani et al., 2012a). I labelled HCT with AlexaFluor555-
maleimide. 750 µg of purified HCT was mixed with 85 µl 2.5x buffer (50 mM HEPES 
NaOH, pH 7.4, 250 mM NaCl) and 29 µl of 10 mM TCEP (tris(2-
carboxyethyl)phosphine hydrochloride). dH2O was added to reach a final volume of 
375 µl. 0.5 mg AlexaFluor maleimide was dissolved in dimethyl sulfoxide (DMSO) 
and was then added drop-by-drop under continuous mixing. The reaction mixture 
was incubated overnight at 4°C, on a rotating wheel. The reaction was stopped the 
following day by adding 80 µl of STOP solution (50 mM Tris pH 8.0, 25 mM 
reduced glutathione). To separate the unbound dye from AlexaFluor555-HCT, the 
reaction mix was applied on a PD-10 desalting column (GE Healthcare) and the 
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presence of HCT was tested with a dot blot. The fractions containing 
AlexaFluor555-HCT were combined and dialysed against the storage buffer (10 mM 
HEPES-NaOH pH 7.4, 150 mM NaCl) at 4°C for three days. The storage buffer 
was exchanged every day. After three days, the labelled HCT solution was 
aliquoted, frozen in liquid N2 and stored at -80°C. The protein concentration and 
labelling efficiency were determined using a NanoDrop spectrophotometer. 
2.3 Methods 
2.3.1 Statistical analyses 
To test for statistical significance, all results were plotted in Graphpad Prism. 
Data was tested for normality using three tests: 
1. D’Agostino&Pearson omnibus normality test 
2. Shapiro-Wilk normality test 
3. KS normality test 
If any of the three tests confirmed that the data is normally distributed, 
Student’s t-test or analysis of variance (ANOVA) was used depending on the 
number of groups to compare (<2 – Student’s t-test; >2 - ANOVA). To compare 
individual groups within these samples, I used Dunnett’s multiple comparison test.  
If none of the tests confirmed that the data is normally distributed, Mann-
Whitney or Kruskal Wallis test was used depending on the number of groups to 
compare (<2 – Mann-Whitney test; >2 – Kruskal Wallis test). When the 
observations were paired, Friedman test was used. To compare individual groups 
within these samples, I used Dunn’s multiple comparison test. 
Significance was determined using the confidence interval of 95% (p<0.05 *). 
Additional * were give if the p value fell below 0.01 (**), 0.005 (***) and 0.001 (****). 
The test used is indicated within the description of each method. 
Error bars indicate standard deviation (SD) unless stated otherwise. 
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2.3.2 Genotyping 
2.3.2.1  Extraction of genomic DNA 
Mice earsnips were lysed overnight in 120 µl of DirectPCR Lysis Reagent 
(Viagen Biotech) with 0.1 mg/ml Proteinase K at 55 °C with gentle shaking. The 
reaction was then inactivated at 85°C for 30 min. 
During preparation of primary neuronal cultures, the rapid lysis method was 
used to extract genomic DNA quickly. A piece of embryo tail was incubated in 50 µl 
of Rapid Lysis Buffer (10 mM Tris-HCl pH8.3, 50 mM KCl, 0.1 mg/ml gelatin, 0.45% 
NP-40, 0.45% Tween 20) with 0.4mg/ml Proteinase K, and incubated at 55°C for 
10 min, then at 95°C for 5 min. 
2.3.2.2  Genotyping PCR 
Genotyping PCR was carried out using the Megamix-Blue (Microzone Ltd.), 
a PCR master-mix containing recombinant Taq polymerase. 15 µl of Megamix-
Blue, 0.125 µl of sequencing primers (forward and reverse), and 1 µl of fresh 
genomic DNA were mixed for a PCR reaction. The programme used for the PCR is 
shown in  
 
Table 5. Genotyping PCR programmes 
 Nidogen-1 Nidogen-2 wt Nidogen-2 mutant (Neo) 
    
1. Melting 94°C, 2 min 95°C, 4 min 95°C, 2 min 
2. Melting 94°C, 30 sec 95°C, 30 sec 95°C, 30 sec 
3. Primer annealing 55°C, 1 min 61°C, 30 sec 69°C, 30 sec 
4. Elongation 68°C, 2 min 72°C, 1 min; 72°C, 30 sec 
5. Elongation 68°C, 5 min 72°C, 5 min 72°C, 5 min 
Number of cycles (2-4) 34 29 30 
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2.3.2.3  Agarose Gel Electrophoresis 
DNA amplified by PCR was subjected to agarose gel electrophoresis. 
Agarose gels were prepared by dissolving 2% agarose in TBE (90 mM Tris-HCl, 90 
mM boric acid, 2 mM EDTA pH 8.0), with ethidium bromide (0.5 µg/ml) and after 
loading 10 µl of PCR products, the gel was electrophoresed at 150 V in TBE buffer. 
2.3.3 In vitro assays 
2.3.3.1 HCT mutagenesis 
M. Wallace (Molecular Neuropathobiology laboratory, UCL-Institute of 
Neurology) performed the site directed mutagenesis of the HCT fragment. Based on 
the biomolecular model (Figure 4-6), the following HCT sites were selected for 
mutagenesis: HCTT1146A, HCTP1212W, HCTG1215F, HCTR1226F, HCTY1229A. The mutations 
were generated using PfuTurbo® DNA polymerase, according to the 
manufacturer’s instructions using the primers listed in Table 4. Briefly, each 50 µl 
reaction comprised 50 ng of plasmid template: pGEX-4T3-HCT441 (24), 5 µl 10× 
reaction buffer, 125 ng each of the forward and reverse primers, 150 µM of each 
dNTP and 1 µl PfuTurbo® DNA polymerase (2.5 U/µl). PCR conditions were as 
follows: 95 °C for 2 min, followed by 16 cycles of 95 °C for 30 s, 55 °C for 1 min, 
and 68 °C for 8 min. After digestion with Dpn1, 2 µl of each PCR reaction were 
transformed in E. coli XL-1 Blue and grown overnight at 37 °C. DNA was purified 
using the QIAprep Spin Miniprep Kit (Qiagen, UK), and mutations were verified by 
direct sequencing. Once the sequences were verified, G. Schiavo (Molecular 
Neuropathobiology laboratory, UCL-Institute of Neurology) expressed the proteins 
as previously described (Restani et al., 2012a). 
 
2.3.3.2 Fluorescent binding assay 
2.3.3.2.1 Peptide Screen and Alanine scanning 
To test the peptides for HCT binding, I dried 10 ng of biotin-labelled peptides 
and their alanine mutants on a 96-well plate overnight and incubated the wells with 
Tris-buffered saline (TBS) containing 0.05% Tween-20 and 1% bovine serum 
albumin (BSA) for 1 h to block unspecific interactions. Plates were then washed 
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with TBS containing 0.05% Tween-20 (TBST) three times before adding 40 nM 
AlexaFluor555-HCT in TBS and incubating it overnight at 4°C. Plates were then 
extensively washed with TBS and the fluorescent signal was measured using an 
EnVision® Multilabel Plate Reader. The highest fluorescence intensity for each 
plate was set at 100% for all three independent experiments. The results were 
plotted and tested for significance using Friedman test (**, p<0.01) followed by 
Dunn’s multiple comparisons test against TBS (Figure 3-2). One-way ANOVA was 
used for the analysis in Figure 3-7 (****, p<0.001) followed by Dunnett’s multiple 
comparisons test against N1 (B), or N2 (C) (Table 12). 
2.3.3.2.2 Competition binding assay 
To get an estimate on the dissociation constant (Kd) of the interaction 
between the N1 peptide and HCT, I prepared 96-well plates with the N1, N1AA and 
other YEW-like peptides as described above, and following blocking, 
AlexaFluor555-HCT was added at increasing concentrations (3.75, 37.5, 75 and 
150 nM). To test whether the interaction was stable at pH 5; the same 
concentrations of AlexaFluor555-HCT were added to the N1 peptide in TBS 
adjusted to pH 5 by the addition of HCl. 
2.3.3.3 Classic ELISA 
For classic ELISA, 96-well plates were prepared as described above, 
washed with TBST three times before adding 4 nM VSVG-HCT (Herreros et al., 
2001),or 80 nM HA-HCT (wild type and point mutants) in TBS and then incubated 
overnight at 4 °C (VSVG-HCT, Figure 3-4) or 1 h at room temperature (HA-HCT, 
Figure 4-7). Wells were extensively washed with TBS and incubated with a 
monoclonal mouse antibody against the VSVG or HA epitopes for 2 h at room 
temperature. Following washes with TBST, an HRP conjugated goat anti-mouse 
secondary antibody was added for 1 h at room temperature. Wells were then 
washed with TBST and blocked with TBST, 1% BSA before adding ortho-
phenylenediamine (OPD) substrate for colorimetric detection. The reaction was 
quenched with 2 M HCl and the absorbance measured at 490 nm. For the peptide 
screen (Figure 3-4), the results were normalised to samples where HCT was 
omitted and analysed using paired Student’s t test. For the mutant HCT ELISA 
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(Figure 4-8), the mean values of triplicates from one assay were determined and 
the results of four independent experiments were tested for significance using 
paired Student’s t test comparing the mutants to wild type HCT.  
2.3.3.4 SDS-PAGE 
Protein samples were mixed in 5% Laemmli sample buffer (20% glycerol, 
5% β-mercaptoethanol, 10% sodium dodecyl sulfate (SDS), 120 mM Tris-HCl pH 
6.8, bromophenol blue) (Laemmli, 1970), and denatured for 10 min at 65°C. 
Samples were then loaded on pre-cast 4-12% NuPAGE® polyacrylamide gels 
(Invitrogen). Gels were ran at 200V for 60 min in 3-(N-morpholino)propanesulfonic 
acid (MOPS) buffer (Invitrogen). 
2.3.3.5 Western-blotting 
Proteins were transferred from the NuPAGE® gels to methanol-activated 
polyvinylidene fluoride (PVDF) membrane in transfer buffer (20 mM Tris-OH, 150 
mM glycine and 20% methanol). The membranes were stained with Ponceau S to 
monitor the efficiency of transfer, and blocked in 5% skimmed milk in PBST 
(blocking buffer, Marvel) for 1 h at room temperature. Membranes were then 
incubated with primary antibodies diluted in blocking buffer at room temperature for 
1 h, or alternatively overnight at 4 °C. Membranes were washed five times with 
PBST, and then incubated with HRP-conjugated secondary antibody diluted in 
blocking buffer for 1 h at room temperature. After washing in PBST and in dH2O, 
immunoreactivity was detected using enhanced chemiluminescence (ECL, GE 
Healthcare) according to manufacturer’s instructions.  
 
2.3.3.6 Immunoprecipitation 
2.3.3.6.1 In vitro peptide pull down 
For the in vitro pull down assay, biotin-tagged peptides (20 nM) were bound 
to streptavidin-coated agarose beads, and used to quantify the binding between the 
peptides and VSVG-HCT: 1 µg of VSVG-HCT was added to the beads, and after 
extensive washes in TBS, samples were analysed by SDS-PAGE and western 
blotting using the P5D4 antibody. The intensity of the bands was measured using 
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Image J and the results analysed by paired Student’s t test comparing the peptide-
bound beads to the empty bead control.  
2.3.3.6.2 Direct binding assay 
For the in vitro immunoprecipitation, we bound HA-HCT (1 µg) to anti-HA 
antibodies (2 µg) coupled magnetic Dynabeads® (10 µl; Life Technologies). After 
blocking with 0.1 mg/ml BSA in PBS for 1 h, samples were incubated with peptides 
(24 µM) or DMSO for 1 h at room temperature, washed and recombinant nidogens 
(0.5 µg of human nidogen-1; 2570-ND-050; or 1 µg of human nidogen-2; 3385-ND-
050; both from R&D Systems) were added to the samples and incubated overnight 
at 4 °C. Beads were then washed with PBS and bound proteins were analysed by 
SDS-PAGE and western blotting using rabbit anti-nidogen-1 and anti-nidogen-2 
and rat anti-HA antibodies. 
2.3.3.6.3 Immunoprecipitation of endogenous proteins 
For the immunoprecipitation of endogenous HCT receptor complexes, HA-
HCT (80 nM) was added to primary motor neurons for 5 min at 37 °C to allow 
endocytosis. The cells were immediately cooled on ice, washed with ice-cold 
Hank’s buffer and proteins were cross-linked using bis[2-
(succinimidooxycarbonyloxy)ethyl] sulfone (BSOCOES; 1 mM; Thermo Scientific) 
in PBS for 30 min at 4 °C. The reaction was stopped by the addition of 50 mM (final 
concentration) Tris-HCl, pH 7.5. Following washes with PBS, cells were lysed on 
ice using IP lysis buffer (20 mM Tris-HCl pH 8, 137 mM NaCl, 1 mM EDTA, 10% 
glycerol, 0.5% NP40, HALT protease/phosphatase inhibitors; Thermo Scientific). 
The lysates were cleared by centrifugation at 14,000 g for 10 min and proteins 
binding non-specifically to empty beads were cleared by incubating the samples 
with pre-washed Dynabeads for 30 min at room temperature. Monoclonal mouse 
anti-HA antibody (12CA5; 2 µg) was cross-linked to Dynabeads (20 µl) using 5 mM 
bis(sulfosuccinimidyl) suberate (BS3; Thermo Scientific) in 20 mM sodium 
phosphate, 150 mM NaCl, (pH 8). After 30 min incubation at room temperature on 
a rotating wheel, the reaction was terminated by addition of 50 mM Tris-HCl pH 7.5 
and further incubation for 15 min at room temperature. Beads were then added to 
lysates on a rotating wheel for 2 h at 4 °C, captured proteins magnetically isolated 
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as described above, washed and analysed by SDS-PAGE and immunoblotting 
using rabbit anti-nidogen-2 and rat anti-HA antibodies. 
2.3.3.7 Motor neuron lysates 
Following washes with PBS, motor neurons (DIV7-14) were lysed on ice 
using IP lysis buffer (20 mM Tris-HCl pH 8, 137 mM NaCl, 1 mM EDTA, 10% 
glycerol, 0.5% NP40, HALT protease/phosphatase inhibitors). The lysates were 
cleared by centrifugation at 14,000 g for 10 min and the supernatants were 
transferred to new tubes. The protein concentration was determined by Bradford 
assay (Bradford, 1976) and the lysates were denatured by adding 5x Laemmli 
sample buffer and heated for 10 min at 65°C. The lysates were either used for SDS 
PAGE or stored at -20°C for future experiments.  
 
2.3.3.8 Molecular modelling of the nidogen-1/N1 peptide-HCT interaction 
G. Zanotti (University of Padua) performed this analysis. The crystal 
structure of HCT with the bound tri-peptide YEW (PDB ID 1YXW) (Jayaraman et al., 
2005) was used as a template. The N1 peptide (THIYQWRQT) was constructed 
using Coot software (Emsley and Cowtan, 2004)replacing the glutamic acid with a 
glutamine within the YEW peptide. The remaining residues (THI---RQT) were 
manually constructed and adjusted inside the crevice of HCT. The structure was 
optimised by several runs of energy minimisation with CNS software (Brunger, 
2007). 
A model of the human nidogen-1 fragment (amino acids 389 to 661), was 
built by homology modelling using the Swiss-Model web server (Arnold et al., 2006) 
based on the crystal structure of mouse nidogen-1 G2/perlecan Ig3 complex as a 
template (PDB code 1GL4) (Hopf et al., 2001). The human and mouse proteins 
display 85% sequence identity (Figure 4-6). 
The peptide 604-612 of human nidogen-1 was manually superimposed to 
the N1 peptide in the nidogen-1-HCT complex using Coot (Emsley and Cowtan, 
2004) (Figure 3-7). The model of the two proteins was optimised by energy 
minimisation and subjected to molecular dynamics with CNS software. Several 
steps of dynamics at room temperature were performed, keeping the structure of 
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nidogen-1 fixed. The Cα atoms of HCT were harmonically restrained during the 
dynamics, with the exception of residues 1142-1149 and 1212-1227 in the 
interaction region of the two proteins, which were left free to move. 
2.3.3.9 Isothermal calorimetry (ITC) 
To assess the association constant (Ka) of the interaction between the N1 
peptide and HCT, I used isothermal titration calorimetry under the supervision of J. 
Lally (Cancer Research UK, London Research Institute). To ensure that the HCT 
sample did not contain any protein multimers, we used dynamic light scattering; 
which confirmed that the vast majority (81.6%) of the proteins were present as 
monomers (estimated diameter 6.52 nm≃60 kDa). 15 µM of HCT in storage buffer 
(20 mM HEPES-NaOH pH 7.4, 150 mM NaCl) was added to the sample cell, and 
300 µM of N1 peptide dissolved in the same buffer was loaded into the injector. 
The temperature of the reference cell and sample cell were set at 20°C and the 
ligand (N1) was titrated into the sample cell (containing HCT) in precise aliquots 
(0.4 µl at the first injection, 2 µl for the rest of the experiment) every 2 min. The 
temperature of the sample cell increased compared to the temperature of the 
reference cell when the N1 peptide was injected, due to the heat release during 
binding between the peptide and HCT (exothermic reaction). The input of power 
required to keep the temperature equal between the sample and reference cell was 
recorded. The pattern of the changes in the feedback power were plotted as a 
function of the molar ratio in Figure 3-8. Enthalpy changes (ΔH) and (Ka) can be 
directly calculated using the equation below (where ΔG is change in Gibbs free 
energy, R is the gas constant, T is absolute temperature, ln is natural logarithm and 
ΔS is change in entropy): 
 𝛥𝐺 = −𝑅𝑇𝑙𝑛𝐾𝑎 = 𝛥𝐻 − 𝑇𝛥𝑆 
The dissociation constant (Kd) is the inverted association constant (Ka): 𝐶 ↔ 𝑅 + 𝐿 𝐾𝑑 = 1𝐾𝑎 = 𝑅 [𝐿][𝐶]  
Where C stands for complex, R for receptor and L for ligand. 
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2.3.4 Primary motor neuron mass cultures and immunofluorescent assays  
2.3.4.1 Preparation of primary motor neuron cultures 
Spinal cord motor neurons were prepared from E13.5 old mouse embryos 
(C57/Bl6, Charles River) and plated onto glass coverslips, plastic bottom culture 
dishes and microfluidic chambers. Coverslips and culture dishes were coated with 
a solution of 15 µg/ml poly-ornithine (Sigma, P-8638) in PBS over night at room 
temperature. Coverslips and tissue culture dishes were then dried and 0.33 µg/ml 
laminin (Sigma, L-2020) was added in Neurobasal medium for 2 h at 37 °C. Cells 
were plated after two washes with Neurobasal. Microfluidic dishes were coated 
following a special protocol, described in 2.3.7. 
Following Schedule 1 termination of the pregnant mouse, the uterus was 
extracted and the embryos were kept on ice during the dissection to maintain tissue 
preservation. The head and tail of the embryo were removed using two straight 
no.5 jeweller forceps (Sigh Ltd, OS.56/5) and the back of the embryo was opened 
with one sharp incision in the midline. Since the roof plate of the developing spinal 
cord is very thin and lies directly beneath the skin, it was cut through during the 
incision. The opened spinal cord was gently removed from the embryo, the 
meninges were peeled off and the dorsal horn was cut off with a scalpel. The 
ventral horn was triturated with a scalpel and added to a 15 ml Falcon tube with 1 
ml PBS. For wild type embryo dissections, isolated ventral horns from several 
embryos were pooled together, while for nidogen-1 and -2 KO motor neuron 
dissections, samples of tails were saved for genotyping and ventral horns were 
processed individually. The tissue was digested with 0.025% trypsin (Sigma, T-
1426) for 10 min in a water bath at 37°C. For further digestion, two 15 ml Falcon 
tubes were prepared containing DNAse (Sigma, DN-25) in decreasing 
concentration (100 ng-10 ng DNAse in 1 ml L-15 medium containing 100 µl 4% 
BSA). The trypsin-digested samples were gently triturated and transferred to the 
first 15 ml Falcon tube containing 100 ng/ml DNAse. Following further trituration, 
the undigested fragments were allowed to settle and the supernatant was 
transferred to the second 15 ml Falcon tube containing 10 ng/ml DNAse and gently 
mixed to ensure that there were no undigested spinal cord fragments left. A 
cushion of 4% BSA was applied to the bottom of the tube and cells were 
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centrifuged at 370 g for 5 min at room temperature. The supernatant was discarded 
and the cells were resuspended in complete motor neuron medium (Table 6), 
which contain essential neurotrophins, ciliary neurotrophic factor (CNTF), glial cell 
line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor 
(BDNF). The typical yield of the preparation was 1-2x106 cells per spinal cord. Cells 
were kept at 37 °C in a 7.5% CO2 incubator. 
 
Table 6. Composition of complete motor neuron medium (50 ml) 
Ingredients Required volume (ml) 
Neurobasal 46.25 
B27 supplement (50x) 1 
Heat inactivated horse serum (2%) 1 
L-Glutamine (430x dil.) 0.104 
β-mercaptoethanol (1 mM) 1.25 
CNTF (100 µg/ml) 0.005 
GDNF (100 ng/ml) 0.05 
BDNF (25 µg/ml) 0.002 
Penicillin/Streptomycin (250x) 0.25 
 
2.3.4.2 HCT binding assays 
2.3.4.2.1 Testing the effect of peptides on HCT binding 
For the initial HCT binding studies, wild type motor neurons were cooled on 
ice prior to incubation with AlexaFluor555-HCT (20 nM), which was pre-treated with 
either DMSO, or the D/J/O/N1/N2/N3/N1AA peptides (20 µM).  Cells were incubated 
with the mixture for 45 min at 37 °C to allow internalisation. Following washes with 
Hanks’ buffer (HBSS, 20 mM HEPES-NaOH pH 7.4, 0.44 mM KH2PO4 0.42 mM 
NaH2PO4, 5.36 mM KCl, 136 mM NaCl, 0.81 mM MgSO4, 1.26 mM CaCl2, 6.1 mM 
glucose), the cells were fixed with 4% paraformaldehyde (PFA) in PBS, pH 7.4 for 
15 min at room temperature. The coverslips were mounted with Mowiol and imaged 
on a Zeiss LSM510 confocal microscope equipped with a Zeiss 40x objective. 
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2.3.4.2.2 Testing the effect of exogenous nidogens on HCT binding 
To assess the effect of recombinant nidogens on HCT binding, cells were 
preincubated with HCT (20 nM), which was pre-treated with either DMSO, the 
N1/N1AA peptides, recombinant nidogens (1 nM), or a combination of the above for 
1 h at room temperature at a molar ratio of 1:20:20,000 (recombinant 
nidogens:HCT:N1/N1AA peptide, respectively). Cells were incubated with 
AlexaFluor555-HCT for 10 min before washing with ice-cold HBSS and fixing with 
4% PFA in PBS for 15 min at room temperature. To obtain a mask for fluorescence 
intensity quantification, I stained the cells with a mouse monoclonal antibody 
against βIII tubulin and an AlexaFluor488-conjugated goat anti-mouse secondary 
antibody. Twenty images were acquired for each condition using a Zeiss LSM510 
confocal microscope equipped with a Zeiss 40x objective and acquired images 
were analysed for HCT binding using Cell Profiler. The mean fluorescence intensity 
was plotted for each condition and statistical significance was analysed using 
Kruskal-Wallis test (****, p<0.001) followed by Dunn’s multiple comparisons test.  
To confirm that His9-tagged recombinant nidogen-1 binds to motor neurons, 
the cells were not tested for βIII tubulin, but probed with mouse anti-His antibody 
instead, followed by an AlexaFluor488-conjugated goat anti-mouse secondary 
antibody. 
2.3.4.2.3 Time competition between HCT and the N1 peptide 
To assess the ability of the N1 peptide to block HCT accumulation when 
applied after HCT, wild type motor neurons were incubated with AlexaFluor555-HCT 
together with either the vehicle control (DMSO) or the N1/N1AA peptide, with the 
latter being added either together with or 10 min after the application of 
AlexaFluor555-HCT. The cells were allowed to internalise HCT for 45 min at 37 °C 
before cooling on ice, acid washing for 2 min (100 mM citrate-NaOH, 140 mM NaCl, 
pH 2.0) to remove the surface-bound probes, and fixation with 4% PFA in PBS (as 
above). The cells were subjected to the same immunofluorescence protocol 
against βIII tubulin as described above, and 4x4 tile scan images were taken using 
a Zeiss LSM780 confocal microscope equipped with a 63x objective. Images of 
HCT binding were analysed using Cell Profiler. The mean intensity of HCT alone 
(DMSO) was set at 100% for both the 0 and 10 min samples and the effects of 
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N1/N1AA addition were analysed using one-way ANOVA (***, p<0.005) followed by 
Dunnett’s multiple comparisons test.  
2.3.4.2.4 HCT binding to primary motor neurons lacking nidogens 
To assess the ability of nidogen-1 and -2 KO primary motor neurons to bind 
HCT, I isolated motor neurons from nidogen-1 and -2 KO and wild type E13.5 
embryos as described above and cultured them for 7-10 days (DIV 7-10). Cells 
were cooled on ice, and incubated with HA-HCT (40 or 10 nM) for 10 min. Following 
a wash with ice-cold Hanks’ buffer, the cells were fixed with 4% PFA in PBS for 15 
min at room temperature and immunostained with a rat anti-HA and mouse anti-βIII 
tubulin antibodies. Primary antibodies were detected using AlexaFluor555-
conjugated goat anti-rat and AlexaFluor488-conjugated goat anti-mouse secondary 
antibodies (dilution 1:500) to reveal HCT binding and the neural network, 
respectively. Ten images were acquired for each condition using a Zeiss LSM510 
confocal microscope equipped with a Zeiss 40x objective. Images were analysed 
for HCT binding using Cell Profiler. Image acquisition parameters were adjusted by 
setting the signal detection threshold to 0 for the sample where HCT was omitted 
and the mean fluorescence intensity was plotted for each genotype. Statistical 
significance was analysed using unpaired Student’s t test. 
2.3.4.3 Colocalisation between HCT and other proteins 
• Nidogen-2 
Motor neurons were incubated with AlexaFluor555-HCT  (40 nM) together 
with rabbit polyclonal antibody against nidogen-2 at 37 °C for 45 min, then cooled 
on ice and subjected to an acid wash before fixation with 4% PFA in PBS for 15 
min at room temperature. Cells were permeabilised using 0.1% Triton X-100 in 
PBS (PBSTr) for 10 min at room temperature and blocked with 5% BSA in PBS for 
1 h. The primary antibody was revealed using an AlexaFluor488-conjugated goat-
anti-rabbit secondary antibody. The cells were washed and the coverslips were 
mounted using Mowiol. Samples were imaged using a Zeiss 63x, Plan Apochromat 
oil-immersion objective of a LSM780 confocal microscope. The microscope was 
optimised for co-localisation analysis. The sampling was set to maximum and the 
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level of co-localisation was quantified using ImageJ. Mander’s coefficient was 
determined on randomly chosen fields. 
 
• Nidogen-2 and LAR 
The experiment was performed as above, but after permeabilisation, a 
mouse anti-LAR PMD antibody (Yang et al., 2006) was added to the cells for 1 h at 
room temperature. AlexaFluor488-conjugated goat-anti-rabbit secondary antibody 
was added to reveal internalised nidogen-2, and AlexaFluor647-conjugated goat 
anti-mouse antibody was added to reveal the localisation of LAR. The cells were 
washed and the coverslips were mounted using Mowiol. Samples were imaged 
using a Zeiss 63x, Plan Apochromat oil-immersion objective of the Zeiss LSM510 
confocal microscope. 
• TrkB 
AlexaFluor555-HCT was added to primary motor neurons for 45 min at 37 °C 
to allow internalisation. The cells were cooled on ice, acid washed as before, fixed 
with 4% PFA for 15 min at room temperature before permeabilising using 0.1% 
Triton X-100 in PBS for 10 min at room temperature and blocking with 5% BSA in 
PBS for 1 h. A rabbit anti-TrkB antibody was added to the cells for 1 h at room 
temperature. The cells were then washed and an AlexaFluor488-conjugated goat 
anti-rabbit secondary antibody was added for 1 h at room temperature to detect the 
presence of TrkB. The cells were washed with PBS and the coverslips were 
mounted with Mowiol before imaging with a Zeiss LSM510 confocal microscope. 
For the competition experiments, the motor neurons were cooled on ice, and either 
the mouse anti-TrkB antibody or AlexaFluor555-HCT was added first to the cells for 
10 min. The excess probes were washed off and AlexaFluor555-HCT or mouse 
anti-TrkB antibody was then added. Coverslips were washed with ice-cold HBSS, 
cells were fixed and the immunofluorescence protocol using the AlexaFluor488-
conjugated anti-rabbit antibody was performed as above. Samples were imaged 
using a Zeiss 63x, Plan Apochromat oil-immersion objective on a Zeiss LSM510 
confocal microscope. 
• SV2 
For the SV2 co-localisation studies, motor neurons were incubated either 
with fluorescent HCT alone (40 nM), or together with recombinant nidogen-1 (1.6 
nM) for 45 min at 37 °C. Cells were then acid washed, fixed, permeabilised and 
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blocked using a special blocking buffer (2% BSA and 10% foetal bovine serum 
(FBS) in PBS) prior to staining with a rabbit polyclonal antibody against SV2A 
(SYSY119002; Synaptic System; 1:500) or SV2C (a kind gift from T. Südhof; 
1:100) and a mouse monoclonal antibody against βIII tubulin. Primary antibodies 
were detected using AlexaFluor488-conjugated anti-rabbit antibody and 
AlexaFluor647-conjugated anti-mouse antibody. The cells were washed and the 
coverslips were mounted with Mowiol. Samples were imaged using a Zeiss 63x, 
Plan Apochromat oil-immersion objective on a Zeiss LSM510 confocal microscope. 
The microscope was optimised for co-localisation analysis. The sampling was set 
to maximum and the level of co-localisation was quantified using ImageJ. Mander’s 
coefficient was determined on randomly chosen fields. Statistical significance was 
assessed using unpaired Student’s t test with Welch’s correction. 
2.3.4.4 Nidogen-2 uptake in primary motor neurons 
Primary motor neuron cultures were left untreated, or were treated with 
either BDNF (100 ng/ml), HCT (40 nM), or incubated in Neurobasal medium for 2 h 
(starved). Rabbit anti-nidogen-2 antibody was added to the culture for 30 min at 
37°C; this allowed internalisation of the probe before acid washing to remove 
surface bound antibodies. The cells were fixed, permeabilised and blocked as 
before and stained with goat AlexaFluor488-conjugated anti-rabbit antibody to 
reveal the internalised pool of nidogen-2 and a mouse anti-βIII tubulin antibody 
followed by AlexaFluor647-conjugated anti-mouse antibody to stain the neuronal 
network. The cells were washed and the coverslips were mounted with Mowiol. 
Samples were imaged using a Zeiss 63x, Plan Apochromat oil-immersion objective 
on a Zeiss LSM510 confocal microscope. 
2.3.5 Differentiation of motor neurons from embryonic stem (ES) cells 
2.3.5.1 Maintenance of pluripotency 
Low passage (up to 4) embryonic stem (ES) cells were defrosted in a water 
bath at 37 °C. The cells were spun down at 1,000 rpm (rotation per min) for 3 min. 
The pellet was resuspended in ES growth medium (Table 7) and plated in a fish 
skin gelatin-coated T25 flask. The cells were never allowed to reach full confluency, 
as it promotes differentiation. The cells were detached from the surface of the flask 
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by Accutase (Life Technologies, according to manufacturer’s instructions) 
treatment for 5 min and vigorous shaking. Once in suspension, they were spun 
down at 1,000 rpm for 3 min, the pellet was resuspended in 1 ml of ES growth 
medium and split in 3 to decrease cell density. The cells were plated in a 
gelatinised T25 flask and kept at 37° C in 5 % CO2. 
 
Table 7. Composition of the ES growth medium (125 ml) 
Ingredient 
Required volume 
(ml) 
Glasgow Minimal Essential Medium (GMEM, Gibco) 110 
ES cell tested foetal bovine serum (FBS) 6.25 
Knockout serum replacement 6.25 
Glutamax 1.25 
Β-Mercaptoethanol (1:1400 stock in GMEM) 1.25 
Leukaemia inhibitory factor (LIF, 107 units/ml ESGRO 
stock; Millipore) 0.0125 
 
2.3.5.2 Differentiation 
The ES cell cultures were washed with warm PBS before adding Trypsine-
Versene (Life Technologies, 0.125%) for 1 min at room temperature. The flask was 
shaken vigorously to detach the cells. 4 ml ES growth medium was added to the 
cell suspension before centrifuging at 1,000 rpm for 3 min. The cell pellet was 
resuspended in ES growth medium and the cells were counted. 2x105 cells were 
carried forward for ‘small’ (5 ml) differentiation, while 2x106 were carried forward for 
‘big’ (10 ml) differentiation. 5 ml DNFK medium (Table 8) was added to the cell 
suspension before centrifuging at 1000 rpm for 3 min. The supernatant was 
removed and the appropriate volume of DNFK medium was added to the pellet. 
The ES cells were plated into uncoated Petri dishes (Sterilin) and kept at 37 °C in 
5 % CO2. The medium was changed every day, with additional retinoic acid (RA; 
1:10,000) and Smoothened agonist (SAG, Enzo Life Sciences, 1:6,000) present 
from day 2. The embryoid bodies (EB) were allowed to grow until day 5. 
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On day 5 of the differentiation protocol, EB were disaggregated following the same 
protocol as the primary motor neuron disaggregation. Motor neurons were plated 
on poly-ornithine/laminin coated coverslips, or BSA/poly-ornithine/laminin-coated 
microfluidic chambers. 
 
Table 8. Composition of the DNFK medium (50 ml) 
Ingredient Required volume (ml) 
DMEM supplemented with F12 62.25 
Neurobasal 62.25 
GLUTAMAX 0.6 
KO serum replacement 13 
β-Mercaptoethanol 0.0014 
 
 
2.3.6 Design and preparation of microfluidic chambers 
Microfluidic chamber templates were already present in the laboratory; 
however, these did not favour the crossing of motor neuron axons. To overcome 
this, I designed new chambers with shorter microgrooves (500 µm) using the 
software Canvas (ADC Systems), under the guidance of G. Menendez (Molecular 
Neuropathobiology laboratory, Cancer Research UK). The height of the grooves 
was set at 1-2 µm to maintain the microfluidic isolation between the somal and 
axonal compartments. The photo masks were custom-made microLIQUID 
(Mondragón, Spain). The final design was replicated onto SU9 silicone wafers 
using photolithography and I used these wafers to make the initial 
Polydimethylsiloxane (PDMS, also known as Sylgard 184; Dow Corning) replicas, 
which can be mounted on plastic or glass bottom dishes and used as a microfluidic 
chamber. PDMS is a polymer, which is a liquid in its unpolymerised form, and turns 
into a semi-flexible material when polymerised. Polymerised PDMS pieces were 
produced by mixing the base component of PDMS with a curing agent (mixed 10:1, 
according to manufacturer instructions). This liquid mixture was put under vacuum 
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to eliminate bubbles for approximately 30 minutes and then poured into the SU9 
wafers. These were put in an oven at 65°C to polymerise the PDMS. PDMS 
devices were then peeled from the wafers. To avoid any damage to the original 
wafer, I refrained from using them for repetitive chamber preparation. I used the 
first PDMS insets to create identical epoxy resins and I used these as templates for 
the chamber preparations. To make the resin replicas, all components of the epoxy 
resin (Table 9) were mixed and air bubbles were removed under vacuum for 60 min. 
This was poured into a tin cup and a PDMS microfluidic chamber copied from the 
model SU9 silicon wafer was used as a mould. The PDMS device was set to float 
on the liquid mix of epoxy resin with the pattern facing downwards. The epoxy resin 
was polymerised at 65°C overnight. The PDMS mould was then peeled from the 
hardened epoxy block. A first PDMS device produced by replica moulding from 
these new masters was inspected with a scanning electron microscope to confirm 
that all dimensions of the original design were copied with high fidelity. 
 
Table 9. Ingredients for EPON resin preparation (final weight 20 g) 
Ingredient Required weight (g) 
Taab 812 resin 9.6 
MNA (g) 6.6 
DDSA (g) 3.8 
Accelerator DMP-30 0.4 
 
 
The PDMS pieces were cut to shape using a 28 mm diameter Wad Punch 
(Roebuck). Finally four wells were cut, one at each end of each of the two lateral 
compartments. These wells were cut with a 5 mm borer.  
I used 50 mm diameter glass bottom dishes (IntraCel, UK) for live cell 
imaging and immunofluorescence applications. PDMS insets were irreversibly 
attached to the dish using plasma cleaner. Plasma cleaner creates temporarily 
reactive chemical groups on the surface of the glass and PDMS that can form 
irreversible bonds if put in contact immediately after treatment. Complete 
microfluidic chambers were incubated at 65°C for 5 minutes to complete the 
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binding reaction. The plasma treatment sterilises microfluidic devices, but it renders 
the surface of PDMS hydrophobic. Therefore, coating must be applied immediately 
after chamber assembly.  
First, the hydrophobic surface must be neutralised and made more 
hydrophilic by the addition of 0.8% BSA in L-15 medium at 37°C over night. A 
higher volume of coating media was added to the future somatic side of the 
chambers, and they were tipped towards the axonal side to aid the coating for the 
microgrooves. The following day this media was removed and the chambers were 
coated with poly-L-ornithine and laminin following the protocol described above for 
coating coverslips. A higher volume of coating reagent was added to the somatic 
side and the chambers were incubated tipped towards the axonal side. 
2.3.7 Scanning Electron Microscopy 
Microfluidic chambers were observed under a JEOL 6700 Field Emission 
Scanning Electron Microscope to assess that the size of all features corresponded 
to our design. For this purpose, microfluidic PDMS devices were cut, mounted on a 
cylinder stub and attached with a piece of carbon tab. The exposed surface was 
covered with a film of platinum in a sputter coater. The analysis was performed by 
A. Weston (Cancer Research UK London Research Institute). 
2.3.8 Plating primary or ES derived motor neurons in microfluidic chambers 
Primary motor neurons or ES derived embryoid bodies were disaggregated 
as explained before. The cells were resuspended in a low volume of complete 
motor neuron medium and counted using a Neubauer chamber. Briefly, I performed 
a 1:10 dilution of the cell suspension and 10 µl was loaded into the chamber. Cells 
were counted in 3 big squares along the diagonal angle. Since the volume of 1 big 
square is 1 µl and there is a pre-dilution factor of 10, the concentration of the 
suspension is as follows: 
 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 = 𝑁𝑢𝑚𝑒𝑟  𝑜𝑓  𝑐𝑒𝑙𝑙𝑠×100,0003  
 
A high cell density is required to encourage motor neuron axons to cross. 
50.000 cells were plated from primary motor neuron dissections, while 100.000 
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cells were required from ES derived motor neurons due to the higher mortality of 
cells after in vitro differentiation. 
2.3.9 Immunofluorescence assays in microfluidic chambers 
Since there is microfluidic isolation between the two compartments; the 
antibodies cannot penetrate into the microgrooves. Antibodies were always added 
to both compartments at the same dilution to ensure that both the axons and cell 
bodies are stained to an equal level. 
2.3.9.1 βIII tubulin and SMI31 staining in microfluidic chambers 
To test whether motor neurons were able to cross the short microgrooves 
(500 µm), I plated ES derived motor neurons into the somatic compartment of 
microfluidic chambers. The ES line express GFP under the motor neuron specific 
HB9 promoter (HB9::GFP) and GFP is present throughout the cytosol of every 
motor neuron in the culture. 4 days after plating, the level of crossing was 
determined under a light microscope, and both the somatic and axonal 
compartments were fixed with 4% PFA in PBS for 15 min at room temperature. To 
fix the axons within the isolated microgrooves, a higher volume (200 µl) was 
applied to the axonal compartment compared to the somatic compartment (100 µl) 
and the chambers were tipped towards the lower liquid column, this promotes liquid 
flow within the microgrooves. The cells were permeabilised and blocked as before 
and both compartments were stained with rabbit anti-βIII tubulin and mouse anti-
SMI31 antibodies for 1 h at room temperature. βIII tubulin labels all neuronal cells, 
while SMI31 specifically recognises a heavily phosphorylated form of neurofilament, 
which is highly enriched in axons. The primary antibodies were washed off with 
PBS and AlexaFluor647-conjugated goat anti-rabbit and AlexaFluor555-conjugated 
goat anti-mouse secondary antibodies were added for 1 h at room temperature to 
both sides. Following several washes with PBS, the compartments were post-fixed 
with 4% PFA in PBS for 15 min at room temperature. The fixing solution was 
replaced with PBS and the axonal side of the chambers was imaged with a Zeiss 
LSM 510 confocal microscope in a custom-design chamber holder. 
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2.3.9.2 HCT transport in microfluidic chambers 
To test if HCT is taken up at the axonal compartment and transported to the 
somal compartment, I plated primary motor neurons into microfluidic chambers, 
and once the axons crossed the microgrooves (DIV 7), I added a higher volume of 
motor neuron medium to the somatic side (200 µl) and a lower volume of the same 
medium (100 µl) containing AlexaFluor555-HCT (40 nM) to the axonal side. The 
neurons were left to internalise HCT for 2 h at 37 °C before washing the axonal 
compartment with HBSS. Both compartments were processed the same way as 
previously described, but the SMI31 antibody was omitted. Both sides of the 
chamber were imaged as before. 
2.3.9.3 Uptake and differential sorting of HCT and cholera toxin B (CTB) 
To show that HCT undergoes synaptic transfer in motor neuron cultures, I 
plated primary motor neurons in microfluidic chambers and let them extend their 
axons through the microgrooves (DIV 7). I added a higher volume of motor neuron 
medium to the somatic side (200 µl) and a lower volume of the same medium (100 
µl) containing AlexaFluor555-HCT (40 nM) and AlexaFluor488-CTB to the axonal 
side and left the cells to internalise and transport the probes for 2 h at 37 °C. Both 
sides of the chambers were stained for βIII tubulin and imaged as before. Every 
axon in the axonal compartment contained both CTB and HCT, but there were a 
few cell bodies in the somatic side, which contained HCT but not CTB. 
 
2.3.9.4 Transcytosis of HCT and nidogen-2 
To test whether nidogen-2 was re-exposed together with HCT on the surface 
of motor neurons after axonal retrograde transport, we added AlexaFluor555-HA-
HCT (40 nM) together with a rabbit polyclonal antibody against nidogen-2 to the 
axonal side of the chamber and incubated it for 2 h at 37 °C. Cells were prepared 
for immunofluorescence as before and the somatic compartment was stained with 
a rat monoclonal anti-HA antibody in detergent-free conditions. After removing the 
unbound antibody with three PBS washes, the somatic compartment was stained 
with AlexaFluor647-conjugated goat anti-rabbit and AlexaFluor488-conjugated goat 
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anti-rat secondary antibodies to reveal the transcytosed pool of nidogen-2 and HCT, 
respectively. The chambers were post-fixed and imaged as before. 
 
2.3.10 Immunofluorescence assays on neuromuscular junctions and 
hindbrains 
2.3.10.1 Colocalisation between choline-acetlytransferase, nidogen-2 and HCT 
at the NMJ 
To determine whether nidogen-2 and HCT colocalise to presynaptic sites at 
the NMJ, we injected the tibialis anterior (TA) muscle of age and sex matched 
C57/Bl6 mice (n = 3) with HA-HCT (14 µg, 4 µl total volume) using a 10 µl Hamilton 
syringe under brief isoflurane-induced anaesthesia. After 60 min animals were 
terminally anaesthetised and transcardially perfused with saline followed by 4% 
PFA in 0.05 M (pH 7.8) TBS. Both the TA and extensor digitorum longus (EDL) 
muscles were dissected, post-fixed for 1 h in 4% PFA in TBS and cryoprotected in 
20% sucrose in TBS overnight at 4 °C. Muscles were mounted in O.C.T. (Tissue-
Tek) and frozen on dry-ice before being sectioned on a cryostat (20 µm thickness) 
and collected onto poly-lysine coated slides. Sections were air-dried for 1 h prior to 
staining according to standard immunofluorescence staining protocols. Briefly, 
sections were washed three times with TBS, blocked with 5% normal goat serum 
(NGS) in TBS, 0.1% Triton X-100 before application of primary antibodies: rat anti-
HA antibody rabbit anti-nidogen-2, goat anti-choline acetyltransferase (blocked and 
diluted in donkey serum), which were diluted in TBS, 2% NGS, 0.1% Triton X-100 
and incubated overnight at room temperature in a humidified chamber. After three 
5 min washes with TBS, appropriate secondary antibodies were applied: 
AlexaFluor647-conjugated goat anti-rat; AlexaFluor488-conjugated goat anti-rabbit 
or AlexaFluor488-conjugated donkey anti-goat, blocked and diluted in donkey 
serum. Secondary antibodies were diluted in combination with AlexaFluor555-α-
bungarotoxin (α-BTx) and applied to sections for 1 h at room temperature, after 
which sections were washed three times with TBS. Coverslips were mounted with 
fluorescence mounting media (Dako) and slides were then imaged using a Zeiss 
LSM780 confocal microscope equipped with a Zeiss 40x Plan Apochromat oil-
immersion objective. The integrated intensity of HCT and nidogen-2 was tested 
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using Spearman correlation in Graphpad Prism. The injection and 
immunohistochemistry was performed by J. B. Bryson (UCL-Institute of Neurology) 
and I imaged the sections and analysed the colocalisation. 
2.3.10.2 The effect of the N1 peptide on HCT binding at the NMJ 
To test whether the N1 peptide is capable of blocking the entry of HCT at the 
NMJ, levator auris longus (LAL) muscles were isolated from wild type animals and 
incubated with HCT (20 nM), which had been pre-treated with either DMSO, or the 
N1/N1AA peptide (20 µM) for 1 h at 37 °C. The muscles were washed, fixed in 10% 
NBF overnight at 4 °C, permeabilised using 0.1% Triton X-100 in PBS for 1 h at 
room temperature and blocked with 5% BSA in PBS for 1 h. Rat anti-HA antibody 
was added for 1 h at room temperature. The muscles were washed with PBS 
before the addition of AlexaFluor555-α-BTx and AlexaFluor488-conjugated goat 
anti-rat antibody. The samples were mounted with Mowiol and imaged as 
described above. I used α-BTx staining as a mask to identify NMJs and determined 
the ratio between HCT positive and negative NMJs. The results were plotted and 
tested for significance by Kruskal-Wallis test (**, p<0.001) followed by Dunn’s 
multiple comparisons test.  
2.3.10.3 HCT binding to nidogen KO NMJs 
Freshly-isolated LAL muscles from adult nidogen-1 and nidogen-2 KO mice 
were used to assess the requirement of nidogens to internalize HCT at the NMJ. 
The muscles were incubated with HCT (40 or 20 nM) in motor neuron medium for 2 
h at 37 °C, then processed and imaged as above. The results were plotted and 
tested for significance by Kruskal-Wallis test (****, p<0.001) followed by Dunn’s 
multiple comparisons test. To test whether exogenous nidogen-1 rescue the 
phenotype of nidogen-1 KO NMJs and restore HCT binding, the experiment was 
performed as above, but His9-tagged recombinant nidogen-1 (1 nM) was added 
together with HA-HCT. The recombinant nidogen-1 was then detected using mouse 
anti-His5 antibody and an AlexaFluor647-conjugated goat anti-mouse secondary 
antibody. 
 
Chapter 2 Materials and Methods 
 
 72 
2.3.10.4 Testing synaptic vesicle recycling in nidogen KO NMJs 
To test whether nidogen KO NMJs exhibited normal synaptic vesicle 
recycling, the GST-tagged binding fragment of botulinum neurotoxin A (HCA; 12 µg 
in 4 µl) was injected into the TA muscle of wild type, nidogen-1 and nidogen-2 KO 
mice, as described above, and muscle sections were immunostained with rabbit 
anti-GST (ab9085, Abcam; 1:100), followed by AlexaFluor488-conjugated goat 
anti-rabbit antibodies.  
2.3.10.5 HCT binding to nidogen-1 and -2 dual knock out (nidogen DKO) 
hindbrains 
To assess the requirement of nidogens to bind HCT in vivo, freshly isolated 
hindbrains of nidogen DKO E11.5 embryos were incubated with AlexaFluor555-
HCT in motor neuron medium for 2 h at 37 °C, followed by 10% NBF fixation 
overnight at 4 °C. The samples were then immunostained for βIII tubulin as 
described above, mounted with Mowiol and imaged using a Zeiss LSM780 confocal 
microscope equipped with a Zeiss 20x Plan Apochromat objective. The mean grey 
value of the HCT signal for the entire sample was determined using Image J, plotted 
and tested for significance using unpaired Student’s t test with Welch’s correction. 
 
2.3.11 The effect of peptides on HCT binding in a hemidiaphragm assay 
Mouse phrenic nerve-hemidiaphragms were dissociated from male Swiss-
Webster CD1 mice weighing about 20 g and mounted in 2-4 ml of oxygenated 
(95% O2, 5% CO2) Krebs-Ringer solution of the following composition: 137 mM 
NaCl, 5 mM KCl, 1.8 mM CaCl2, 1.0 mM MgCl2, 24 mM NaHCO3, 1 mM NaH2PO4 
and 11 mM glucose, pH 7.4, at 37 °C. Two innervated hemidiaphragm preparations 
were isolated from each animal; muscles were stretched to the optimal length for 
twitch response and allowed to equilibrate for at least 20 min at 37 °C before the 
start of the experiment. The phrenic nerve was stimulated via two ring platinum 
electrodes with supramaximal stimuli of 10 V amplitude and 0.1 ms pulse duration 
with a frequency of 0.1 Hz. Muscle contraction was monitored with an isometric 
transducer (Harvard Apparatus); data was recorded and analysed via an i-WORX 
118 system with Labscribe software (Harvard Apparatus). TeNT aliquots (final 
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concentration 5 nM) were preincubated with vehicle (DMSO) or with the N1 peptide 
(2.5 µM), corresponding to a molar ratio of 1:500 (TeNT:peptide), for 1 h at room 
temperature, and then added directly to the tissue bath of two nerve-muscle 
preparations obtained from a single animal. Muscular twitch was monitored until 
complete paralysis. Data were expressed as the time required to decrease the 
twitch to 50% of the initial value (paralysis half-time). The experiment was 
performed by P.Caccin (University of Padova). 
 
2.3.12 In vivo assays 
2.3.12.1  The effect of the N1 peptide on local tetanus  
2.3.12.1.1 Local tetanus of the triceps surae muscle (TS) analysed by a 
footprint assay 
Age- and body weight-matched C57/Bl6 male mice were injected with TeNT 
(1 or 2 ng/kg, concentration set to have an injection volume of 5,5 µl) preincubated 
with either DMSO, the N1 or the N1AA peptide at a molar ratio of 1:13,800 
(TeNT:peptide) for 1 h at room temperature into the right TS muscle. Mice were 
monitored for period of 96 h unless they reached the humane endpoint 
(appearance of moderate symptoms: hunched back and paralysis of rear limbs, or 
disappearance of the righting reflex for 30 s) earlier.  
Footprint assays were performed following the previously described protocol 
(Carter et al., 1999). Briefly, the non-injected paws were painted black and the paw 
of the injected hindlimb (right) was painted red. The mice were let to walk on a 
white stripe of paper. To quantify the extent of paralysis, the distance between the 
contralateral (injected side) front and hind paw prints was measured. This 
parameter provides a reliable assessment of normal foot positioning during walking 
in mice, with increased distance between the front and hind footprints reflecting 
triceps surae muscle paralysis. Data were analysed using one-way ANOVA (****, 
p<0.0001) followed by Dunnett’s multiple comparisons test to compare the groups. 
Following termination, the triceps surae muscles were isolated and weighed to 
determine the exact TeNT dose/mg TS muscle (Table 10). The body weight 
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correlates well with the weight of the TS muscle, but for future experiments I used 
weight-matched mice. 
 
Table 10. Determination of TeNT dosage in the TS muscle 
1 ng/kg Body weight (g) Inj. vol.(µl) Weight TS (mg) Dose (pg/mg TS) 
TeNT alone 
23.5 5.6 123 0.19 
21.2 5.1 117 0.18 
TeNT+N1AA 
23.3 5.6 138 0.17 
23 5.5 120 0.19 
TeNT+N1 
23 5.5 142 0.16 
23 5.5 112 0.21 
 
2 ng/kg Body weight (g) Inj. vol.(µl) Weight TS (mg) Dose (pg/mg TS) 
TeNT alone 
22.8 5.5 132 0.35 
23 5.5 128 0.36 
TeNT+N1AA 
22.7 5.4 127 0.36 
22.4 5.4 111 0.41 
TeNT+N1 
22.3 5.4 110 0.41 
22.4 5.4 117 0.39 
 
 
2.3.12.1.2 Local tetanus analysed by isometric muscle tension physiology 
8-week old female C57Bl6 mice received unilateral intramuscular injection of 
TeNT into the tibialis anterior (TA) muscle (0.125 ng/kg, 4 µl injected volume per 20 
g body mass), after preincubation with vehicle (DMSO), N1 or N1AA peptides at a 
molar ratio of 1:13,800 (TeNT:peptide) for 1 h at room temperature. After 24 h, 
isometric muscle tension force was recorded under terminal anaesthesia from the 
distal TA tendon following electrical stimulation (40-100 Hz, 0.02 ms square-wave 
pulses, for 450 ms) of the exposed sciatic nerve to induce maximal tetanic muscle 
contraction, as previously described (37). Contractile force of injected muscles was 
compared to contralateral (non-injected) TA muscle, as an internal control, and 
average changes within each group were analysed using unpaired Student’s t test. 
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The experiment was performed by J. B. Bryson (UCL-Institute of Neurology) and I 
analysed the results for significance. 
2.3.12.2  The effect of exogenous nidogen-1 on local tetanus 
The right TS muscle of weight matched C57/Bl6 mice was injected with 1 
ng/kg of TeNT, following preincubation with DMSO as a vehicle control, nidogen-1 
alone or the N1 peptide followed by nidogen-1 (molar ratio; TeNT:N1:nidogen-1 = 
1:13,800:0.25). Mice were closely monitored and scored blind according to the 
scoring system shown in Table 11. Before injection, and 45 and 69 h after injection, 
a footprint analysis was performed as described before and the coordination 
(distance between the prints on the same side) was measured. I performed the 
experiment together with N. Schmieg (Molecular Neuropathobiology laboratory, 
Cancer Research UK) and members of the Molecular Neuropathobiology 
laboratory assisted with the scoring of the behaviour of the mice. To assess the 
progression of tetanic paralysis, we distinguished between 6 different stages of 
progression (scale 5-0, Table 11). The animals’ behaviour was assessed at 29, 27, 
52 and 73 h after injection. During tetanic paralysis, the toes and the paw show the 
first signs of paralysis, the paw is touching the floor progressively less (Score 4), 
then the animal starts walking using its toes only (Score 3). This is followed by the 
extension of the injected hindlimb when the mouse is lifted up by its tail (Score 2). 
The TS muscle gets completely paralysed (Score 1), then the animal bends to one 
side when lifted up by its tail (Score 0). Mice were monitored for period of 96 h 
unless they reached the humane endpoint (appearance of moderate symptoms: 
hunched back and paralysis of rear limbs, or disappearance of the righting reflex 
for 30 s) earlier. 
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Table 11. Scoring system to assess in vivo local tetanus progression 
Scores Behaviour 
5 Normal walking 
4 Partial loss of paw print 
3 Walking on toes 
2 Extended leg 
1 Loss of TS movement 
0 Stiff back muscles 
 
2.3.12.3  Analysis of TeNT toxicity in nidogen-2 KO mice 
Age and body mass-matched wild type and nidogen-2 KO mice were 
injected intraperitoneally with different doses of TeNT (1.5, 3, 6, or 12 ng/kg). Mice 
were regularly monitored for up to 96 h after injection. Animals were terminated by 
Schedule 1 method when mice showed moderate tetanus symptoms (hunched 
back and paralysis of rear limbs or disappearance of the righting reflex for 30 s). 
The time of survival prior to termination was plotted against the administered dose 
of TeNT and data was analysed using Kolmogorov-Smirnov test for each dose. The 
experiment was performed by N. Schmieg and G. Schiavo (Molecular 
Neuropathobiology laboratory, Cancer Research UK and UCL-Institute of 
Neurology) and I analysed the results. 
2.4 Supplemental material 
2.4.1 Description of movies 
2.4.1.1 Movie 1. The N1 peptide prevents TeNT-induced paralysis in vivo 
Mice injected in the right triceps surae muscle with TeNT showed signs of local 
paralysis (the affected limb is extended) with no grip reflex. Pre-treatment of TeNT 
with vehicle control or the N1AA peptide had no effect on the progression of tetanic 
paralysis. In contrast, when mice were injected with TeNT pre-treated with the N1 
peptide, they showed an overall normal posture, strong grip reflex and no gait 
abnormalities, demonstrating a blockade in TeNT induced paralysis. From 
(Bercsenyi et al., 2014). Reused with permission from AAAS. 
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2.4.1.2 Movie 2. Model of the interaction of HCT and nidogen-1 
The crystal structure of HCT (cyan) is shown bound to the N1 peptide or to human 
nidogen-1 (orange). The model of the molecular complex was built and minimised 
as described in Figure 3-8 and Figure 4-6. The modeling was performed by G. 
Zanotti (University of Padova). From (Bercsenyi et al., 2014). Reused with 
permission from AAAS. 
2.4.1.3 Movie 3. Localisation of nidogen-2 and HCT at the NMJ 
3-D rendering of a NMJ from the extensor digitorum longus muscle, fixed 1 h after 
HCT injection, compiled from a z-stack of confocal images. Individual channels 
show fluorescent labeling of α-bungarotoxin (blue), combined with immunolabelling 
of nidogen-2 (green) and HCT (red). The merged image reveals colocalisation of 
HCT with nidogen-2 within the NMJ (see also Figure 4-24). The 3-D rending was 
perfomed by J. B. Bryson (UCL-Institute of Neurology). From (Bercsenyi et al., 
2014). Reused with permission from AAAS. 
2.4.1.4 Movie 4. Additional nidogen-1 speeds up the progression of tetanic 
paralysis 
The triceps surae muscle was injected with lethal dose of TeNT (1.5 ng/kg) 
intraperitoneally. 24 h post-injection wild type mice were showing typical signs of 
early general tetanus (stiff muscles, hyperventilation and delay in exploration), 
while nidogen-2 KO animals have a close to normal posture, breath normally and 
explore their surrounding without delay (see also Figure 4-13). The video was 
taken with the help of N. Schmieg (Cancer Research UK, London Research 
Institute). 
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Chapter 3. The N1 peptide blocks tetanic paralysis 
3.1 YEW peptide screening for TeNT binding 
It was proposed that protein receptors play a role in CNT binding at the NMJ 
alongside polysialogangliosides (Montecucco, 1986, Rummel et al., 2007). There 
are several arguments indicating that a protein is likely to play part in the process of 
TeNT binding: 
1. Firstly, polysialogangliosides are highly abundant acidic lipids, 
decorating all neuronal membranes, and binding to these alone 
cannot provide specificity to the motor neuron membrane.  
2. Moreover, the affinity of TeNT to polysialogangliosides is in the 
nanomolar range, whereas it binds to neuronal membranes at 
femtomolar concentrations, making it lethal at very low doses 
(Habermann and Dreyer, 1986). 
 
A tripeptide (YEW) was crystallised in the ‘R’ site of HCT, where sialic acid 
was previously shown to bind (Figure 3-1 A)(Jayaraman et al., 2005). This work 
brought up the possibility that a protein receptor could engage with this site 
simultaneously with gangliosides binding to the lactose site, and this dual receptor 
complex could provide a very efficient, high affinity-binding platform for TeNT at the 
neuromuscular junction (Rummel et al., 2003, Rummel et al., 2007).  
To investigate whether a protein containing the YEW motif, or its variants 
binds to this site, we queried a list of candidate receptors from an HCT magnetic 
pull-down screen performed in our laboratory for the presence of YEW like 
sequences (Deinhardt et al., 2006b). In the screen, HCT was conjugated to 
magnetic beads, allowed to internalise in primary motor neurons and endosomes 
containing this probe were purified on a magnetic column, lysed and subjected to 
mass spectrometry analysis to determine their molecular composition (Figure 3-1 
B). 
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Figure 3-1. The YEW peptide binds to HCT and the HCT carriers’ main 
components are transmembrane and extracellular proteins 
(A) HCT was co-crystallised with the tripeptide, YEW bound in the ‘R’ site (1YXW). The 
YEW peptide is highlighted with the ball and stick model (Jayaraman et al., 2005). (B) 
The composition of HCT carriers in motor neurons. HCT was coupled to magnetic beads 
and the endosomes containing this probe were purified using a magnet. The 
composition of the endosomes was determined by mass spectrometry analysis 
(Deinhardt et al., 2006b, Wade et al., 2012). 
 
Candidates, in which the putative binding motif was found within the luminal 
part of the endosomes (topologically equivalent to the extracellular side of the PM) 
were carried forward and subjected to a series of tests for binding to HCT. The 
Peptide Synthesis Service, Cancer Research UK London Research Institute 
synthesised 9mer peptides containing the YEW motif in the middle with biotin tag at 
their amino terminal and purified these peptides by high-performance liquid 
chromatography (HPLC) (Table 12). I then performed a fluorescent binding assay, 
an enzyme-linked immunosorbent assay (ELISA) and an in vitro pull-down assay to 
test these peptides for HCT binding. 
  
cytoplasmic/
transmembrane/
extracellular
keratins ribosomal
mitochondria/peroxysome
nuclear
216 (62.1%)
48 (13.8%)
37 (10.6%)
30 (8.6%)
17 (4.9%)
B
Y
W
E
A
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Table 12. Components of signalling endosomes containing variants of the YEW 
motif 
The peptide sequences are shown on the right, while the unique identifiers are shown 
on the left. Peptides binding to HCT in any of the in vitro assays (Figure 3-2, Figure 3-3 
and Figure 3-4) are in bold, and the N1 (nidogen-1) and N2 (nidogen-2) peptides are in 
red. The YEW-like motif is underlined. 
 
Peptide Gene name Sequence 
A Coxsackievirus and adenovirus receptor homolog PLQFEWQKL 
B glypican-4 DLDFEWNNF 
C neural cell adhesion molecule 1 VAVYTWEGN 
D nicastrin SRSFFWNVA 
DA nicastrin SRSFFANVA 
DAA nicastrin SRSAFANVA 
D3 nicastrin LYEYSWVQG 
E Poliovirus receptor-related protein 2/Nectin-2 PTDYDWSTT 
F msn KIGFPWSEI 
G sodium/potassium-transporting ATPase subunit a1 ILEYTWLEA 
H sodium/potassium-transporting ATPase subunit a3 ILGYTWLEA 
I V-dependent calcium channel subunit a2/d1 NRTYTWTPV 
J Vdac3 voltage gated anion channel PTIYGWAVL 
JAA vdac3 voltage gated anion channel PTIAGAAVL 
K V-dependent anion-selective channel protein 1 ETKYRWTEY 
L V-dependent anion-selective channel protein 2  ETKYKWCEY 
N1 nidogen-1 THIYQWRQT 
N1AA nidogen-1 THIAQARQT 
N2 nidogen-2 NQTWSYHID 
N2AA nidogen-2 NQTASAHID 
N3 nidogen-1 LVGFLWKSN 
N3AA nidogen-1 LVGALAKSN 
N4 nidogen-1 STGYCWCVD 
ND3-1 nidogen-2 GGLFGWLFA 
ND3-2 nidogen-2 STGFCWCVD 
ND3-3 nidogen-2 KSDFCWCVD 
ND3-5 nidogen-2 KEFYHYRDS 
O lysosome membrane protein 2 GLIFTWLAC 
P putative phospholipase B-like 2 CPPFQWSKS 
R St13 Hsc70-interacting protein AQPYKWRGK 
SV2A SV2A IPHYGWSFQ 
SV2B SV2B IPHYGWGFS 
SV2C SV2C IPHYGWSFS 
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3.1.1 D, N1 and N3 peptides bind HCT in a fluorescent binding assay  
For the fluorescent binding assay, the peptides were immobilised on the 
surface of a black 96-well plate and AlexaFluor555-HCT was added to the wells 
following blocking with 2% bovine serum albumin (BSA) in tris-buffered saline pH 
7.4 (TBS). The wells were washed extensively with TBS and fluorescence intensity 
was determined, which correlates with the amount of AlexaFluor555-HCT bound to 
the peptides. The percentage of maximal binding in 3 experiments was pooled 
together to get a correct representation of the binding intensity. Peptides D, N1 and 
N3 bound AlexaFluor555-HCT with N1 being the only one significantly different from 
the TBS control; the other peptides did not display any binding (Figure 3-2).  
 
 
Figure 3-2. Peptides from nicastrin and nidogen-1 bind to HCT in a fluorescent 
binding assay 
In vitro screen for peptides binding AlexaFluor555-HCT (see Table 12). In every 
experiment, the highest value was set at 100% and the results of 3 experiments were 
pooled together. The data was analysed with Friedman test followed by Dunn’s 
multiple comparisons test against TBS control (n=3; *, p<0.05; error bar: SD). Modified 
from (Bercsenyi et al., 2014). Reprinted with permission from AAAS. 
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3.1.2 D, J, N1, N3 and O peptides bind HCT in an in vitro pull-down assay 
To test whether the peptides can bind HCT on the surface of beads, we used 
an in vitro pull-down assay. The biotinylated peptides were bound to streptavidin 
coated agarose bead and blocked with BSA; these were then incubated with 
VSVG-HCT (vesicular stomatitis virus glycoprotein tag) on a rotating wheel. 
Following a series of washes, the beads were lysed and the supernatant was 
subjected to sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) and immunoblotting with anti-VSVG tag antibody (Figure 3-3 A). The 
intensity of the bands was measured and the percentage of maximal binding in 3 
experiments was pooled together to get a correct representation of the binding 
intensity. The mutant peptide DA showed equal binding compared to its wild type 
counterparts, D and D2 (both peptides are the same sequence, for internal control 
during the screen); while the double alanine substitution of amino acids F and W 
(DAA) abolished binding. Surprisingly, the J peptide binds VSVG-HCT the strongest 
in this assay and the double substitution of amino acids Y and W to A (JAA) blocks 
this peptide from binding. Both the N1 and N3 peptides bind VSVG-HCT, but not 
their double alanine mutants (N1AA and N3AA, respectively). The O peptide also 
emerged as a candidate in this assay, as it pulls down VSVG-HCT, albeit not 
significantly more than the empty beads. The peptides from SV2A and SV2C 
showed a low degree of binding compared with the other peptides (Figure 3-3 B). 
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Figure 3-3. The same peptides show strong binding to HCT in an in vitro pull-
down assay as in an the fluorescent binding assay 
Selected biotin-tagged peptides containing variants of the YEW motif and their alanine 
mutants (see Table 12) were bound to streptavidin beads and incubated with 
recombinant VSVG-tagged HCT. (A) After washing, the captured HCT was eluted from 
the beads, subjected to SDS-PAGE and detected by western blotting. One 
representative experiment is shown. (B) Band intensity was determined by 
densitometry using ImageJ. The results were normalised to empty beads and the 
maximal value was set at 100% in each experiment. The final results were analysed 
using paired t-test comparing the peptide bound beads to the empty bead (TBS) 
control (n=3 for wild type peptides, n=2 for mutants; *, p<0.05, **, p<0.01; error bars: 
SD). Modified from (Bercsenyi et al., 2014). Reprinted with permission from AAAS. 
 
3.1.3 Only the N1 peptide shows specific binding to HCT in an ELISA 
For the ELISA, the peptides were immobilised on the bottom of the wells 
before adding VSVG-HCT. Following several washes, VSVG-HCT was revealed 
using a mouse antibody against VSVG and an HRP-conjugated goat anti-mouse 
secondary antibody. I noticed that the anti-VSVG antibody bound unspecifically to 
some of the peptides, so in control samples VSVG-HCT was omitted (blank). These 
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blank values were subtracted from the experimental readings. Among the top 
candidates, only the N1 peptide showed significant binding to VSVG-HCT (Figure 
3-4). 
 
 
Figure 3-4. The N1 peptide is the top candidate for HCT binding in ELISA 
Selected peptides (see Table 12) were dried on 96-well plates, blocked for non–
specific binding and incubated with VSVG-tagged HCT, which was detected by ELISA 
at 490 nm using TBS as a control. Results were normalised to samples where HCT was 
omitted and analysed for statistical significance using paired t-test (n=3; *, p<0.05; 
error bars: SD). Modified from (Bercsenyi et al., 2014). Reprinted with permission from 
AAAS. 
 
3.2 The N1 and N2 peptides block HCT binding on primary 
motor neurons 
One of the aims of this study was to find a potential blocking agent to fight 
tetanus. The N1 peptide originates from nidogen-1 and there are two nidogen 
isoforms in mammals. There is a very similar peptide to N1 in the corresponding 
region of nidogen-2, which has an inverted sequence. We included this peptide 
(N2) in further analyses (Table 12). To determine which peptides were capable of 
blocking HCT internalisation in primary motor neurons, the peptides were 
preincubated with AlexaFluor555-HCT and the mixture was added to primary motor 
neuron cultures (DIV 7-10) at 37 °C and after 45 min to allow internalisation. The 
cells were washed with Hank's Balanced Salt Solution (HBSS) then fixed with 4% 
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paraformaldehyde (PFA) for 15 min at room temperature. The coverslips were 
mounted in Mowiol and imaged to determine the extent of AlexaFluor555-HCT 
internalisation (Figure 3-5). The D peptide caused aggregation of AlexaFluor555-
HCT, while the J and N3 peptides did not have a significant effect on the amount of 
probe internalised compared to the dimethylsulfoxide (DMSO)-treated control 
sample. The N1 and N2 peptides both caused a dramatic decrease in the 
internalised pool of AlexaFluor555-HCT, while the double alanine mutant of N1 
(N1AA) did not have any effect. The finding that both peptides from the same 
regions of nidogens block HCT internalisation in motor neurons suggests that both 
nidogen-1 and -2 could potentially act as protein receptors for TeNT at the NMJ. 
 
 
Figure 3-5. The N1 and N2 peptides block HCT internalisation on primary motor 
neurons 
AlexaFluor555-HCT was preincubated with peptides D, J, O, N3, N1, N1AA and N2, or 
vehicle control (DMSO) and it was added to primary motor neurons at 37°C for 45 
minutes. The cells were acid washed on ice, then fixed and imaged on a confocal 
microscope. Scale bar: D, N1, N1AA, N2, DMSO: 20 µm; J, O, N3: 10 µm. From 
(Bercsenyi et al., 2014). Reprinted with permission from AAAS. 
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3.3 Biomolecular analysis of the interaction between HCT and 
the N peptides 
3.3.1 Peptide array – an attempt to identify a synthetic peptide with the 
highest possible affinity for TeNT 
To determine the specificity of the nidogen-binding motif, we designed a 
peptide array, where the four key residues in both the N1 and N2 peptides (YEWR 
and TWSY, respectively, Table 12) were modified with single substitution to all 20 
natural amino acids. Dhira Joshi in the Peptide Synthesis Service, Cancer 
Research UK London Research Institute prepared the array. I incubated the array 
with AlexaFluor555-HCT for 1 h at room temperature. After several washes with 
TBS, a Typhoon gel reader was used to measure the amount of AlexaFluor555-
HCT bound to the peptide spots. 
Unfortunately there was a huge variability between the peptide content of 
each spot and this made the assay non-quantitative and hard to reproduce. Due to 
these limitations we could only conclude that the R residue within the N1 peptide 
can solely be replaced by a K and no other amino acids to retain its binding ability 
(Figure 3-6 C). Since all four residues are highly conserved among all species with 
known sensitivity to tetanus, we could not contemplate on the potential effect of this 
substitution in vivo (Figure 3-6 A, Table 13). 
We also noted that if the W residue in the N2 peptide is replaced with an R 
or a Q, the peptide loses its binding ability (Figure 3-6 D). When comparing the 
amino acid sequence of the corresponding region in nidogen-2 in species with 
known sensitivity to tetanus, we found that in Rattus norvegicus (rat) this residue is 
replaced with an R, making the protein potentially unable to bind TeNT (Figure 3-6 
B, Table 14). This could explain why rats are partially insensitive to tetanus 
intoxication (Rozanova, 1964). 
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Table 13. Sequence conservation of the N1 peptide region of nidogen-1 among 
species with known sensitivity to tetanus 
The last 6 residues, including the 4 key residues (YQWR) are highly conserved among 
vertebrates. Substitutions compared to the mouse sequence are highlighted in red. 
 
Mus Musculus Mouse T H I Y Q W R Q T 
Rattus norvegicus Rat T H I Y Q W R Q T 
Cricetulus griseus Chinese hamster T H I Y Q W R Q T 
Homo sapiens Human I Y T Y Q W R Q T 
Pongo abelii Orangutan I Y T Y Q W R Q T 
Pan troglodytes Chimpanzee I Y T Y Q W R Q T 
Callithrix jacchus Marmoset I Y T Y Q W R Q T 
Nomascus leucogenys Gibbon V Y T Y Q W R Q T 
Sus scrofa Wild Boar V H I Y Q W R Q T 
Heterocephalus glaber  Mole rat T Y T Y Q W R Q T 
Meleagris gallopavo Turkey T G A Y Q W R Q T 
Canis lupus Dog I Y T Y Q W R Q T 
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Table 14. Sequence conservation of the N2 peptide region of nidogen-2 among 
species with known sensitivity to tetanus 
Substitutions are highlighted in red. The 4 middle residues (WSYH) are less conserved 
among vertebrates than those of nidogen-1. The substitution of W to R or Q 
(highlighted in blue) lead to a potential loss of binding between nidogen-2 and TeNT 
and this might explain the low sensitivity of these species to tetanus intoxication. 
	   	   	   	   	   	   	   	   	   	   	  Mus Musculus Mouse N Q T W S Y H I D Q 
Rattus norvegicus Rat N Q T R S Y R I D Q 
Cricetulus griseus Chinese hamster N Q T W S Y H I D Q 
Homo sapiens Human N Q T W S Y H I H Q 
Pongo abelii Orangutan N Q T W S Y H I H Q 
Pan troglodytes Chimpanzee N Q T W S Y H I H Q 
Callithrix jacchus Marmoset N Q T W S Y R V H Q 
Nomascus leucogenys Gibbon N Q T W S Y R I H Q 
Bos taurus Bull N Q T Q T Y R I H Q 
Sus scrofa Wild boar N Q T R S Y S I H Q 
Heterocephalus glaber  Mole rat N Q T G S Y R V H Q 
Meleagris gallopavo Turkey N Q T L S Y R L H Q 
Canis lupus Dog N Q T R S Y R I Y Q 
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Figure 3-6. Peptide array to refine the binding motif of the N1 and N2 peptides 
(A,B) We analysed the sequence of the corresponding region of nidogen-1 in a variety 
of species. (A) The last six amino acids, including the three key residues of the N1 
peptide (YQW) are conserved from fish to humans. (B) Nidogen-2 is less conserved in 
the putative binding region (TWSY) than nidogen-1, the W is substituted with four 
different amino acids, S can be replaced with a T and the Y is highly conserved. (C) 
Representative result of a peptide array on the N1 peptide. The weblogo diagram 
shows the probability of a certain residue to be present at the given position and still 
bind HCT. R in position 7 can only be substituted with a K, this residue must play a key 
role in HCT binding (n=3 experiments, all the positive peptides were represented in the 
weblogo diagram). The double alanine mutant (AQAR) does not bind HCT in this assay 
(data not shown), which is expected based on the results of the previous binding 
assays. (D) Representative result of a peptide array on the N2 peptide. Due to the 
variability between experiments, none of the residues appear to be irreplaceable 
without affecting HCT binding. However, W cannot be replaced by a Q or R, which are 
present in this position in nidogen-2 in cows and rats. 
 
Despite the high conservation within this region of nidogens, there are 
subtle differences between the human and murine sequences, so we also tested if 
the human peptides bind HCT. Based on the fluorescent binding assay, the human 
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versions of both N1 and N2 (hN1 and hN2, respectively) bind HCT, but significantly 
less than their murine counterparts (Figure 3-7)  
To further elucidate the importance of each residue within the murine 
peptides in a more quantitative manner, single alanine mutants of the 3 residues 
forming the YEW-like motif and the flanking residues, R (N1) and H (N2) were 
synthesised. Binding was assessed using the fluorescent binding assay as before 
(Figure 3-2). The double alanine mutants of both the N1 and N2 peptides (N1AA, 
N2AA, respectively) show no binding to HCT. Single alanine substitution of the W in 
both peptides (N1WA, N2WA) completely abolished HCT binding, while alanine 
substitution of the other residues caused a smaller, yet significant decrease (Figure 
3-7 B). The effect of alanine substitution of W is in agreement with the peptide 
array for N2, but it is different for N1.  
 
Figure 3-7. Single alanine mutants of the N1 and N2 peptides bind HCT less than 
their wild type counterparts 
(A) There is a high level of conservation between human and murine nidogens, but the 
first three residues of the N1 peptide are replaced with IYT in humans, while there is a 
DH substitution in N2, which is predicted to bind HCT with less efficiency based on 
Figure 3-6 A. (B) The double alanine mutant (N1AA) and the single alanine mutant 
(N1WA) do not bind HCT, while other alanine substitutions show a varied degree of 
decrease in HCT binding compared to the N1 peptide. The human N1 peptide (hN1) 
binds HCT, but less efficiently than the murine N1 peptide (N1). (C) The single alanine 
mutants of N2 bind significantly less HCT than N2. The human N2 peptide (hN2) binds 
HCT but with a lower affinity than the murine N2. Repeated measures one-way ANOVA 
(****, p<0.001), followed by Dunnett’s multiple comparisons test against the wild type 
murine peptides was used to assess significance (n=2, **, p<0.01; ****, p<0.001, error 
bars: SD). From (Bercsenyi et al., 2014). Reprinted with permission from AAAS. 
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3.3.2 Biomolecular modelling reveals the docking site of the N1 peptide 
Next, to test whether it is possible to saturate the interaction between the N1 
peptide and HCT, I performed a titration fluorescent assay, where AlexaFluor555-
HCT was incubated with immobilised peptides at increasing molar ratio (Figure 3-8 
A). The YEW peptide, which was previously co-crystallised with HCT (Jayaraman et 
al., 2005), was used as a positive control (Figure 3-8 A, blue line). The N1 peptide 
displayed a stronger binding (Figure 3-8 A, red line) than the YEW peptide, which 
indicated that its affinity to HCT must be high enough to allow co-crystallisation. 
However, the HCT-YEW co-crystal was obtained at pH 5, hence N1 interaction 
must be preserved at low pH to allow co-crystallisation. To test this, the incubation 
was run at pH 5 (Figure 3-8 A, yellow line), which simulated the conditions used for 
crystallisation. Unfortunately the binding between HCT and N1 appeared to be 
highly sensitive to changes in pH. This might be a physiological property of this 
complex and be required during tetanus intoxication; in particular, the acidic pH 
triggers the insertion of the N terminal part of the heavy chain into the endosomal 
membrane and the translocation of the L chain into the cytosol. In contrast to N1, 
the N1AA peptide does not bind to HCT in this assay, further proving the importance 
of the Y and W residues in this interaction (Figure 3-8 A, orange line).  
 We made a number of attempts at determining the Kd between the N1 
peptide and HCT but the results were inconclusive. In our hands, the most reliable 
approach was isothermal calorimetry (ITC), in which the N1 peptide solution (150 
µM) was injected into a bath of HCT (15 µM) and the thermal changes occurring 
during the interaction were measured under these experimental conditions at 37°C 
(Figure 3-8 D). The reaction was found to be exothermic with an estimated Kd of 
7.4±0.11 µM. This is surprisingly low considering the results of previous binding 
experiments. The HCT solution was tested for the presence of dimers with dynamic 
light scattering (DLS, data not shown) and it was mainly monomeric. Based on this 
analysis there is only one binding site for the N1 peptide on HCT, which is in 
agreement with the results of biomolecular modelling.  
Following unsuccessful attempts at the crystallisation of the complex, we 
turned to biomolecular modelling to gain deeper insights on the molecular details of 
binding. G. Zanotti (University of Padua) performed this analysis, which revealed 
that the N1 peptide is able to dock to the ‘R’ site of HCT, where sialic acid, 
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disialyllactose and the tri-peptide YEW, bind (Jayaraman et al., 2005). The surface 
concealed by the formation of the N1 peptide-HCT complex is predicted to be 518 
Å2 for the HCT domain and 592 Å2 for the N1 peptide (Figure 3-8 C). This site is 
located on the opposite side of the main binding domain for polysialogangliosides, 
which have an established role as clostridial neurotoxin co-receptors (Binz and 
Rummel, 2009), thus it should not interfere with ganglioside binding. The molecular 
surface predicted to be concealed by the N1 peptide-HCT complex constitutes more 
than 40% of the total peptide surface (Figure 3-8 C), suggesting that this interaction, 
which is driven by the potential formation of five hydrogen bonds and other polar 
interactions (Table 15) is very strong. 
  
  
Chapter 3 Results 
 
 93 
 
Figure 3-8. Molecular modelling of the interaction between the N1 peptide bound 
to HCT 
(A) Binding assay of fluorescent HCT to immobilised peptides. The pH of the incubation 
buffer was changed to pH 5 (yellow line) to test if the binding between the N1 peptide 
and HCT is pH sensitive. (B) Polynomial regression analysis on an isothermal 
calorimetry recording where the N1 peptide was injected into the sample cell containing 
HCT. The Kd is estimated to be 7.4±0.11 µM with one binding site on HCT. (C) Details 
of the crystal structure of HCT (orange) bound to peptide N1 (green, stick model; PDB 
code 1XYW (Jayaraman et al., 2005)). The N1 peptide was built using Coot, the 
glutamic acid of the YEW sequence present in the PDB structure 1XYW (Jayaraman et 
al., 2005) was replaced with a glutamine; the remaining residues (THI---RQT) were 
manually built and adjusted inside the crevice of the toxin. The modelling was 
performed by G. Zanotti (University of Padova). From (Bercsenyi et al., 2014). 
Reprinted with permission from AAAS. 
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Table 15. Potential hydrogen bonds and other polar interactions between HCT (A) 
and the N1 peptide from nidogen-1 (P)  
The predicted distance between the interacting residues is indicated. Distances must 
be considered as indicative, since they are based on a theoretical model. Contacts and 
concealed surfaces were calculated with server PISA (http://www.ebi.ac.uk). These 
calculation are based on the model shown in Figure 3-8 were performed by G. Zanotti 
(University of Padova). From (Bercsenyi et al., 2014). Reprinted with permission from 
AAAS. 
 
Bond HCT Distance (Å) 
nidogen-1 
(N1 peptide) 
H-bond    
1 A:ASP1214[OD2] 2.81 P:THR1[OG1] 
2 A:ARG1226[NE] 3.47 P:GLN5[OE1] 
3 A:LYS1143[NZ] 2.91 P:GLN8[OE1] 
4 A:LYS1143[NZ] 3.22 P:GLN8[O] 
5 A:ASP1278[OD1] 3.08 P:GLN8[NE2] 
Polar    
6 A:ILE1224[O] Via a water molecule P:GLN5[OE1] 
7 A:LYS1213[O] Via a water molecule P:ILE3[O] 
8 A:GLY1233[ O ] 3.15 P:HIS2[ND1] 
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3.4 The N1 peptide blocks HCT uptake in situ 
To test whether the N1 peptide can significantly block HCT binding, the cells 
were cooled on ice before adding AlexaFluor555-HCT for 10 min. Because this 
temperature does not allow internalisation, AlexaFluor555-HCT decorates the 
membrane, but it is not taken up by the neurons. Following washes with HBSS and 
fixing with 4% paraformaldehyde (PFA) for 15 min at room temperature, the cells 
were permeabilised using phosphate buffered saline (PBS) containing 0.01% 
Triton-X for 10 min at room temperature. To avoid non-specific staining from the 
antibodies, the cells were blocked with 5% bovine serum albumin (BSA) in PBS 
(immunofluorescence blocking buffer, IFBB) for 1 h at room temperature and 
stained for βIII tubulin, a specific marker of neuronal microtubules, prior to imaging. 
A mouse anti-βIII tubulin was added to cells in IFBB for 1 h at room temperature. 
The excess of primary antibody was washed off with multiple rounds of PBS 
washes before adding goat AlexaFluor488-anti-mouse secondary antibody to 
reveal the βIII tubulin staining. Unbound secondary antibody were removed with 
PBS washes and the coverslips were mounted in Mowiol. βIII tubulin staining was 
used as a mask in Cell Profiler to identify neurons and the fluorescence intensity of 
AlexaFluor555-HCT was measured. The N1 peptide significantly blocked HCT 
binding, while its alanine mutant (N1AA), did not have a significant effect (Figure 
3-9). The N1 peptide does not only bind to HCT, but it is able to block its interaction 
with its cell surface receptor(s). 
Next, I wanted to test whether the N1 peptide can interfere with HCT 
internalisation. AlexaFluor555-HCT was incubated on primary motor neurons and 
DMSO, the N1 or the N1AA peptide was added either together with the probe or 
with a delay of 10 min. The experiment was performed at 37°C for 45 min, which 
allows the internalisation of HCT. The presence of the N1 peptide decreases HCT 
internalisation in the absence of preincubation (Figure 3-10), and even when it is 
added with a 10 min delay (Figure 3-11). These results indicate that the peptide 
successfully competes with the endogenous receptor(s) of HCT and stops it from 
entering motor neurons.  
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Figure 3-9. The N1 peptide significantly blocks HCT binding on primary motor 
neurons 
(A) AlexaFluor555-HCT was preincubated with DMSO (vehicle control, HCT alone) or 
wild type and mutant N1 peptides for 1 h at room temperature and added to primary 
motor neurons on ice before staining for βIII tubulin and confocal imaging. (B) Twenty 
images were taken for each condition and fluorescence intensity of AlexaFluor555-HCT 
bound to neurons (βIII tubulin mask) was quantified. Results were tested for statistical 
significance using one-way ANOVA (****, p<0.001) followed by Dunnett’s multiple 
comparisons test (n=3; NS, non significant; ****, p<0.001; error bar: SEM). Scale bar, 
40 µm. Modified from (Bercsenyi et al., 2014). Reprinted with permission from AAAS. 
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Figure 3-10. The N1 peptide blocks HCT entry into motor neurons when added 
simultaneously to the medium 
(A) AlexaFluor555-HCT was added to primary motor neurons before adding DMSO 
(vehicle control; HCT alone), N1 or N1AA peptides to the medium for 45 min at 37°C. 
The cells were then washed and stained for βIII tubulin and imaged on a confocal 
microscope. (B) Three tile scans of 16 images were taken for every condition, and 
fluorescence intensity of AlexaFluor555-HCT internalised in neurons (βIII tubulin mask) 
was quantified. Results were tested for statistical significance using one-way ANOVA 
(***, p<0.005) followed by Dunnett’s multiple comparisons test. (n=3; NS, non 
significant; ***, p<0.005; error bar: SD). Scale bar, 10 µm. Modified from (Bercsenyi et 
al., 2014). Reprinted with permission from AAAS. 
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Figure 3-11. The N1 peptide blocks HCT entry into motor neurons when added to 
the medium with a 10 min delay 
(A) AlexaFluor555-HCT was added to primary motor neurons before adding vehicle 
control (HCT alone), wild type or mutant N1 peptides with a delay of 10 min. The total 
length of the incubation was 45 min at 37°C. The cells were then washed and stained 
for βIII tubulin and imaged on a confocal microscope. (B) Three tile scans of 16 images 
were taken for every condition, and fluorescence intensity of AlexaFluor555-HCT 
internalised in neurons (βIII tubulin mask) was quantified. Results were tested for 
statistical significance using one-way ANOVA (***, p<0.005) followed by Dunnett’s 
multiple comparisons test. (n=3; NS, non significant; **, p<0.001; error bar: SD). Scale 
bar, 10 µm. Modified from (Bercsenyi et al., 2014). Reprinted with permission from 
AAAS. 
3.5 The N1 peptide is a potent inhibitor of tetanic paralysis in 
vivo  
3.5.1 The N1 peptide blocks HCT binding at the NMJ 
Next, I wanted to test if the N1 peptide was capable of blocking HCT from 
binding to the NMJ. To do this, I isolated levator auris longus (LAL) muscles from 
wild type adult mice. These muscles are extremely thin (only a couple of cell layers) 
and can be incubated with HCT in a motor neuron medium bath without sectioning. 
However, due to the lack of transcardial perfusion, the strong autofluorescence of 
haemoglobin makes imaging more challenging (Figure 3-12).  
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Figure 3-12. BTX labels NMJs in the LAL muscle 
Levator auris longus (LAL) muscles of adult mice were dissected, fixed and stained 
with AlexaFluor555-BTX (pseudocolored in green) to label NMJs. Due to the lack of 
transcardial perfusion, there is a high background in the 488 channel 
(autofluorescence). Scale bar: 10 µm. 
 
The muscles were incubated with HA-HCT, which was preincubated either 
with DMSO (HCT alone), N1 or N1AA, washed, fixed and stained for HA with a rat 
anti-HA primary antibody followed by a donkey AlexaFluor488-anti rat secondary 
antibody and AlexaFluor555-α-Bungarotoxin (BTX) to label the NMJs. There is a 
big variability among NMJs in their HCT binding ability (63.6±6.0% SEM bind HCT), 
but preincubation with the N1 peptide significantly reduces the ratio of HCT positive 
NMJs (14.3±4.7% SEM, Figure 3-13).  
 
BTX autofluorescence (488 nm)
Chapter 3 Results 
 
 100 
 
Figure 3-13. The N1 peptide significantly blocks HCT binding at the NMJ 
LAL muscles were incubated with HCT pretreated with DMSO (HCT alone), N1 or N1AA. 
Samples were then washed, fixed and counterstained with AlexaFluor555-α-BTX 
(pseudocolored in green) and a rat monoclonal antibody against HA (pseudocolored in 
grey). Low magnification images were taken and the number of HCT positive vs. HCT 
negative NMJs was determined. The results were plotted and tested for significance by 
Kruskal-Wallis test (**, p<0.001) followed by Dunn’s multiple comparisons test. (NS, 
non significant; ****, p<0.001; n=3 experiments, >100 NMJs per condition). Scale bar: 
10 µm. Modified from (Bercsenyi et al., 2014). Reprinted with permission from AAAS. 
 
3.5.2 The N1 peptide blocks tetanic paralysis on hemidiaphragm 
preparations 
Mouse phrenic nerve-hemidiaphragm (HD) preparations were extensively 
used in the field to test the action of TeNT and BoNTs and it is considered as a 
reliable alternative to in vivo mouse experiments. To test the effect of the N1 
peptide preincubation on the toxicity of TeNT, two HD preparations were isolated 
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from mice; one was submersed in Ringer solution containing TeNT (5 nM) 
preincubated with DMSO, the other was submersed in Ringer solution containing 
TeNT preincubated with the N1 or the N2 peptide, which were previously dissolved 
in DMSO. The phrenic nerve was stimulated with supramaximal stimuli and muscle 
contraction was monitored with an isometric transducer. Muscular twitch was 
monitored until complete paralysis and the time required to decrease the twitch to 
50% of the initial value (paralytic half-time) was recorded. P. Caccin (University of 
Padova) performed the experiment. The N1 peptide increased the time for 
achieving complete paralysis, while the N2 peptide appeared to have the opposite 
effect (Figure 3-14). These differences were not significant. It has to be noted 
however, that this is not the most reliable assay to assess TeNT activity, since it is 
based on local TeNT-mediated paralysis (NMJ based), which occurs independently 
of the physiologically targeted interneurons. When used at high doses, the normal 
entry and transport pathway of TeNT is over-saturated and the toxin enters via an 
alternative route, enabling it to cleave synaptobrevin (VAMP2) at the NMJ. This in 
turn leads to the silencing of the motor neuron and the subsequent paralysis of the 
muscle. 
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Figure 3-14. The N1 peptide prolongs tetanic paralysis half time, while the N2 
peptide has a mild acceleration effect. 
TeNT preincubated with vehicle control (DMSO), or the indicated peptides was added 
to HD preparation in Krebs-Ringer solution at 37°C. Muscle twitch was induced by 
nerve stimulation and paralysis times were monitored. Data is expressed as paralysis 
half time and reported as paired observations (n=4). Modified from (Bercsenyi et al., 
2014). Reprinted with permission from AAAS. 
 
3.5.3 Treatment of native TeNT with the N1 peptide prior injection prevents 
the appearance of tetanic paralysis in the triceps surae muscle 
Since the N1 peptide is capable of blocking HCT binding at the NMJ as well 
as on primary motor neurons, we wanted to test if the pre-treatment of native TeNT 
with the N1 peptide was sufficient to block its entry into motor neurons and the 
following tetanic paralysis. Age- and weight-matched adult C57Bl6 mice were 
injected with the sub-lethal dose of 1 or 2 ng/kg TeNT (8 µl total volume per 20 g 
body mass) in the right triceps surae muscle. Prior to the injection, TeNT was 
incubated with DMSO, the N1 or the N1AA peptide. The administration of this dose 
causes local tetanus, which leads to coordination defects at an early stage of the 
pathology (Figure 3-15) followed by spastic paralysis of the injected hindlimb 
(Figure 3-16). To assess the coordination defects of these mice in a quantitative 
manner, I used the footprint assay (Carter et al., 1999). The experiment was 
performed with the help of Francesco Giribaldi (Molecular Neuropathobiology 
Laboratory). The paw of the injected hindlimb was painted red, while all the other 
paws were painted black. Mice were then allowed to walk along a white stripe of 
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paper (Figure 3-15 A,B). When mice walk, the hind paw is always placed very close 
(d≃0.5 cm) to the position of the front paw during the previous step. This distance 
increases when the mice display coordination defects. The coordination of mice in 
groups TeNT+DMSO and TeNT+N1AA at 24 h post-injection was significantly worse 
than the non-injected group (control), when 2 ng/kg dose of TeNT was used. In 
contrast, the TeNT+N1 peptide group showed no significant change in coordination 
at this time point (Figure 3-15 C). Pre-treatment of TeNT with the N1 peptide 
prevented tetanic paralysis at both doses. 
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Figure 3-15. Preincubation with the N1 peptide prevents the coordination defects 
observed in mice injected with TeNT 
The right triceps surae muscle was injected with either 1 or 2 ng/kg of TeNT, following 
preincubation with DMSO as a vehicle control, N1AA or N1 peptide. (A) 24 h after 
injection, a footprint analysis was performed where the paw of the injected leg was 
painted red, while all the other paws were painted black. (B) Mice were let to walk on a 
white stripe of paper, and the coordination (distance between the prints on the same 
side) was measured (red circle: hind paw, black circle: front paw, only the group, which 
received a 2ng/kg dose is shown). (C) Data were analysed using one-way ANOVA 
followed by Dunnett’s multiple comparisons test to compare the groups to the control 
value. Following termination, triceps surae muscles were dissected and weighed to 
determine whether the administered dose based on total body weight was in 
accordance with the dose/mg muscle. (n=2; NS, non significant; **, p<0.01; ****, 
p<0.001; error bar: SD). Modified from (Bercsenyi et al., 2014). Reprinted with 
permission from AAAS. 
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Pictures were taken of the mice at 48 h post-injection. Strikingly, the N1 
peptide treated group did not show any symptoms of local tetanus. The injected leg 
of the DMSO and N1AA treated groups was completely paralysed at this time point; 
they were not able to grip the cage and moved around slowly and with great 
difficulty. In contrast to the other two groups, these mice were able display the grip-
reflex, did not extend their right hindlimb and they showed no delay in exploring the 
environment once they set free outside the cage (Figure 3-16, Movie 1). 
 
Figure 3-16. Posture of mice injected with TeNT preincubated with DMSO control, 
N1AA or the N1 peptide 
The triceps surae muscle was injected with 2 ng/kg TeNT intramuscularly and mice 
were photographed 48 h later. Both the DMSO and N1AA treated group showed severe 
local paralysis, while the N1 treated group appeared normal.  
  
TeNT+DMSO
TeNT+N1AA
TeNT+N1
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3.5.4 Treatment of native TeNT with the N1 peptide prior injection prevents 
the physiological effects of TeNT in the tibialis anterior muscle 
Next, I wanted to show using physiological methods that the N1 peptide 
prevents the appearance of tetanus symptoms by reducing tetanic paralysis of the 
muscle. To do this, 8-week-old weight matched C57Bl6 mice were injected with the 
sub-lethal dose of 0.125 ng/kg TeNT (4 µl total volume per 20 g body mass) in the 
right tibialis anterior (TA) muscle after preincubation with DMSO (vehicle control), 
N1AA or the N1 peptide. After 24 h, the mice were terminally anaesthetised and the 
isometric muscle tension force was recorded from the distal TA tendon following 
supramaximal electrical stimulation of the sciatic nerve. The injection and 
subsequent recordings were performed by J. B. Bryson (UCL-Institute of 
Neurology). The contractile force of the TeNT-injected muscle was minimal 
(3.11±0.88% SEM of non-injected control; Figure 3-17 A), as was the case for 
muscles co-injected with TeNT and the N1AA peptide (2.14±1.44% SEM of non-
injected control; Figure 3-17 B). However, co-administration of the N1 peptide 
significantly reduced the TeNT-mediated decline in contractile force compared to 
the other two groups (47.46±10.31% SEM of non-injected control; Figure 3-17 C). 
These results confirmed that the N1 peptide prevents symptoms of clinical tetanus 
by blocking the effect of TeNT on the muscle contraction. 
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Figure 3-17. Preincubation with the N1 peptide reduces the effect of TeNT on 
isometric muscle tension force 
The tibialis anterior (TA) muscle was injected with TeNT preincubated with either 
DMSO (vehicle control), N1AA or N1 peptides. Following anaesthesia, the tendon of the 
TA muscle was attached to a tension sensor, the peroneal nerve was stimulated and 
isometric muscle force was measured. (A-C) Representative isometric muscle force 
recordings obtained from the ipsilateral (ipsi; injected side) and contralateral (contra; 
non-injected internal control) TA muscles, 24 h after administration of TeNT 
preincubated with vehicle control (DMSO) (A), the N1AA peptide (B) or the N1 peptide 
(C). Ten-fold lower scale was applied to ipsilateral and contralateral traces in (A) and 
(B), while the scales are identical for both traces in (C). (D) Maximal muscle force was 
measured, normalised to muscle weight and tested for significance (control vs. injected 
muscle). The N1-treated group retained a significantly higher muscle force than the 
vehicle- or N1AA-treated groups. Significance was assessed by unpaired t-test 
comparing the DMSO, or N1AA treated group to the N1 treated group (n=6 mice per 
group; **, p<0.01; error bar: SD). From (Bercsenyi et al., 2014). Reprinted with 
permission from AAAS. 
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3.6 Summary 
• The N1 peptide emerged as the strongest and most reliable candidate in the 
initial peptide screen. 
• Both the N1 (nidogen-1) and N2 (nidogen-2) peptides block HCT binding and 
entry into primary motor neurons. 
• Single alanine mutation of the W residue abolished the interaction with HCT for 
both the N1 and N2 peptides. 
• The correspondent human N1 and N2 peptides bind HCT, but with lower affinity 
than the murine peptides. 
• The interaction between the N1 peptide and HCT is pH sensitive, suggesting a 
possible mechanism of dissociation of the complex in the endosomal lumen. 
• Based on biomolecular modelling, the N1 peptide fits into the ‘R’ pocket of HCT 
and over 40% of the surface of the peptide is involved in the interaction. 
• The Kd between N1 and HCT is in the low micromolar range based on 
isothermal calorimetry data. 
• The N1 peptide decreases HCT entry in primary motor neurons when added 
simultaneously, or even with a 10 min delay. 
• 65% of the NMJs of LAL muscle binds HCT. This is decreased to 18% when 
HCT is preincubated with the N1 peptide 
• The N1 peptide blocks the tetanic paralysis in the nerve-hemidiaphragm 
preparation. 
• The N1 peptide blocks tetanic paralysis in vivo.  
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Chapter 4. Nidogens are the protein receptors for 
tetanus toxin 
4.1 The N1 peptide is derived from an extracellular protein, 
nidogen-1  
The N1 peptide is present within the second globular domain (G2) of nidogen-1 ( 
Figure 4-1 A). This domain has a β-barrel structure and both the Y and W of the 
N1 peptide face the inner cavity of the barrel ( 
Figure 4-1 B, Table 12) (Hopf et al., 2001, Kvansakul et al., 2001). When 
nidogen-1 is in its intact form, these residues are not accessible to HCT. However, 
some of the metalloprotease cleavage products might have their YQWR motif 
exposed and available for HCT binding.  
 
 
Figure 4-1. Nidogen-1 contains a YEW-like domain 
(A) Module structure of nidogen-1 showing the position of the N1 peptide within the β-
barrel G2 domain (cyan; top). In addition to the G2 domain, nidogen-1 contains a 
nidogen domain (NIDO), six EGF-like domains (EGFs), a thyroglobulin type 1 domain 
(TG) and five low-density lipoprotein receptor (LY) domains. (B) Top and lateral view of 
the crystallised G2 domain of human nidogen-1 (1GL4). The YQW sequence is 
highlighted with the ball and stick model (Kvansakul et al., 2001).  
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4.2 The basal lamina (BL) of the NMJ 
Skeletal muscle is made up of multinucleated myofibrils that are innervated 
by motor neurons. The cell bodies of these neurons are located either in the 
brainstem or in the ventral horn of the spinal cord. Motor units are made up of the 
collection of myofibrils innervated by branches of one motor neuron axon. Each 
axonal branch innervates a particular patch on the muscle; these are called 
neuromuscular junctions (NMJs). The NMJ is a specialised synapse, with three 
major structural elements: the presynaptic membrane (the motor neuron end 
terminal), the synaptic cleft and the postsynaptic surface. All three compartments 
contain molecules, which are not found outside of the synapse. The synaptic cleft is 
filled with specialised extracellular matrix (sECM), which contains a thin acellular 
layer; the basal lamina (BL) (Hughes et al., 2006). The BL lies on the basal side of 
every epithelial cell, including cells derived from the neuroepithelium. It provides 
mechanical support for tissues, but it also acts as an important regulator of cell 
behaviour (Kalluri, 2003). The individual components of the BL regulate many 
different biological processes, such as cell division, migration, differentiation, shape 
maintenance and growth via cell surface receptors (Erickson and Couchman, 2000). 
The BL also binds and modulates the local concentration of cytokines, growth 
factors and neurotrophins (Hari et al., 2004, Clark, 2008, Hynes, 2009, di Summa 
et al., 2013). 
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Figure 4-2. Schematic representation of the basal lamina at the NMJ 
The NMJ is made up of three components: the presynaptic membrane, the synaptic 
cleft and the postsynaptic membrane. Schwann cells shield the NMJ on both sides, 
and their BL (green dashed line) appears to be anatomically continuous with the 
synaptic BL (orange dashed line), but their composition is dramatically different. The 
glial cells produce their own BL, while the motor neuron and the muscle release the 
components of the synaptic BL. The extrasynaptic BL (pink dashed line) is produced 
solely by the muscle and lacks some of the synaptic BL components (see Table 16). 
Recreated based on (Fox et al., 2008). 
 
There are four main ECM components: laminins, type IV collagens, HSPGs, 
such as syndecan and dallylike and nidogens. The BL at the NMJ contains a highly 
specialised combination of these four main proteins (Table 16).  
 
Table 16. Specialised ECM components at the NMJ basal lamina (Chiu and Ko, 
1994, Fox et al., 2008) 
Laminin Collagen HSPG Nidogens 
α2β2γ1 IV α3α4α5 syndecan-2 nidogen-2 
α4β2γ1 IV (α5)2α6 dallylike (Dlp) 
nidogen-1 
(9H6) 
α5β2γ1 XIII agrin z8  
Schwann cell
Motor neuron
end plate
Myofibril
Schwann cell BL
Extrasynaptic BL
Synaptic BL
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4.3 Nidogen-2 is internalised together with HCT in primary 
motor neurons 
4.3.1 Both nidogen-1 and -2 are expressed in primary motor neuron cultures 
First, I wanted to test if nidogens are expressed in primary motor neuron 
cultures (Figure 4-3). Both antibodies appeared to be very specific for nidogen-1 
and -2, respectively. Immunoblotting for nidogen-1 revealed a band slightly higher 
than the predicted molecular weight (136 kDa). This might be due to glycosylation 
of the protein in primary motor neuron cultures. Immunoblotting for nidogen-2 gives 
two bands, one at 153 kDa (expected molecular weight) and one slightly above that. 
Since both bands were present in a recombinant nidogen-2 sample purified from 
chinese hamster ovary cells, they might be different glycosylation variants. Both 
nidogen-1 and -2 are present in motor neuron cultures, but nidogen-1 is expressed 
at much higher quantities than nidogen-2. It is currently unknown which cell type is 
the source of nidogens in the spinal cord.  
 
Figure 4-3. Both nidogen-1 and nidogen-2 are expressed in primary motor 
neurons 
Primary motor neurons (DIV 7) were lysed in IP lysis buffer (2.3.3.7), the protein 
concentration was determined with a Bradford assay and 40 µg of protein was 
subjected to SDS-PAGE followed by immunoblotting with rabbit anti-nidogen-1 and -2 
antibodies. βIII tubulin was used as a loading control. To estimate the abundance of 
nidogens in the primary motor neuron culture, 100 ng of recombinant nidogen-1 and -2 
were loaded in separate lanes.  
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4.3.2 Nidogen-2 is taken up together with HCT in primary motor neurons 
Unfortunately the antibody against nidogen-1 was not suitable for 
immunofluorescence assays. I used the nidogen-2 antibody to assess whether 
nidogen-2 binds to motor neurons and is internalised together with HCT.  
Anti-nidogen-2 and AlexaFluor555-HCT were added together to primary motor 
neurons, and left to internalise for 45 min at 37°C. The cells were cooled down and 
acid washed to remove any probes still bound to the surface.  Following PFA 
fixation and permeabilisation, the cells were blocked with IFBB. AlexaFluor488-
conjugated anti-rabbit antibody was added to detect internalised anti-nidogen-2. 
Unbound antibodies were removed with a series of washes before post-fixing and 
mounting. There is 65% colocalisation between the two probes, indicating that the 
vast majority of HCT is taken up together with nidogen-2 in motor neurons (Figure 
4-4). 
 
 
Figure 4-4. Nidogen-2 is taken up together with HCT in primary motor neurons 
Primary motor neurons were incubated with AlexaFluor555-HCT and rabbit anti-
nidogen-2 at 37°C for 45 min before acid washing, fixing and immunostaining with 
AlexaFluor488 anti-rabbit antibody. 20 images were taken of single cells and the 
colocalisation was measured in ImageJ using the JACoP plugin. Mander’s coefficient 
showing the portion of HCT colocalising with nidogen-2 was plotted for all 3 
experiments. Scale bar: 10 µm. Modified from (Bercsenyi et al., 2014). Reprinted with 
permission from AAAS. 
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endocytosis to occur. Since the interaction between HCT and polysialogangliosides 
is detergent-sensitive, it is not possible to efficiently immunoprecipitate this probe in 
complex with its protein receptors on the motor neuron surface. Once HCT enters 
early endosomes, the disruption of its interaction with polysialogangliosides does 
not lead to its release into the medium and does not affect its recovery during 
immunoprecipitation. Following the 5 min incubation at 37°C the cells were cooled 
on ice, the proteins were cross-linked with bis[2-
(sulfosuccinimidooxycarbonyloxy)ethyl] sulfone (BSOCOES) and lysed with an IP 
buffer containing 0.5% NP40. It was previously demonstrated in our laboratory, that 
the immunoprecipitation of proteins bound to HCT is more efficient following 
crosslinking (Herreros et al., 2000a, Herreros et al., 2001) and I opted for this 
method after several failed attempts at immunoprecipitating the two proteins 
without crosslinking. The lysates were cleared by centrifugation and proteins 
binding to empty beads were excluded from the lysate. Mouse anti-HA antibody 
was crosslinked to magnetic Dynabeads using BS3, and these were used to 
immunoprecipitate HCT and its interacting partners. To test whether nidogen-2 is 
bound to HCT, the eluate from the beads was subjected to SDS-PAGE followed by 
immunoblotting with rabbit anti-nidogen-2 and rat anti-HA. There were several 
nidogen-2 bands present in the eluate, including a strong band at 250 kDa (Figure 
4-5), which is present in motor neuron lysates, but at much lower quantities than 
the native form of nidogen-2 (running at 153 kDa, Figure 4-3). 
 
 
 
Figure 4-5. Nidogen-2 and HCT are co-immunoprecipitated from motor neurons 
HA-HCT was allowed to enter early endosomes in primary motor neurons before cross-
linking and immunoprecipitation. Immunoprecipitated proteins were subjected to SDS-
PAGE followed by Western blotting for nidogen-2 and HA. Modified from (Bercsenyi et 
al., 2014). Reprinted with permission from AAAS. 
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4.4 Biomolecular modelling predicts a high affinity interaction 
between nidogen-1 and HCT  
4.4.1 The G2 domain of nidogen-1 fits into the binding pocket (‘R’ site) of 
HCT  
Since our attempts to co-crystallise nidogens with HCT failed due to the pH 
sensitivity of the interaction, we turned to biomolecular modelling to gain a 
molecular understanding of the potential binding site between the two proteins. G. 
Zanotti (University of Padua) performed the analysis. A model of the human 
nidogen-1 fragment, amino acids from 389 to 661, was built by homology modelling 
with the webserver Swiss-Model (Arnold et al., 2006) using the crystal structure of 
the nidogen-1 G2/perlecan Ig3 complex from Mus musculus as a template (PDB 
code 1GL4) (Hopf et al., 2001). The latter presents an overall 85% sequence 
identity with the human orthologue of nidogen-1.  The model shows that nidogen-1 
nicely fits into a large crevice of HCT (the ‘R’ site, where sialic acid and the YEW 
peptide were previously shown to bind), with only minor adjustments of the loop 
1144-1147 and of area 1211-1223 (Figure 4-6 A, Movie 2). The contact surface is 
quite extended, since the solvent-accessible area concealed by the complex is 
1114 Å2 and 1106 Å2 for HCT and nidogen-1, respectively. The area of nidogen-1 
involved in the interaction includes four antiparallel β-strands (residues 517-523, 
571-576, 580-586, 608-614) whilst the surface of the neurotoxin corresponds to the 
large crevice where also the YEW-like peptide binds. The latter includes four loops 
and some extended conformations, residues 1144-1147, 1211-1226, 1230-1235, 
1273-1280. The electrostatic surfaces are also complementary: the interacting 
surface of nidogen-1 is negatively charged in the central area and positively at the 
border (Figure 4-6 B), while the centre of the crevice in HCT is slightly positively 
charged, and the two borders are mostly negative (Figure 4-6 C). 
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Figure 4-6. Nidogen-1 fits into the 'R' pocket of HCT  
(A) The G2 domain of nidogen-1 can potentially form a strong interaction covering a 
long surface area within the ‘R’ pocket of HCT. (B) The electrostatic surface of the G2 
domain of nidogen-1 is negatively charged in the middle, and positive on the two sides. 
(C) The binding area of HCT is positively charged in the centre and is surrounded by 
negative borders. Modified from (Bercsenyi et al., 2014). Reprinted with permission 
from AAAS. 
 
 
Fifteen potential H-bonds can be formed between HCT and nidogen-1 (Table 
17). These interactions together with the electrostatic complementarity suggest that 
the binding between the two proteins is very strong, but it may be highly sensitive 
to changes in pH. I observed that the interaction between the N1 peptide and HCT 
is disrupted at pH 5 (Figure 3-8 B), and based on this model (Figure 4-6, Table 17),  
the interaction between nidogen-1 and HCT is likely to be pH-sensitive too. This 
might be important for the release of TeNT from its receptor binding complex after 
the acidification of the endosome in the somatodendritic compartment of motor 
neurons, which is indispensable for the release of TeNT from these cells and its 
entry into spinal cord interneurons, where the cleavage of its intracellular target, 
VAMP/Synaptobrevin takes place (Schiavo et al., 1992, Bercsenyi et al., 2013).  
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Table 17. Potential hydrogen bonds between HCT and the nidogen-1 G2 domain. 
The predicted distance between the interacting residues of HCT (A) and the intact G2 
domain of nidogen-1 (D) is indicated. Distances must be considered as indicative, 
since they are based on a theoretical model. Contacts and concealed surfaces were 
calculated with server PISA (http://www.ebi.ac.uk). The effects of mutating the 
highlighted residues (T1146 and Y1229) on the binding to the N1 and N2 peptides are 
shown in Figure 4-7. From (Bercsenyi et al., 2014). Reprinted with permission from 
AAAS. 
 
 
Bond HCT 
Distance 
(Å) 
nidogen-1 
(G2 domain) 
1 A:ASN1144[ND2] 2.64 D:HIS 575[O] 
2 A:ASN1144[ND2] 2.85 D:VAL 580[O] 
3 A:THR1146[OG1] 3.48 D:THR 582[O] 
4 A:ASN1216[ND2] 3.67 D:GLU 521[OE2] 
5 A:TYR1229[OH] 2.91 D:SER 584[OG] 
6 A:ASN1277[N] 2.63 D:THR 614[OG1] 
7 A:ASN1277[ND2] 3.83 D:THR 614[O] 
8 A:ILE1145[O] 3.85 D:THR 582[OG1] 
9 A:LYS1213[O] 3.88 D:THR 586[OG1] 
10 A:ASP1214[O] 2.82 D:ARG 610[NH1] 
11 A:GLY1215[O] 2.71 D:ARG 610[NH2] 
12 A:GLY1215[O] 3.56 D:THR 523[OG1] 
13 A:ALA1217[O] 3.06 D:ASN 530[ND2] 
14 A:TYR1229[OH] 3.74 D:THR 586[N] 
15 A:TYR1229[OH] 2.94 D:GLN 608[NE2] 
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4.4.2 Single point mutations in the ‘R’ pocket significantly reduce binding 
between HCT and the N peptides 
To test the accuracy of the model, we mutated selected residues (some are 
highlighted in Table 17) and tested the binding between mutant HCT and the N 
peptides in an ELISA following the same protocol as before. The site-directed 
mutagenesis was performed by M. Wallace (Molecular Neuropathobiology 
laboratory, UCL-Institute of Neurology) and the recombinant proteins were 
expressed in E.coli and purified by G. Schiavo (Molecular Neuropathobiology 
laboratory, UCL-Institute of Neurology) (Figure 4-7 A). All point mutants showed 
significantly reduced binding to both N1 and N2 when compared to the wild type 
control (Figure 4-7 B,C). The R1226F mutation, which replaces a positively 
charged amino acid with a bulky hydrophobic residue, proved to be the most 
disturbing for the binding. Interestingly when this mutation is grafted into full-length 
TeNT, the mutant toxin displayed dramatic loss in toxicity in the mouse phrenic 
nerve assay (1.4% of wild type; MPN assay) (Rummel et al., 2003). G1215F also 
binds less to both N1 and N2 peptides. This mutant has a loss of toxicity of 15% in 
the MPN assay, which is less dramatic than that of R1226F (Rummel et al., 2003). 
This correlates with the binding affinity of these mutants to the N peptides, 
implicating that the loss of toxicity might be a result of the decreased affinity of 
these mutants to nidogens. 
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Figure 4-7. The binding of HCT to the N1 and N2 peptides is significantly reduced 
by point mutations in the ‘R’ site of HCT.  
(A) Single point mutants of the ‘R’ site of HCT were generated, expressed as 
glutathione s-transferase (GST) fusion proteins, and after purification and GST 
cleavage, subjected to SDS-PAGE to assess purity. The position of HA-HCT (filled 
triangle) and a small amount of GST contaminant (empty triangle) are shown. (B,C) 
HCT ‘R’ site mutants display impaired binding to the N1 (B) and N2 (C) peptides. These 
peptides were immobilised on the surface of 96-well plates, blocked for non–specific 
binding and incubated with wild type HA-HCT (HCTWT) or the indicated mutants. Binding 
was detected by ELISA using TBS as a control. Averages of triplicates within one 
assay were determined and the results of four independent experiments were analysed 
for significance using paired t-test comparing the mutants to wild type HCT.  (n=4; *, 
p<0.05; **, p<0.01; error bars: SD). From (Bercsenyi et al., 2014). Reprinted with 
permission from AAAS. 
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4.5 The N peptides block the direct interaction between 
recombinant nidogens and HCT 
The biomolecular modelling suggested a strong interaction between 
nidogen-1 and HCT, which is dependent on the N1 peptide region within the G2 
domain of nidogen-1. To test this prediction and to get further insights into the 
molecular interactions of the HCT/nidogen complex, I sought to test if both nidogens 
bind HCT in isolation and if the N peptides can block this binding.  
I incubated full-length nidogen-1 or 2 in the presence or absence of the N1 
and N2 peptides with HA-HCT immobilised on Protein G-Dynabeads for 2 h at 4°C. 
The beads were washed with TBS before lysing with Laemmli sample buffer (LSB) 
for 15 min at 65°C. The lysates were subjected to SDS-PAGE followed by 
immunoblotting for nidogens and HCT. This experiment demonstrated that both 
nidogens bind HA-HCT directly under these experimental conditions (Figure 4-8 A). 
The N1 and N2 peptides play a key role in this interaction since pre-incubating HCT 
with an excess of these peptides, but not the N1AA or N2AA mutants, abolished 
binding (Figure 4-8). On average, 10% and 7.5% of the total amount of nidogen-1 
and nidogen-2 were recovered with the HCT immunoprecipitate. However, analysis 
of the amount of HCT associated to the anti-HA beads revealed that only a small 
percentage of HCT added to the samples was recovered in the pellet under our 
experimental conditions used to test the binding (5-7.5%). This corresponds to a 
molar ratio between nidogen-1/HCT of 1, and nidogen-2/HCT of 0.5, which suggests 
that there is a stoichiometric interaction between HCT and nidogens. 
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Figure 4-8. Nidogens bind directly to HCT and the N peptides can block this 
interaction 
(A) In vitro pull down of HA-HCT preincubated with full length nidogen-1 (upper panel) 
or nidogen-2 (lower panel) with a mouse monoclonal anti-HA antibody followed by 
SDS-PAGE and western blotting with rabbit anti-nidogen-1, rabbit anti-nidogen-2 or rat 
anti-HA antibodies. ‘Empty beads’ corresponds to samples in which HA-HCT was 
omitted, and DMSO to samples treated with vehicle control. Both nidogen-1 and -2 
bind directly to HA-HCT, and pre-treatment with the N1 or N2 peptide blocks this 
interaction. In contrast, mutant peptides in which both the Y and W residues have been 
replaced by alanines (N1AA and N2AA, respectively) are ineffective. The heavy chain of 
the capture antibody runs at 50 kDa (empty beads). (B) The mean grey value of each 
band has been determined using ImageJ, the results were normalised to the mean 
grey value of the HA-HCT pull down and expressed as percentage of DMSO control 
(n=2 for both proteins). 
 
 
4.6 Increase in soluble nidogen-1 to motor neurons enhances 
HCT binding and uptake 
4.6.1 Exogenous nidogen-1 increases the amount of HCT bound and 
internalised in primary motor neurons 
The N1 peptide blocks HCT binding and internalisation in primary motor 
neurons (Figure 3-5, Figure 3-9). This effect is most probably due to its high affinity 
binding to an important receptor-binding site on HCT. Based on the results of the in 
vitro IP, the N peptides can block the interaction between HCT and nidogens 
(Figure 4-8). However, this does not exclude the possibility that there is another 
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crucial receptor, whose binding is inhibited by the N peptides leading to the block of 
HCT binding to motor neurons.  
To show that the blocking effect of the N peptides is due to the inhibition of 
the interaction between HCT and nidogen-1, I sought to test HCT binding and 
internalisation following preincubation of cells with recombinant full-length nidogens 
and block their effect using the N peptides.  
Firstly, to determine the effect of exogenous nidogens on HCT binding and 
internalisation, the proteins (HCT+ nidogen-1, HCT+nidogen-2, HCT+mix of both 
nidogens) were incubated for 1 h at room temperature and added to motor neurons 
either on ice to assess binding, or at 37°C to test internalisation. The internalised 
samples were acid washed and cells were fixed and stained for βIII tubulin to 
reveal the neuronal network. There was a robust increase in both HCT binding and 
internalisation when additional nidogen-1 was present (HCT+nidogen-1 and 
HCT+mix of both nidogens) and this increase was significant compared to the HCT 
alone control (Figure 4-9). However, when nidogen-2 was added alone, there was 
only a small increase, which was significant for internalisation, but not for binding 
(Figure 4-9).  
The expected effect of adding an excess of exogenous receptor to a binding 
assay is a decrease in the binding and uptake of the ligand, since the exogenous 
receptor would act as a sink, sequestering the ligand without promoting its 
internalisation. But nidogens are extracellular proteins, linking laminin and collagen, 
and they are tightly packed in the basal lamina. Thus it is likely that some of the 
nidogen binding sites are not accessible for HCT for binding in normal conditions. 
By adding soluble exogenous nidogen-1, there is an increase in the pool available 
for HCT capture, and this in turn leads to a significant increase in both binding and 
internalisation of HCT. Since exogenous nidogen-2 has a much smaller effect on 
HCT binding and internalisation, nidogen-1 is likely to play a greater role in HCT 
binding than nidogen-2 in primary motor neuron cultures.  
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Figure 4-9. Recombinant nidogen-1 increases HCT binding to primary motor 
neurons 
(A) AlexaFluor555-HCT was preincubated with full-length recombinant nidogen-1, -2 or 
the mixture of these two proteins prior to addition to primary motor neurons. The cells 
were incubated with the protein mixture either on ice (Binding) or at 37°C 
(Internalisation). (B,C) The fluorescence intensity of AlexaFluor555-HCT 
(pseudocolored grey) was quantified using βIII tubulin (pseudocolored grey) as a mask. 
The results of 20 images per condition were plotted and analysed for significance using 
one-way ANOVA followed by Dunnett’s multiple comparisons test, **** p<0.001 (** 
p<0.01; **** p<0.001; NS non significant; n=3 experiments). Scale bars: 10 µm. 
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To test if recombinant nidogen-1 enhances HCT uptake by binding to 
primary motor neurons and bringing HCT to close proximity of the PM, we exploited 
the His9-tag of the recombinant protein. HCT was added to motor neurons together 
with recombinant nidogen-1 on ice, allowing only binding to occur. After washing 
and fixing, the cells were counterstained with mouse anti-His antibody to reveal 
surface bound nidogen-1. The His antibody binds to neuronal cell bodies 
unspecifically (Figure 4-10; HCT alone condition, middle panel), but there is a clear 
difference between the samples where nidogen-1 was omitted, or added to the 
motor neuron medium. It binds to cell bodies as well as the axonal network (Figure 
4-10). 
 
Figure 4-10. Recombinant nidogen-1 binds to primary motor neurons together 
with HCT 
Primary motor neurons were cooled on ice, before the addition of AlexaFluor555-HCT 
(pseudocolored grey, red in merge) alone or preincubated with recombinant His9- 
tagged nidogen-1 for 10 min. Following a high-volume wash with ice-cold HBSS buffer, 
the cells were fixed with PFA, blocked and stained with a mouse anti-His antibody 
(pseudocolored grey, green in merge). Note the unspecific staining of the His antibody 
in motor neuron cell bodies. Nidogen-1 binds to the motor neuron network together 
with HCT. Scale bar: 20 µm. From (Bercsenyi et al., 2014). Reprinted with permission 
from AAAS. 
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4.6.2 Preincubation with the N1 peptide blocks HCT binding even in the 
presence of soluble nidogen-1 
To test if the N1 peptide can block the interaction between HCT and both 
endogenous and exogenous nidogen-1 on primary motor neurons, we 
preincubated AlexaFluor555-HCT with DMSO (vehicle control), the N1 or N1AA 
peptide prior to addition to the motor neuron medium already containing 
recombinant nidogen-1. The experiment was performed on ice, to allow binding but 
not internalisation. 
Preincubation with the N1 peptide completely blocked HCT binding both in 
the absence and presence of recombinant nidogen-1, but the N1AA peptide did not 
have any effect (Figure 4-11). This result shows that the N1 peptide is able to block 
the interaction between both endogenous and exogenous nidogen-1 and HCT on 
primary motor neurons when HCT is preincubated with it and this is sufficient to 
abolish HCT binding. 
This result does not exclude the possibility that the N1 peptide also blocks 
other potentially important receptors from binding to HCT, but clearly highlights the 
importance of the interaction between nidogen-1 and HCT for its entry in primary 
motor neurons.  
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Figure 4-11. The N1 peptide blocks the effect of nidogen-1 on HCT binding to 
primary motor neurons 
(A) Motor neurons were incubated with AlexaFluor555-HCT on ice, following 
preincubation with vehicle control (DMSO, ‘HCT alone’) or wild type and mutant 
versions of the N1 peptide in the absence or the presence of exogenous nidogen-1 
before staining for βIII tubulin and confocal imaging. Scale bar, 50 µm. (B) Twenty 
images were taken for each condition and fluorescence intensity of AlexaFluor555-HCT 
bound to neurons (βIII tubulin mask) was quantified. Results were tested for statistical 
significance using Kruskal Wallis test followed by Dunn’s Multiple Comparisons Test 
(n=3; NS, non significant; **, p<0.01; ****, p<0.001; error bar: SD). Modified from 
(Bercsenyi et al., 2014). Reprinted with permission from AAAS. 
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4.7 The progression of tetanic paralysis accelerates when 
soluble nidogen-1 is present 
Since the addition of nidogen-1 caused a significant increase in HCT binding 
and internalisation in motor neurons, I wanted to assess its effect on TeNT 
intoxication in vivo. To do this, the triceps surae muscle of wild type adult mice was 
injected with 1 ng/kg TeNT, preincubated with vehicle control (DMSO) or nidogen-1 
(9 nM) in the presence or absence of the N1 peptide (50 mM). The preincubation 
was performed at a molar ratio of TeNT:N1:nidogen-1 1:13,800:0.125. The mice 
were kept under observation for 96 h in total, or until the loss of righting reflex. The 
experiment was performed with the help of N. Schmieg (Molecular 
Neuropathobiology laboratory, UCL-Institute of Neurology). 
The intramuscular administration of this dose causes local tetanus, first 
affecting the coordination by causing mild local paralysis, then progressing to 
general spastic paralysis of the injected hindlimb and subsequent stiffness of the 
back muscles.  
The mice injected with TeNT preincubated with nidogen-1 in the absence of 
the N1 peptide showed an earlier onset and faster progression of paralysis than the 
other two groups (Figure 4-12, Figure 4-13). At later stages of disease all three 
groups progressed at a similar rate. Preincubation of TeNT with the N1 peptide 
partially blocks the early effect of added nidogen-1, however at the concentrations 
used in this assay it did not entirely block tetanic paralysis. We used the footprint 
assay described before (Figure 3-15) to assess the coordination defects in a 
quantitative manner (Figure 4-12), and set up a scoring system, which allowed us 
to follow both the early and later stages of the disease (Figure 4-13). Mice injected 
with nidogen-1 in the absence of N1 start to show defects in coordination at an 
earlier stage than the other two groups, and at 69 h the injected hindlimb is hardly 
functional for walking (Figure 4-12).  
The scoring system is a decreasing scale from 5 to 0, where 5 corresponds 
to normal walking and muscle movement, and 0 corresponds to completely 
paralysed injected hindlimb and stiff back muscles. When mice were terminated 
early, they were given a score of -1. The affected hindlimb of mice injected with 
nidogen-1 in the absence of N1 is stiff, but still functional 29 h after injection. The 
triceps surae muscle gets completely paralysed by 52 h and 2 out of 3 mice 
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reached the humane endpoint of the experiment at 73 h (-1 score). The remaining 
mouse showed the first signs of paralysis in the back muscles at 73 h (Figure 4-13). 
In contrast, the other two groups progressed at a much slower rate at the early 
stages of intoxication and the injected leg was completely paralysed only at 73 h 
(Figure 4-12). Various members of the Molecular Neuropathobiology laboratory 
scored the animals without information on the grouping (blind). 
The results of this experiments recapitulated the observations made earlier 
in primary motor neurons (Figure 4-9); the addition of recombinant nidogen-1 
increases the binding and internalisation of TeNT in motor neurons and this in turn 
leads to a faster progression of tetanic paralysis.  
 
 
 
Figure 4-12. Recombinant full-length nidogen-1 makes coordination defects 
worse after TeNT injection 
The right triceps surae muscle was injected with 1 ng/kg of TeNT, following 
preincubation with DMSO as a vehicle control, nidogen-1 alone or the N1 peptide 
followed by nidogen-1. Before injection, and 45 and 69 h after injection, a footprint 
analysis was performed as before (Figure 3-15) and the coordination (distance 
between the prints on the same side) was measured. 
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Figure 4-13. Additional nidogen-1 increases the progression of tetanic paralysis 
The right triceps surae muscle was injected with 1 ng/kg TeNT, following preincubation 
with DMSO as a vehicle control, nidogen-1 alone or the N1 peptide followed by 
nidogen-1. Animals were scored according to the scoring system explained in Table 11 
at 29 (empty circles), 47 (yellow circles), 52 (orange circles) and 73 (red circles) h and 
the results were plotted for the 3 different groups. 
 
 
4.8 The cell entry route for the HCT-nidogen complex 
4.8.1 Both nidogen-2 and HCT colocalise with LAR after uptake in primary 
motor neurons 
The complex of HCT bound to nidogens must engage with a transmembrane 
protein to ensure its uptake into signalling endosomes. It was previously published 
that nidogen and laminin bind to LAR (O'Grady et al., 1998). Furthermore, LAR was 
present in the endosomal carriers of HCT in the magnetic pull down experiment 
performed by S. Debaisieux (Molecular Neuropathobiology laboratory, Cancer 
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HCT internalisation, AlexaFluor555-HCT and anti nidogen-2 were internalised 
together for 45 min at 37°C. The cells were acid washed, fixed, permeabilised and 
blocked before staining with mouse anti-LAR PMD primary antibody (proximal 
transmembrane domain, kind gift from Frank M. Longo, Stanford University). 
Unbound antibodies were washed away before staining with goat AlexaFluor488-
anti-rabbit and goat AlexaFluor647-anti-mouse antibodies. The mouse anti-LAR 
PMD antibody recognises a single band at 90 kDa in primary motor neurons, which 
corresponds to the molecular weight of the intracellular fragment of LAR (Figure 
4-14 A) (Yang et al., 2006). There is a strong overlap between HCT, nidogen-2 and 
LAR staining in the axonal network (Figure 4-14 A). This result suggests that LAR 
might be a component of the HCT binding complex. 
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Figure 4-14. LAR is taken up together with nidogen-2 and HCT in primary motor 
neurons 
(A) Primary motor neuron lysate was subjected to SDS-PAGE followed by 
immunoblotting for LAR-PMD. There is one band at 90 kDa recognised by the antibody, 
which corresponds to the estimated molecular weight of the PMD fragment. (B) Anti-
nidogen-2 and AlexaFluor555-HCT (red) were added to primary motor neuron cultures 
and allowed to internalise for 45 min at 37°C. The cells were washed, then stained for 
the rabbit anti-nidogen-2 antibody (green) and anti-LAR-PMD (pseudocolored grey). 
The axonal network was imaged. Scale bar: 10 µm. 
 
4.8.2 HCT colocalises with TrkB 
TrkB is the main neurotrophin receptor present on motor neurons. Its ligand, 
BDNF was previously shown to enhance binding and internalisation of HCT (Roux 
et al., 2006). Furthermore, HCT is known to trigger the downstream signalling 
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2006). Since nidogens are likely promote the uptake of HCT via LAR, its BDNF 
dependent interaction with TrkB could explain the enhancing effect of BDNF on 
HCT binding and internalisation. Furthermore, TrkB was present alongside nidogen-
1 in the proteomic screen of HCT containing endosomes (Deinhardt et al., 2006b). 
First, I wanted to test if TrkB colocalises with HCT after uptake. To do this, I 
added AlexaFluor555-HCT to primary motor neurons and left it to internalise for 45 
min at 37°C. The cells were cooled on ice and acid washed to remove surface 
bound probes before fixing, permeabilising and blocking. The determine the extent 
of colocalisation between internalised HCT and TrkB, the cells were stained with a 
rabbit anti-TrkB antibody followed by donkey AlexaFluor488-anti-rabbit secondary 
antibody. 
The rabbit anti-TrkB antibody recognises a singe band at 90 kDa in primary 
motor neurons, which corresponds to the molecular weight of TrkB (Figure 4-15 A). 
The colocalisation between HCT and TrkB is very high, confirming the mass 
spectrometry data and suggesting that TrkB might be involved in the binding 
complex of HCT. 
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Figure 4-15. TrkB is taken up together with HCT in primary motor neurons 
(A) Primary motor neuron lysate was subjected to SDS-PAGE followed by 
immunoblotting for TrkB. There is one band at 90 kDa recognised by the antibody, 
which corresponds to the estimated molecular weight of TrkB. (B) AlexaFluor555-HCT 
(red) were added to primary motor neuron cultures and allowed to internalise for 45 
min at 37°C. The cells were washed, then stained with an anti-TrkB antibody (green) 
and βIII tubulin (blue). Scale bar: 10 µm. 
 
4.8.3 Addition of anti-TrkB antibody prior to HCT impairs HCT binding and 
vice versa 
Following the extensive colocalisation observed in Figure 4-15, I wanted to 
show that TrkB is taken up together with HCT in primary motor neurons. To do that, 
the rabbit anti-TrkB antibody was added to motor neuron cultures together with HCT 
for 45 min at 37°C. I observed that both the TrkB and HCT staining were less 
intense then in the previous experiment suggesting that there is a competition 
between the antibody and HCT for binding sites on the motor neuron surface.  
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To test this hypothesis, the cells were cooled down on ice, before adding 
either anti-TrkB (top panel, Figure 4-16) or AlexaFluor555-HCT (bottom panel, 
Figure 4-16) alone for 10 min. The unbound probes were washed away before 
adding AlexaFluor555-HCT (top panel, Figure 4-16) or anti-TrkB (bottom panel, 
Figure 4-16) for another 10 min. The cells were washed extensively, fixed and 
stained with donkey AlexaFluor488-conjugated anti-rabbit antibody to reveal 
surface-bound anti-TrkB. It appears that there is a two-sided competition, 
depending on which probe is added first, the other one cannot access its binding 
site on the motor neuron surface. This is most probably due to steric hindrance. If 
the initial hypothesis is correct, and HCT-nidogen-2-LAR-TrkB form a complex, the 
presence of the polyclonal antibody might block the entry of TrkB into the complex. 
However, if HCT is added to the cells first, it triggers the formation of the complex 
and recruits TrkB, making it inaccessible for the anti-TrkB antibody. Future 
experiments would be required to test this hypothesis in more detail. 
 
 
Figure 4-16. The anti-TrkB antibody blocks HCT binding and vice versa 
Primary motor neurons were incubated on ice either with anti-TrkB (top panel), or 
AlexaFluor555-HCT (bottom panel) first, before washing with ice-cold HBSS and 
addition of AlexaFluor555-HCT(top panel), or anti-TrkB (bottom panel). Anti-TrkB 
binding (green) is inhibited if HCT is bound first, while HCT binding (red) is blocked by 
the presence of anti-TrkB. Scale bar: 10 µm. 
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4.8.4 Both starvation, BDNF and HCT increase the uptake of nidogen-2 in 
primary motor neurons 
ECM components are generally thought to be stable, with a slow turnover, 
since they are integrated into the matrix. To test whether nidogen-2 is taken up 
during general maintenance in motor neuron cultures, the anti-nidogen-2 antibody 
was added to motor neurons under resting conditions. In the absence of HCT, there 
is very little uptake in glial cells, and almost no uptake in motor neurons (Figure 
4-17). When cultures were treated with BDNF (50 ng/ml, 10 min) without prior 
starvation, the glial uptake of nidogen-2 increased. When HCT was added together 
with nidogen-2, motor neurons internalised the antibody together with HCT. 
However, the most striking change in nidogen-2 uptake was observed under 
starvation conditions, which trigger massive internalisation of nidogen-2 in both 
neurons and glial cells (Figure 4-17). 
 
 
Figure 4-17. Nidogen-2 is taken up in a BDNF- and HCT-dependent manner 
Primary motor neuron cultures were non-treated, or treated with either BDNF (100 
ng/ml), HCT (40 nM), or incubated in neurobasal medium for 2 h (Starved). Anti-
nidogen-2 antibody was added to the culture for 30 min at 37°C; this allowed 
internalisation of the probe before acid washing to remove surface bound antibodies. 
The cells were fixed, permeabilised, blocked and stained with donkey AlexaFluor488-
anti-rabbit antibody to reveal the internalised pool of nidogen-2 (pseudocolored grey, 
top panel) and anti-βIII tubulin antibody to stain the neuronal network (pseudocolored 
grey, middle panel). Scale bar: 50 µm. 
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4.8.5 The colocalisation between SV2A and HCT is blocked by the addition of 
soluble nidogen-1 
Synaptic vesicle protein A and C (SV2A-C) have been implicated in BoNT 
binding to motor neurons (Dong et al., 2006, Peng et al., 2011, Benoit et al., 2014), 
and TeNT binding to central neurons (Yeh et al., 2010), but their role in binding and 
internalisation of TeNT into motor neurons remains to be elucidated. First, I wanted 
to test if HCT colocalised with either SV2A or SV2C after uptake in motor neurons 
and if this was affected by the presence of nidogen-1. Primary motor neurons were 
incubated with either AlexaFluor555-HCT alone, or with additional soluble nidogen-
1 for 45 min at 37°C. The cells were acid washed, fixed, permeabilised, blocked 
and stained for SV2C (Figure 4-18 A) or SV2A (Figure 4-19 A). SV2C showed very 
little colocalisation with HCT, and the addition of soluble nidogen did not have any 
effect (Mander’s coefficient 0.1, Figure 4-18 B). However, around 50% of HCT 
resides in SV2A positive vesicles when it is used at relatively high concentration 
(40nM in this assay, Figure 4-19 B). When additional soluble nidogen-1 is applied 
together with HCT, they are increasingly taken up into different compartments, 
which are targeted to the retrograde transport pathway and accumulate in close 
vicinity of the nucleus (white arrowheads, Figure 4-19 A). These vesicles do not 
contain SV2A and this leads to a significant drop in the colocalisation to around 
20% (Figure 4-19 B). This result is very important as it showed that HCT is able to 
enter motor neurons via synaptic vesicle recycling (as shown by the high 
colocalisation with SV2A), but prefers an alternative way of entry when sufficient 
number nidogen-1 binding sites are available. Its preferred entry route is dependent 
on nidogen-1 and leads to its retrograde transport and accumulation in the motor 
neuron cell body. 
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Figure 4-18. SV2C does not colocalise with HCT in primary motor neurons 
(A) Wild type primary motor neurons were incubated either with AlexaFluor555-HCT 
(shown in red; 40 nM) alone, or in the presence of full-length recombinant nidogen-1 
(1.6 nM) for 45 min at 37°C. Cells were fixed and immunostained for SV2C (in green). 
(B) Mander’s coefficient was used as an indicator of co-localisation. Significance was 
assessed using unpaired with Welch’s correction (n=3, 10 images per condition; NS, 
non significant; error bar: SD). Scale bar, 10 µm. Modified from (Bercsenyi et al., 2014). 
Reprinted with permission from AAAS. 
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Figure 4-19. The colocalisation between SV2A and HCT is decreased upon 
addition of soluble nidogen-1 
(A) Wild type primary motor neurons were incubated either with AlexaFluor555-HCT 
(shown in red; 40 nM) alone, or in the presence of full-length recombinant nidogen-1 
(1.6 nM) for 45 min at 37°C. Cells were fixed and immunostained for SV2A (in green). 
The inset shows that there is an increase in the cell body pool of HCT upon the addition 
of soluble nidogen-1 and this area contains no SV2A. (B) Mander’s coefficient was 
used as an indicator of co-localisation. Significance was assessed using unpaired t test 
with Welch’s correction (n=3, 10 images per condition; ***, p<0.005; error bar: SD). 
Scale bar, 10 µm. Modified from (Bercsenyi et al., 2014). Reprinted with permission 
from AAAS. 
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4.9 Nidogen-2 KO motor neurons show decreased HCT binding 
Single nidogen knock out (KO) mice are viable, but nidogen-1 KO animals 
display an ascending paralysis that worsens with age and females are not able to 
give birth (Dong et al., 2002). Both mutant lines were kindly provided by R. Nischt 
(University of Cologne). 
I obtained primary motor neuron cultures from E13,5 nidogen-1 and 
nidogen-2 KO embryos and tested them for HCT binding. When AlexaFluor555-HCT 
was added to cells at a concentration of 40 nM for 45 min at 37°C, there was no 
striking difference between wild type cells and neurons lacking nidogen-1, or -2 
(nidogen-1 KO: Figure 4-20, nidogen-2 KO: Figure 4-21). However, when HCT-HA 
was added to nidogen-2 KO motor neurons at 10 nM on ice, I detected a small, but 
significant drop in HCT binding in the KO cells (Figure 4-22). Since both nidogens 
are involved in the binding and subsequent uptake of HCT in motor neurons, it is 
not surprising that the single KO cells did not display a major deficit in HCT binding 
and internalisation. Both nidogen isoforms were shown to fulfil partially overlapping 
roles, and compensate for each other’s loss in the KO animals (Mann et al., 1989, 
Ho et al., 2008, Kruegel and Miosge, 2010), and this in turn may help to maintain 
close to normal HCT internalisation in single KO neurons. 
The observation that there is a defect in HCT binding only when it is used at 
a lower concentration further suggests that HCT could use its alternative entry route 
through SV2A to gain access to the cell in the absence of available nidogen binding 
sites.  
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Figure 4-20. Nidogen-1 KO neurons internalise HCT to a similar extent as wild 
type cells 
Wild type and nidogen-1 KO motor neurons were incubated with 40 nM AlexaFluor555-
HCT for 45 min at 37°C, The cells were washed, fixed, permeabilised, blocked and 
stained for βIII tubulin to reveal the neuronal network. Scale bar: 50 µm. 
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Figure 4-21. Nidogen-2 KO cells internalise HCT to a similar extent as wild type 
cells 
Wild type and nidogen-2 KO motor neurons were incubated with 40 nM AlexaFluor555-
HCT for 45 min at 37°C, The cells were washed, fixed, permeabilised, blocked and 
stained for βIII tubulin to reveal the neuronal network. Scale bar: 50 µm. 
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Figure 4-22. There is a significant impairment in HCT binding of nidogen-2 KO 
neurons when HCT is used at a lower concentration 
(A,C) Wild type and nidogen-2 KO (A) or nidogen-1 KO (C) motor neurons were 
incubated with 10 nM HCT-HA for 10 min on ice. The cells were washed, fixed, 
permeabilised, blocked and stained for βIII tubulin to reveal the neuronal network. 
Modified from (Bercsenyi et al., 2014). Reprinted with permission from AAAS. 
(B,D) Fluorescence intensity was quantified in 10 images using a βIII tubulin mask (in 
green). Scale bar, 20 µm. Following setting the level of samples lacking HCT to zero, 
the mean fluorescence intensity was plotted for each genotype as percentage of wild 
type and statistical significance was analysed using unpaired t-test. (n=3; ****, p<0.001; 
error bar: SD).  Scale bar: 20 µm. 
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4.10 The nidogen-2 content of the NMJ is a limiting factor for 
HCT binding 
4.10.1 HCT is taken up by the motor neuron endplate at the NMJ 
To show that HCT is taken up by the presynaptic terminal of the motor 
neuron endplate, the anterior part of the lower hindlimb of a wild type mouse was 
injected with HA-HCT and after 60 min the animal was terminally anesthetised and 
transcardially perfused with saline followed by 4% PFA. The extensor digitorum 
longus (EDL) muscle was dissected, cryoprotected and sectioned (20 µm 
thickness) on a cryostat. The sections were post-fixed, air dried, blocked and 
stained with rat anti-HA and goat anti-choline acetyl transferase (ChAT) antibodies 
over night at room temperature in a wet chamber. Following several washes, 
AlexaFluor555-BTX, goat AlexaFluor647-conjugated anti-rat and donkey 
AlexaFluor488-conjugated anti-goat (green) were added for 1 h at room 
temperature. BTX labels the postsynaptic terminal of the NMJ, while ChAT labels 
the presynaptic membrane. J. B. Bryson (UCL-Institute of Neurology) performed 
the experiment and I imaged the slides (Figure 4-23). HCT localises to the 
presynaptic side of the NMJ and it is taken up by motor neuron axons innervating 
the muscle (top right panel).  
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Figure 4-23. HCT is taken up at the presynaptic side of the NMJ 
The anterior part of the lower hindlimb of adult mice was injected with HA-HCT. After 60 
min, animals were transcardially perfused; the muscles were dissected, post-fixed, 
sectioned and stained for HA (pseudocolored red), ChAT (green) and AlexaFluor555-α-
BTX (pseudocolored grey) to label NMJs. HCT binds to the presynaptic site of the NMJ, 
where ChAT is localised (inset). HCT is taken up by the motor neuron and it is 
retrogradely transported in the motor neuron axons (top right panel). Scale bar: 10 µm. 
Modified from (Bercsenyi et al., 2014). Reprinted with permission from AAAS. 
 
4.10.2 The nidogen-2 content of the NMJ correlates with HCT binding 
I sought to test if HCT is taken up together with nidogen-2 at the NMJ. To do 
this, the lower hindlimb of a wild type mouse was injected with HCT-HA and the 
mouse was anesthetised after 60 min for transcardial perfusion with saline followed 
by 4% PFA. The extensor digitorum longus (EDL) muscle was dissected, 
cryoprotected and sectioned (20 µm) on a cryostat. The sections were blocked and 
stained with rat anti-HA and rabbit anti-nidogen-2 primary antibodies for 1 h at 37°C. 
Following several washes, AlexaFluor555-BTX, AlexaFluor647-anti-rat and 
AlexaFluor488-anti-rabbit were added for 1 h at 37°C. The unbound probes were 
washed off and the sections were mounted for imaging. J. B. Bryson (UCL-Institute 
of Neurology) performed the injection and processed the tissue; I performed the 
immunohistochemistry and imaged the slides. Nidogen-2 and HCT localises to the 
same compartment of the NMJ, but nidogen-2 is only partially taken up into 
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endosomes together with HCT (Figure 4-24, Movie 3). It became clear however, 
that there is a strong correlation between the nidogen-2 content and HCT binding 
ability of the NMJ. Some NMJs did not contain nidogen-2 and these did not bind 
HCT, whilst others with high nidogen-2 content bound vast amount of HCT (Figure 
4-25). I have observed that not every NMJ in the LAL muscle bind HCT (Figure 
3-13). To assess the level of correlation between nidogen-2 and HCT content, 50 
images of NMJs were taken and the fluorescence intensity of HCT vs. nidogen-2 
staining was compared using Spearman correlation. 
 
 
Figure 4-24. Nidogen-2 is present where HCT is taken up at the NMJ 
The anterior part of the lower hindlimb of adult mice was injected with HA-HCT. After 60 
min, animals were transcardially perfused; the muscles were dissected, post-fixed, 
sectioned and stained for HA (pseudocolored red), nidogen-2 (green) and 
AlexaFluor555-α-BTX (pseudocolored grey) to label NMJs. Nidogen-2 accumulates in 
areas where HCT is taken up with high efficiency (bright red spots). Scale bar: 10 µm. 
Modified from (Bercsenyi et al., 2014). Reprinted with permission from AAAS. 
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Figure 4-25. Nidogen-2 content of the NMJ correlates with the amount of HCT 
binding 
The anterior part of the lower hindlimb of adult mice was injected with HA-HCT. After 30 
min, animals were transcardially perfused; the muscles were dissected, post-fixed, 
sectioned and stained for HA (pseudocolored red), nidogen-2 (green) and 
AlexaFluor555-α-BTX (pseudocolored blue) to label NMJs. The fluorescence intensity 
of both HCT and nidogen-2 intensity were measured under the BTX mask. The results 
were paired and plotted to analyse for correlation with Spearman test (r=0.9227; ****, 
p<0.001; n=3; Scale bar: 10 µm). Modified from (Bercsenyi et al., 2014). Reprinted with 
permission from AAAS. 
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wanted to test if the NMJs of nidogen KO animals show a greater decrease in HCT 
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detect nidogen-2 and AlexaFluor555-BTX was used to label NMJs. Initially, due to 
the high background in the 488 channel, a higher concentration of HCT was used 
nidogen-2 Merge
In
t. 
in
te
ns
ity
 (n
id
og
en
-2
)
0 5 10 15 20
0
5
10
15
20
HCT BTX
Int. intensity (HCT)
Chapter 4 Results 
 
 147 
(60 nM). At this concentration both nidogen-1 and nidogen-2 KO NMJs bind HCT 
close to wild type levels (Figure 4-26). 
 However, when the concentration of HCT was dropped to 20 nM, the KO 
NMJs lose their ability to bind and internalise HCT (Figure 4-27). Note the large 
error bar in the fluorescence intensity of HCT staining in wild type NMJs. This is due 
to HCT specifically targeting only a subset of NMJs (the ones with high nidogen-2 
content) since the imaging was done blind; this resulted in some images where no 
HCT was bound to the NMJ. 
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Figure 4-26. HCT binds to nidogen KO NMJs at 60 nM  
LAL muscles of wild type, nidogen-1 and -2 KO animals were incubated with HA-HCT, 
fixed and stained for HA (pseudocolored grey, red in merge), nidogen-2 
(pseudocolored grey, blue in merge) and AlexaFluor555-BTX (pseudocolored green) to 
identify NMJs. Scale bar, 10 µm.  
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Figure 4-27. HCT does not bind to nidogen-1 and nidogen-2 KO NMJs at 20 nM 
LAL muscles of wild type, nidogen-1 and -2 KO animals were incubated with HA-HCT, 
fixed and stained for HA (pseudocolored grey) and AlexaFluor555-BTX (pseudocolored 
green) to identify NMJs. Scale bar, 5 µm. (B) Both nidogen-1 and -2 KO NMJs show a 
significant decrease in their ability to bind and internalise HCT. Significance was tested 
with by Kruskal-Wallis test (****, p<0.001) followed by Dunn’s multiple comparisons test.  
(n=3 animals per group, 20 images per animal; ****, p<0.001; error bar: SD). Modified 
from (Bercsenyi et al., 2014). Reprinted with permission from AAAS. 
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4.10.4 Nidogen-1 and -2 KO NMJs bind BoNT/A at similar levels to wild type 
NMJs 
As disruption of the general structure of the NMJ has been reported in 
nidogen KO animals (Fox et al., 2008), I wanted to test the functionality of the NMJ 
in KO animals by testing whether botulinum neurotoxin (BoNT/A) binding is 
affected by the loss of nidogen expression at the NMJ. BoNTs rely on synaptic 
vesicle recycling and binding to synaptic vesicle proteins (either SV2A-C or 
synaptotagmin I/II) for their entry into motor neurons (Mahrhold et al., 2006, Dong 
et al., 2006, Peng et al., 2011, Benoit et al., 2014). The GST-tagged binding 
fragment of BoNT/A (HCA; 12 µg in 4 µl) was injected into the TA muscle of wild 
type, nidogen-1 and nidogen-2 KO mice, as described above, and muscle sections 
were labelled with rabbit anti-GST followed by staining with goat AlexaFluor488-
anti-rabbit and AlexaFluor555-BTX to label NMJs. J. B. Bryson (UCL-Institute of 
Neurology) performed the injection and processed the tissue, I performed the 
immunohistochemistry and imaged the slides.  
Both nidogen-1 and nidogen-2 KO NMJs bind HCA (Figure 4-28). This result 
confirms that synaptic vesicle recycling and SV2A presentation on the PM of the 
motor neuron endplate is not impaired in the nidogen KO animals. Hence, the 
dramatic reduction of HCT binding is certainly not due to the lack of synaptic vesicle 
recycling, which would lead to the reduced accessibility of SV2A. 
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Figure 4-28. Single nidogen KO NMJs bind HCA at a comparable level to wild type 
The tibialis anterior (TA) muscle of wild type or nidogen-1 and nidogen-2 KO mice was 
injected with GST-HCA. After 30 min, the animals were transcardially perfused, the 
muscles cryosectioned before staining for GST (pseudocolored grey). NMJs were 
labeled with AlexaFluor555-BTX (pseudocolored green). Scale bar, 10 µm. Modified 
from (Bercsenyi et al., 2014). Reprinted with permission from AAAS. 
 
4.10.5 Additional soluble nidogen-1 rescues the HCT binding defect in 
nidogen-1 KO NMJs 
To prove that the inability of nidogen-1 KO NMJs to bind and internalise HCT 
at 20 nM is due to the loss of nidogen-1, I wanted to prove that binding can be 
rescued by the addition of soluble recombinant nidogen-1 to the medium during 
HCT incubation. LAL muscles were isolated from wild type and nidogen-1 KO 
animals and incubated in motor neuron medium in the presence or absence of full-
length recombinant His9-tagged nidogen-1. 20 nM HCT-HA was added to the 
medium for 2 h at 37°C. The muscles were washed and fixed overnight at 4°C. The 
following day rat anti-HA and mouse anti-His antibodies were added followed by 
goat AlexaFluor488-anti-rat, goat AlexaFluor647-anti-rabbit and AlexaFluor555-
BTX. As expected, nidogen-1 KO NMJs did not bind HCT in the absence of 
recombinant nidogen-1 (middle panel, Figure 4-29). However, when recombinant 
nidogen-1 was present in the medium, the nidogen-1 KO NMJ showed equivalent 
HCT binding to the wild type NMJ (Figure 4-29). The anti-His staining revealed that 
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recombinant nidogen-1 binds to the NMJ, even though its localisation is more 
disperse in the KO than in the wild type NMJ (right panels, Figure 4-29). 
 
 
Figure 4-29. Recombinant exogenous nidogen-1 rescues the HCT binding defect 
in nidogen-1 KO NMJs 
LAL muscles of wild type and nidogen-1 KO animals were incubated with HA-HCT in 
the absence or the presence of full-length His9-tagged recombinant nidogen-1. Muscles 
were fixed and stained for HA (pseudocolored grey, middle), His (pseudocolored grey, 
right) and AlexaFluor555-BTX (pseudocolored green, left). Scale bar, 10 µm. Modified 
from (Bercsenyi et al., 2014). Reprinted with permission from AAAS. 
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permeabilisation with PBSTr for 1 h and blocking with IFBB for 1 h, the hindbrains 
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were stained with rat anti-HA and rabbit anti-βIII tubulin in IFBB for 1 h at room 
temperature. The unbound antibodies were removed with washes and goat 
AlexaFluor555-conjugated anti-rat and goat AlexaFluor647-conjugated anti-rabbit 
secondary antibodies were added for 1 h at room temperature. After three washes 
for 30 min, the tissue was post-fixed for 10 min and mounted with Mowiol. Imaging 
was done as before, but to capture the whole sample, 3x9 tiles were taken. The 
nidogen DKO hindbrains bound significantly less HCT than their wild type 
counterparts (Figure 4-30 A,C), however, a subset of cells within the developing 
mesencephalon bound HCT with high affinity (Figure 4-30 B). At closer inspection it 
became clear that this subset of cells is a much smaller population than in the wild 
type, however I could not investigate the identity of these cells due to the lack of 
expertise in our laboratory. E11,5 is a very early stage in mesencephalic 
development, the first neural precursors do not leave the ventricular zone before 
E12,5. These cells are most probably early precursor cells, which secrete a lot of 
ECM molecules to prepare the environment for the arrival of the migrating neurons. 
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Figure 4-30. Nidogen DKO hindbrains do not bind HCT, with an exception of a 
small region within the mesencephalon. 
(A) Wild type and nidogen DKO hindbrains were dissected from E11,5 mouse embryos 
and tested for HCT-HA binding. 3x9 tiles were taken to observe the whole tissue. Scale 
bar: 1 mm. (B) A small subset of βIII tubulin positive cells within the mesencephalon 
still bind HCT even in the absence of both nidogen isoforms, but within this region there 
are less HCT positive cells than in the wild type. Scale bar: 20 µm. (C) The 
fluorescence intensity of HA staining was quantified using Image J, the average value 
for wild type tissue was set at 100% and the results were plotted to test for statistical 
significance. Unpaired t test was used to assess significance (n=2 animals per group; 
** p<0.01). Modified from (Bercsenyi et al., 2014). Reprinted with permission from 
AAAS. 
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4.12  Mice lacking nidogen-2 are less sensitive to tetanus 
intoxication 
Nidogen-1 KO mice presented with a severe epileptic phenotype alongside 
ascending progressive paralysis (Kohling et al., 2006). As a result of this, we were 
not able to use these mice to test the effects of TeNT in vivo (Figure 4-31). 
Nidogen-2 KO mice show no epileptic symptoms and present milder hindlimb 
paralysis at a later stage in life than nidogen-1 KO mice. We decided to test the 
sensitivity of nidogen-2 KO mice to general tetanus. To do this, adult weight 
matched nidogen-2 KO mice were injected with different lethal doses of TeNT 
intraperitoneally (1.5, 3, 6 and 12 ng/kg). The mice were closely monitored and 
terminated at the loss of righting reflex. Nidogen-2 KO mice survived significantly 
longer than their wild type counterparts when injected with a lower (1.5 ng/kg) dose 
of TeNT (Movie 4). However, when the dosage was increased, there was no 
difference between the different genotypes (Figure 4-32). This might be due to the 
alternative entry pathway used by TeNT when it is applied at high concentrations.  
Mice injected with high doses of TeNT displayed botulism-like symptoms 
(Matsuda et al., 1982). Interestingly we found that nidogen-2 KO mice injected with 
TeNT showed botulism like symptoms: they had a silver crescent in their eyes, 
which resembled keratoconjuctivitis sicca (‘Silver eye syndrome’, Figure 4-32 B). 
Keratoconjuctivitis sicca is due to the block of the lacrimal gland and production of 
tears, it is one of the characteristic symptoms of botulism in mice (Suwan-apichon 
et al., 2006). This result further suggests that TeNT has an alternative entry route 
at the NMJ, which is independent of nidogens, and resembles that used by BoNTs.  
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Figure 4-31. Nidogen-1 KO animals display a coordination defect from a young 
age 
The paws of 3 months old nidogen-1 KO mice (2 females, pink and 3 males, blue) were 
painted, the mice were let to walk on a white stripe of paper and the distance between 
the front and hind footprint was determined on both sides (coordination, cm). The 
distance between the front and hind footprints of nidogen-1 KO animals is higher than 
normal; this is due to severe coordination defects caused by early-onset progressive 
paralysis. 
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Figure 4-32. Nidogen-2 KO mice are less sensitive to tetanus intoxication 
(A) Age and weight matched nidogen-2 KO and wild type mice were injected 
intraperitoneally with TeNT and monitored for up to 96 h. The time of termination due to 
loss of righting reflex was plotted against the TeNT dose. Note that generalised tetanus 
in nidogen-2 KO animals is significantly delayed at lower doses (1.5 ng/kg) compared 
to wild type controls (n=2 experiments, minimum 2 mice per group; t-test; **, p<0.01; 
error bar: SD). Modified from (Bercsenyi et al., 2014). Reprinted with permission from 
AAAS. 
(B) Nidogen-2 KO mice presented with a grey crescent in their eyes (white arrow), the 
symptom of keratoconjuctivitis sicca, which is a characteristic of botulism. 
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4.13  Summary 
• Both nidogen-1 and -2 are present in primary motor neuron cultures. 
• Nidogen-2 is bound and internalised together with HCT in motor neurons 
• The G2 domain of nidogen-1 fits into the ‘R’ pocket of HCT, in the same site 
where the N1 peptide binds. 
• Point mutations within the ‘R’ site decrease HCT binding to both the N1 and N2 
peptides. 
• Both nidogen-1 and -2 bind to HCT directly and this interaction is blocked by 
the N1 and N2 peptides, respectively. 
• Exogenous full-length nidogen-1 enhances both binding and internalisation of 
HCT in motor neurons; this effect is completely blocked by the N1 peptide. 
• Co-injection of TeNT with soluble nidogen-1 leads to an earlier onset of tetanic 
paralysis. 
• The protein tyrosine phosphatase receptor. LAR colocalises with nidogen-2 
and HCT on the surface of motor neurons. TrkB colocalises with internalised 
HCT in motor neurons. The TrkB antibody competes with HCT binding to its 
receptor complex. 
• Nidogen-2 internalisation is increased by BDNF stimulation, HCT internalisation 
and starvation. 
• HCT colocalises with SV2A and this colocalisation is significantly decreased by 
the addition of exogenous full-length nidogen-1. 
• When HCT is used at a high concentration (40-60 nM), nidogen-1 and -2 KO 
motor neurons and NMJs show close to normal level of internalisation. But 
when HCT concentration is dropped to 10-20 nM, nidogen-2 KO motor neurons 
bind significantly less HCT than wild type cells and nidogen-1 and -2 NMJs bind 
significantly less HCT than wild type muscles. 
• Synaptic vesicle recycling is functional in nidogen-1 and -2 KO NMJs.  
• Nidogen double KO animals do not survive until E13,5 and this prevented the 
experiments on primary motor neurons. I dissected hindbrains from E11,5 
embryos and in lack of both nidogens, they do not bind HCT, apart from a small 
subset of cells in the developing mesencephalon. 
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• Nidogen-2 KO animals are less sensitive to tetanus intoxication at lower 
concentrations (1.5 ng/kg). At higher TeNT concentrations, they display silver-
eye syndrome; a characteristic of botulism. 
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Chapter 5. HCT is transcytosed in motor neuron 
cultures together with nidogen-2 
During TeNT intoxication, the light chain of TeNT is released in the 
cytoplasm of inhibitory interneurons, where it cleaves VAMP/synaptobrevin, leading 
to the silencing of inhibitory inputs on motor neurons. However, TeNT has access 
to motor neuron endplates only from the periphery. To get into inhibitory 
interneurons, it must be taken up by motor neurons, undergo axonal retrograde 
transport, get released in the vicinity of inhibitory synapses. 
The trans-synaptic transfer of TeNT between motor neurons and 
interneurons has been accepted in the field for a long time; however, it has never 
been proven experimentally. To test this, HCT must be applied in a 
compartmentalised culture, where the axonal network is isolated from the cell 
bodies. Campenot chambers have been available since 1977 (Campenot, 1977), 
but they are assembled on plastic bottom dishes, making fluorescent imaging 
problematic (Campenot et al., 2009). The other disadvantage of Campenot 
chambers is that their preparation is very labour intensive and the success of the 
chamber assembly relies on the skills of the operator. This in turn leads to high 
intrinsic variability. Microfluidic dishes are made of polydimethylsiloxane (PDMS), a 
transparent polymer, which can be covalently attached to glass bottom dishes after 
plasma cleaning (Park et al., 2006). This approach is less time-consuming, easier 
to master and yields less faulty/leaking chambers. 
G. Menendez (Molecular Neuropathobiology laboratory, Cancer Research 
UK) established efficient protocols for the design and assembly of microfluidic 
chambers in our laboratory. There are 4 wells, or reservoirs, which are connected 
by two vertical channels on each side (16 mm long, 1 mm wide and 150 µm high; 
Figure 5-1 A). The channels are interconnected by microgrooves, which are 
shallow and long enough to provide microfluidic isolation between the two channels. 
Their dimension prevents crossing of freshly plated cells, but allows axons to grow 
through them. In the initial design, the microgrooves were 800 µm long, 10 µm wide 
and 3-4 µm high. These conditions provided microfluidic isolation, and allowed the 
crossing of sensory axons. However, motor neurons were never successfully 
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cultured in these chambers, since the microgrooves proved too long and motor 
neuron axons did not reach the other side. 
 
5.1 Microfluidic chamber design and fabrication 
 
I decided to reduce the length of the microgrooves to improve the crossing 
rate of motor neuron axons. G. Menendez (Molecular Neuropathobiology laboratory, 
Cancer Research UK) has previously observed, that cells had a tendency to 
migrate through microgrooves of up to 500 µm in length (Menendez, 2010). To 
avoid this side effect, I designed the microgrooves to be more shallow, 1-2 µm high, 
but shorter, only 500 µm in length (Figure 5-1). I prepared the new design using the 
software Canvas (ADC Systems), under the guidance of G. Menendez. The final 
design was replicated onto SU9 silicone wafers using photolithography 
(microLIQUID, Spain). These wafers were then used to make PDMS replicas, 
which can be mounted on plastic or glass bottom dishes and used as a microfluidic 
chamber. To avoid any damage to the original wafer, the first PDMS insets were 
used to create identical epoxy resins and use these as templates for the repetitive 
chamber preparations. Epoxy resins are more resistant to scratches and damage, 
than the original SU9 silicone wafer, and they are also easier to replace. I used 50 
mm diameter glass bottom dishes for live cell imaging and immunofluorescence 
applications. PDMS insets were irreversibly attached to the dish using plasma 
cleaner. Plasma cleaner creates temporarily reactive chemical groups on the 
surface of the glass and PDMS that can form irreversible bonds if put in contact 
immediately after treatment.  
Before plating motor neurons, I wanted to make sure that the pattern on the 
silicone wafer was correctly replicated. To check this, I prepared PDMS replicas 
and imaged them using scanning electron microscopy (SEM; performed by A. 
Weston, Cancer Research UK, London Research Institute). This analysis 
confirmed that the microgrooves are 500 µm long (Figure 5-1 B), 10 µm wide and 
only 1-2 µm deep (Figure 5-1 C). The walls of the microgrooves are not entirely 
smooth, and this provides a surface that is favourable for growing axons. There is 
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perfect fluidic isolation between the two channels, if a higher liquid column (volume) 
is added to the other side (Figure 5-1 D).  
 
 
Figure 5-1. Microfluidic chambers with shorter, but shallower microgrooves still 
provide fluidic isolation 
(A) The pattern of two longitudinal channels, and horizontal microgrooves connecting 
the channels was replicated onto a silicon wafer using photo-litography. This wafer was 
then used as a master to produce PDMS insets. Four round wells were punched into 
these insets to create the reservoir wells. (B) 500 µm long microgrooves connect the 
two longitudinal channels. Scale bar: 250 µm. (C) High magnification image from the 
highlighted area in (B). The microgrooves are 10 µm wide, but only 1-2 µm deep to 
avoid the loss of microfluidic isolation due to the shortening of the grooves. Scale bar: 
20 µm on the main panel, 1 µm on the inset. (D) The PDMS inset was attached to a 
glass bottom Willco® dish and the microfluidic isolation was tested by adding 150 µl of 
PBS+bromophenol blue on the left side, and 200 µl PBS on the right side. The 
chamber was left for 24 h before imaging. There is microfluidic isolation between the 
two longitudinal channels. Scale bar: 10 mm.  
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5.2 Primary motor neuron cultures in microfluidic chambers 
 
Once I have confirmed that the new design was correctly replicated on the 
PDMS insets and the chambers provided microfluidic isolation despite the 
decreased length of the microgrooves, I tested their suitability to grow primary 
motor neurons. Following the irreversible attachment of the PDMS inset to the 
glass bottom dish, I added PBS containing 0.8% BSA overnight at 37°C to both 
sides to make the hydrophobic surface produced by plasma cleaning more 
hydrophilic. The dishes were then coated with L-poly-ornithine/laminin overnight at 
37°C, and to make sure that the microgrooves are coated as much as possible, a 
high volume difference was applied to the two sides and the chambers were tipped 
on one side to enhance the liquid flow. Freshly dissected primary motor neurons or 
freshly disaggregated embryonic stem (ES) cell derived motor neurons were 
loaded into one channel (somatodendritic compartment), using a high density (up 
to 100,000 cells) in low volume (10 µl) of motor neuron medium (completed with 1 
ng/ml BDNF). Pipetting directly into the channel helped to avoid cells attaching in 
the reservoirs. A higher volume of motor neuron medium (15 µl) was added to the 
other channel (axonal compartment) to prevent the freshly plated cells from 
migrating through the microgrooves. Extra motor neuron medium of identical 
composition was added drop by drop on both axonal and somatodendritic sides 
once the neurons attached to the glass on the somatodendritic side (2 h at 37°C 
after plating), with a slightly higher volume on the somatodendritic compartment to 
aid axonal crossing. 
The first axons reached the axonal compartment within 3 d after plating and 
there was a well-established dense axonal network by DIV 7. The shortening of the 
microgrooves has improved axon crossing, but the cell density in the 
somatodendritic compartment (100,000 cells per chamber) made imaging 
challenging (Figure 5-2). I have decreased the number of cells plated to 50,000 per 
chamber and this lead to a less dense axonal network, but allowed a better imaging 
of the somatodendritic compartment (Figure 5-3). All further experiments were 
performed using this cell density during plating. 
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Figure 5-2. Primary motor neurons cross in microfluidic chambers when plated 
at a high density 
Freshly dissected motor neurons (100,000 cell/chamber) were plated into the 
somatodendritic compartment (left hand side) of microfluidic chambers. The axons 
crossed and established a dense network by DIV 7 (right hand side). Scale bar: 100 
µm. 
 
Figure 5-3. Primary motor neurons cross in microfluidic chambers when plated 
at medium density 
Freshly dissected motor neurons (50,000 cell/chamber) were plated into the 
somatodendritic compartment (left hand side) of microfluidic chambers. The axons 
crossed and established a less dense, but extended network by DIV 7 (right hand side). 
Scale bar: 100 µm. 
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Next, I wanted to test whether only motor neurons were capable of crossing 
the microgrooves using a mixed ventral horn cell preparation. Unfortunately there is 
no specific antibody to label the axons of motor neurons, so I turned to murine 
neural progenitor cells, which express GFP (green fluorescent protein) under the 
motor neuron specific HB9 promoter. To do this, I differentiated the ES cells into 
ventral horn neurons, and plated them in the somatodendritic compartment. After 4 
d, at the stage of early axonal crossing, I fixed the chambers and stained for βIII 
tubulin and SMI31. The SMI31 antibody recognises heavily phosphorylated 
neurofilament, which is most abundant in axons; this makes it an excellent axonal 
marker. I found that both motor neurons and non-motor neurons’ axons crossed the 
microgrooves (Figure 5-4). This finding was not surprising, since only a proportion 
of the ES-derived neurons are GFP-positive and GFP-negative neurons grow 
extensive and long neurite networks. This experiment also showed that several 
axons coming from different neurons can bundle together in one microgroove. 
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Figure 5-4. Different type of neurons cross in microfluidic chambers 
ES derived HB9::GFP (green) neurons were plated in the somatodendritic 
compartment of microfluidic chambers. The cells were allowed to settle and grow 
axons to the axonal side (DIV 4) before fixation, permeabilisation and blocking. Both 
compartments were stained for βIII tubulin (blue) to label the whole neuronal network 
and SMI 31 (red) to label axons. Note that the antibodies do not stain the axons within 
the microgrooves due to microfluidic isolation. Scale bar: 50 µm. 
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5.3 HCT is taken up at the axonal compartment and transported 
retrogradely to the somatodendritic compartment 
The aim of this approach was to prove that HCT is transcytosed in primary 
motor neuron cultures. Before testing this, I needed to optimise its uptake and 
retrograde transport in microfluidic chambers. I plated primary motor neurons into 
the somatodendritic compartment and let the axons cross for 7 d. Then I added 
AlexaFluor555-HCT in motor neuron medium to the axonal compartment and made 
sure that the somatodendritic compartment contained a higher volume of medium 
to avoid diffusion of the probe. The cells were left to internalise and transport HCT 
for 2 h at 37°C before washing with HBSS and fixing with 4% PFA for 15 min at 
room temperature. Both compartments were permeabilised with PBSTr for 10 min 
at room temperature before blocking with IFBB for 1 h and adding mouse anti-βIII 
tubulin primary antibody for 1 h at room temperature. Both compartments were 
washed and goat AlexaFluor647-conjugated anti-mouse secondary antibody was 
added for 30 min to reveal the neuronal network. The chambers were imaged, 
paying special attention to the cell bodies of neurons, which had axons on the 
axonal side. All axons were positive for HCT, which had been retrogradely 
transported back to the cell body (Figure 5-5 A). The length of the initial incubation 
(2h) appeared to be ideal for studying transcytosis and synaptic transfer, because 
numerous neurons accumulated HCT, which did not have an apparent axon 
crossing to the axonal side (Figure 5-5 B). However, this experiment did not 
formally prove that synaptic transfer had occurred via functional synaptic 
connections between neurons. 
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Figure 5-5. HCT is retrogradely transported in compartmentalised motor neuron 
cultures 
Freshly dissected primary motor neurons were plated into the somatodendritic 
compartment of microfluidic chambers; axons were allowed to cross for 7 d before 
adding AlexaFluor555-HCT to the axonal compartment. (A) HCT (red) bound, 
internalised and underwent axonal retrograde transport in the axonal compartment. 
The neuronal network is stained with βIII tubulin (blue). Scale bar: 100 µm. (B) HCT 
accumulates in cell bodies in the somatodendritic compartment. Note that one of the 
neurons does not possess an axon extended towards the microgrooves, suggesting 
that it did not cross to the other side. Scale bar: 50 µm. 
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5.4 HCT is transferred between neurons in microfluidic 
chambers 
5.4.1 Cholera toxin subunit B is not, but HCT is transferred between neurons 
in the somatodendritic compartment 
To prove that HCT is transcytosed, I turned to a probe, which is a great 
retrograde tracer but does not get transcytosed in neurons. Cholera toxin subunit B 
(CTB) is the binding fragment of cholera toxin and binds to the ganglioside GM1 
with high affinity (Merritt et al., 1994). It is an excellent retrograde tracer (Wan et al., 
1982); it binds to all neurons in primary motor neuron cultures, but never gets 
transferred between neurons (Schwab et al., 1979). CTB was shown to accumulate 
in lysosomes after transport (Llewellyn-Smith et al., 1990) in medullary neurons, 
while other studies conducted on intestinal cells showed that it is transported to the 
endoplasmic reticulum through the trans-Golgi network (TGN) (Lencer and Tsai, 
2003). 
I added AlexaFluor555-HCT and AlexaFluor488-CTB to the axonal 
compartment of microfluidic chambers and allowed both probes to internalise and 
get transported for 2 h at 37°C. The chambers were washed extensively and the 
somatodendritic compartment was stained for βIII tubulin to label the neuronal 
network as before. Both CTB and HCT were retrogradely transported, sharing the 
majority of transport compartments (Figure 5-6; white arrows), this is in agreement 
with previous experiments performed in our laboratory by M. Terenzio (Schmieg et 
al., 2014) and G. Menendez (Menendez, 2010). However, despite the overlap 
between the transport compartments of HCT and CTB, they are differentially sorted 
and the probes are directed into different intracellular destinations. G. Menendez 
showed that CTB accumulates in the TGN in dorsal root ganglia neurons 
(Menendez, 2010). 
The sorting of HCT in motor neurons has not been studied in detail, but it is 
expected to be targeted to a transcytotic route together with the neurotrophin 
receptors, TrkB and p75NTR and get transferred between neurons (Lalli et al., 2003a, 
Bercsenyi et al., 2013). 
In the somatodendritic compartment, I found neurons containing HCT but not 
CTB. Since all axons in the axonal compartment were stained with both probes, 
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this result suggests that these neurons did not have an axon projecting to the 
axonal compartment. The only way they could have been exposed to HCT was 
through synaptic transfer from another neuron, which had an axon extended to the 
axonal compartment. The two neurons imaged in Figure 5-6 have close contact 
sites between their arborisation (yellow arrowheads); and one of them contains HCT 
but not CTB (secondary contact neuron), while the other contains both (projecting 
neuron). HCT must have been released by the projecting neuron and internalised 
by the secondary contact neuron. This result demonstrated for the first time that 
HCT undergoes synaptic transfer between neurons in compartmentalised primary 
motor neuron cultures. 
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Figure 5-6. HCT is transcytosed in primary motor neurons 
Primary motor neurons were plated in microfluidic chambers and left to grow axons 
through the microgrooves for 7 days. AlexaFluor555-HCT (pseudocolored grey, red in 
merge) and AlexaFluor488-CTB (pseudocolored grey, green in merge) were added to 
the axonal side simultaneously and left to get internalised and transported for 2 h at 
37°C. Both compartments were washed with HBSS before fixing, blocking, 
permeabilising and staining for βIII tubulin (pseudocolored grey). The white arrowheads 
show shared transport compartments between HCT and CTB, while the yellow 
arrowheads point at possible transcytosis sites (see schematic). Scale bar: 20 µm. 
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5.4.2 Nidogen-2 is present in the extracellular space in the axonal 
compartment 
The axonal compartment was coated with poly-ornithine and laminin, but 
was completely free of cells and it was microfluidically isolated from the 
somatodendritic compartment. Since HCT was efficiently taken up by the axons in 
the axonal compartment, I asked whether nidogen-2 was present there. To test this, 
I did an immunostaining with the nidogen-2 antibody as described earlier. Nidogen-
2 was highly concentrated around the leading edge of crossing axons and was 
present in the extracellular space and on the surface of axons in large quantities 
(Figure 5-7). 
 
 
Figure 5-7. Nidogen-2 is present in the axonal compartment in microfluidic 
chambers 
The axonal compartment was fixed, permeabilised and stained for βIII tubulin (blue) 
and nidogen-2 (green). Scale bar: 100 µm. 
 
5.4.3 HCT is transcytosed with nidogen-2 
Next, I wanted to test whether nidogen-2 is synaptically transferred together 
with HCT from motor neurons. This includes the capture at the basal lamina, 
binding on the cell surface and internalisation, axonal transport, sorting and 
exocytosis of the transport vesicle through the somatodendritic PM. To test this, I 
added AlexaFluor555-HA-HCT and rabbit anti-nidogen-2 antibody to the axonal side 
of microfluidic chambers and allowed 2 h at 37°C for internalisation, retrograde 
ȕ,,,WXEXOLQ QLGRJHQ
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transport and transcytosis to occur. Cells were fixed and blocked without 
permeabilisation. Keeping the PM intact was important to ensure that antibodies 
can only recognise antigens that are present on the PM. Rat anti-HA primary 
antibody was added to the somatodendritic compartment, followed by goat 
AlexaFluor488-conjugated anti-rat to label AlexaFluor555-HA-HCT, which has been 
exposed on the PM. Goat AlexaFluor647- conjugated anti-rabbit antibody was 
added to label exposed nidogen-2 bound by the rabbit anti-nidogen antibody. Both 
probes underwent exocytosis through the somatodendritic membrane together and 
this lead to the exposure of the probes (Figure 5-8), indicating that nidogen-2 stays 
together with HCT all along its journey inside motor neurons, and maybe even 
beyond. 
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 Figure 5-8. HCT and nidogen-2 are transcytosed together 
Primary motor neurons were plated in microfluidic chambers and let to grow axons 
through the microgrooves for 7 d. AlexaFluor555-HA-HCT (red) and rabbit anti-nidogen-
2 were added simultaneously to axonal side to allow internalisation, axonal transport 
and transcytosis for 2 h at 37°C. The cells were fixed and blocked without 
permeabilisation. Rat anti-HA primary antibody was added, followed by goat 
AlexaFluor488- conjugated anti-rat to label re-presented AlexaFluor555-HA-HCT on the 
PM (pseudocolored grey, green on merge) and goat AlexaFluor647- conjugated anti-
rabbit antibody to label exposed nidogen-2 (pseudocolored grey, blue on merge). Scale 
bar: 10 µm. 
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5.5 Summary 
• I designed new microfluidic chambers, with 500 µm long and 1-2 µm deep 
microgrooves. These chambers provide microfluidic isolation between the 
somatodendritic and axonal compartment and are suitable for motor neuron 
culture. 
• The axons of different neuronal types present in the ES-cell derived and 
primary motor neuron cultures cross the microgrooves successfully within 7 
days after plating. 50,000 cells per chamber is the ideal cell density to be 
plated in the somatodendritic compartment for optimal imaging. 
• HCT is taken up at the axonal compartment; it is retrogradely transported and 
accumulates in the cell body. 
• Both HCT and CTB are taken up and transported together, but their internal 
sorting is different, since CTB accumulated in the TGN, while HCT is targeted 
to the somatodendritic PM, exocytosed and taken up by neighbouring neurons. 
• Nidogen-2 is colocalised with HCT during binding, uptake, transport and re-
presentation on the PM in the soma. 
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Chapter 6. Discussion 
6.1 Aims of the Ph.D. project 
• Find an inhibitor of tetanus intoxication 
• Identify and characterise the protein receptor of TeNT at the NMJ 
• Investigate the synaptic transfer of TeNT between motor neurons and 
interneurons 
 
6.2 The N1 peptide is a potent inhibitor of tetanus intoxication 
One of the main aims of this project was to develop an inhibitor, which could 
serve as a template for therapeutic interventions against tetanus. The N1 peptide 
emerged from the initial peptide screen and it blocks tetanus intoxication in mice; 
which makes it an excellent template for a therapeutic agent to block the onset and 
progression of tetanic paralysis. 
6.2.1 In vitro binding assays – the N1 peptide emerges as the top candidate 
Among the assays used in this study, the fluorescent binding assay is the 
most artefact-free, since the peptides are bound on the bottom of a plate, and 
directly labelled AlexaFluor555-HCT is added after blocking with BSA. The N1 
peptide showed the highest signal in these experiments, although the N3 and D 
peptides were also efficient at binding HCT (Figure 3-2). The main difference in the 
in vitro pull down assay is that instead of binding on the surface of plate, the 
peptides are bound on the surface of agarose beads. This favoured those peptides, 
which were more hydrophobic, and new candidates, such as the D, J and O 
peptides emerged from this assay (Figure 3-3). However, when tested in an ELISA, 
all three peptides (D,J,O) appeared to bind to the anti-VSVG antibody directly, 
which indicated that due to their high hydrophobic features, they were binding to 
proteins unspecifically. In contrast, the N1 peptide bound specifically to HCT and 
not the antibody. When the results were normalised to the values where HCT was 
omitted from the assay (Figure 3-4), it became clear that the N1 peptide was the 
best candidate emerging from the entire screen.  
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6.2.2 The N peptides block HCT binding on primary motor neurons 
All peptides, which showed binding in any of the assays discussed above, 
were carried forward in competition assays on primary motor neurons. We 
identified a peptide within nidogen-2, which was very similar to the N1 peptide 
(THIYQWRQT), but contained inverted motifs (NQTWSYHID) (Kohfeldt et al., 
1998). Both the N1 and N2 peptides blocked HCT binding and internalisation in 
primary motor neurons, while the D and O peptides caused aggregation of 
AlexaFluor555-HCT and the J and N3 peptides did not have any effect (Figure 3-5). 
Furthermore, the N1 peptide still had a blocking effect when added to the cells with 
a 10 min delay, indicating that it might have a higher affinity to HCT than the protein 
receptor(s) (Figure 3-11). However, HCT was present in the motor neuron medium 
throughout the experiment (45 min in total). We know that HCT binding is very 
efficient and occurs very quickly (5-10 min), but the possibility that the N1 peptide 
added at the 10 min time point blocked binding of the ‘late targeting’ HCT pool 
cannot be excluded and this could have caused the decrease in the internalised 
pool of HCT at 45 min. To further test this, HCT should be added in a ‘pulse-chase’ 
experiment, only left on the cells for 10 min, then washed off before the addition of 
the N1 peptide. If the peptide can still cause a decrease in the total internalised 
pool of HCT at 45 min, this effect is likely to be due to interference with receptor 
internalisation/sorting.  
 
6.2.3 The W is crucial for the interaction between N1 and HCT 
The four core residues of N1 (YQWR) are completely conserved in 
mammals, while there are numerous single substitutions in the first and last 
position of the core residues of N2 (TWSY). I performed a peptide array, containing 
all 20 possible amino acid substitutions in the four key residues in both N1 and N2, 
to test which positions are the most important for HCT binding. Due methodological 
problems in the preparation of these peptide arrays, which make this approach only 
semi-quantitative, I could not obtain conclusive results (Figure 3-6). To overcome 
this, I decided to test single alanine mutant peptides for HCT binding in a 
fluorescent binding assay and found that mutating the W for A in both peptides 
completely abolished HCT binding. Both human peptides (hN1 and hN2) bound HCT, 
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albeit less than their mouse counterparts. The N2 peptide had a lower binding 
ability than the N1 peptide and it was much more sensitive to alanine substitution 
(Figure 3-7). 
Next, we attempted to obtain a crystal structure of the N1 peptide bound to 
HCT. I tested the stability of the interaction between the N1 peptide and HCT in 
buffers with different pH and found that the interaction between the peptide and 
HCT is abolished at pH 5, which is the preferred pH for HCT crystal formation 
(Figure 3-8 B). However, the N1 peptide had a far greater binding affinity when 
compared to the YEW tripeptide, which was previously co-crystallised with HCT 
(Jayaraman et al., 2005), indicating that if there were permissive conditions for 
peptide binding and HCT crystallisation, there would be a high chance of obtaining 
co-crystals.  
Unfortunately all crystallisation attempts failed to date, therefore we turned 
to biomolecular modelling. The analysis (performed by G. Zanotti, University of 
Padova) showed that the majority of the peptide surface is buried in the ‘R’ pocket 
of HCT, predicting that the binding affinity is very high (Figure 3-8 C). The 
competing potential of the N1 peptide might be due to competition with more than 
one endogenous receptors. Since it binds into ‘R’ pocket of HCT, it most probably 
blocks all interactions at this site. This might include polysialogangliosides 
(Stoeckel et al., 1977, Kitamura et al., 1999, Chen et al., 2009) as well as protein 
receptors (Rummel et al., 2003, Montecucco, 1986). 
We tried to determine the binding affinity of the N1 peptide experimentally, 
but unfortunately we saw no binding on the Octet system and the ITC experiments 
provided limited information due to technical limitations of this assay. The cellular 
environment and polysialogangliosides were lacking in both of these experiments, 
and this might explain the reason why the estimated Kd based on the ITC 
experiments is 7.5 µM, which is far higher than expected (Figure 3-8 D). 
6.2.4 The N1 peptide blocks HCT binding on the NMJ 
To assess the ability of HCT to bind to the NMJ, I used freshly dissected 
whole-mount LAL muscles. This preparation is excellent for whole-mount 
experiments because it consists of only a few cell layers. I allowed 1 h for 
internalisation and observed that not all NMJs contained HCT (only 63.6±6.0% of all 
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NMJs in the muscle are HCT positive, Figure 3-13). This might be due to multiple 
reasons: 
 
• A region of the muscle might have folded over and it was not available for 
HCT binding.  
• These junctions might have taken up HCT faster than others and the probe 
was retrogradely transported and cleared from the motor neuron endplate. 
• An alternative explanation is that not all NMJs contain determinants for HCT 
binding, including the presence of a protein receptor.  
 
By injecting HCT-HA intramuscularly and sectioning the tissue, we excluded 
the possibility of antibody penetrance issues and still observed that not all NMJs 
contain HCT. This was the case for different time points (30 and 60 min), which 
makes it unlikely that the empty NMJs transport HCT faster and suggests that these 
do not bind HCT due to the lack of determinant(s) for HCT binding. 
When preincubated with the N1 peptide, HCT lost its ability to bind to NMJs 
and the number of HCT containing NMJs dropped to 14.3±4.7% (Figure 3-13). 
6.2.5 The N1 peptide blocks tetanic paralysis in vivo  
6.2.5.1  Hemidiaphragm assay 
TeNT causes paralysis in hemidiaphragm preparations, but the mechanism 
of its action in this experimental setup is unknown. When the diaphragm is 
dissected, the phrenic nerve loses its connections with the spinal cord (Simpson, 
1977, Simpson, 1984). During tetanus, TeNT is retrogradely transported in motor 
neuron axons and gets transcytosed into inhibitory interneurons in the spinal cord 
(Lalli et al., 2003a), but this part of the pathway is not available in this tissue 
preparation. TeNT is used at a relatively high concentration and this might cause its 
accumulation in carriers, which undergo pH changes locally, which in turn leads to 
the release of the L chain and cleavage of its target protein, synaptobrevin, within 
the motor neuron terminal. By blocking synaptic vesicle release from the phrenic 
nerve, it causes the paralysis of the muscle; there is no contraction even when a 
supramaximal stimulus is applied. When TeNT was preincubated with the N1 
peptide, it took longer to paralyse the muscle, but the results were not significant 
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and the N2 peptide appeared to cause the opposite (Figure 3-14). The most 
probable explanation is that TeNT is mainly using an alternative entry pathway in 
this assay, and this does not depend on the ‘R’ site; where the N1 binds, so it does 
not significantly affect the timeframe of tetanic paralysis. 
6.2.5.2  Local tetanus in mice 
To test whether the N1 peptide can efficiently block tetanic paralysis in vivo, 
we injected the triceps surae muscle of mice with TeNT, which was preincubated 
with vehicle, control peptide (N1AA) or the N1 peptide. TeNT used at a low dose 
(0.25-2 ng/kg) and injected intramuscularly causes local tetanic paralysis (Samal et 
al., 1990, Duchen and Tonge, 1973). Since it was injected in the hindlimb, the 
injected limb got stiff and the mice were not using it to support their weight while 
walking. The injected leg was lagging behind and this led to a defect in coordination. 
When mice walk, they place the hind paw where the front paw was located at the 
previous step. As the injected leg was not positioned properly, we could get a 
quantitative measurement on the progression of tetanic paralysis. The mice 
injected with 2 ng/kg TeNT, which was preincubated with the N1 peptide did not 
present any coordination defects at 25 h, while the other two groups showed a 
significant impairment (Figure 3-15). At later stages, the injected leg of the control 
groups got completely paralysed, and the animals refrained from using it to support 
them while walking. When held by their tail, tetanic mice could not stretch their 
injected leg outwards, like control animals do, since the triceps surae muscle was 
paralysed. The N1 peptide treated group had a slight impairment in the holding 
posture, but this was milder than in the other groups (Movie 1). 
To gain some understanding on the underlying physiological effect of 
tetanus intoxication, we performed muscle tension experiments. The tibialis anterior 
muscle was injected with a low dose of TeNT, which was preincubated with vehicle, 
control peptide or the N1 peptide. After 24 h, when spastic paralysis occurred, the 
maximal contractile force was determined following supramaximal stimulus. The N1 
peptide treated group had less muscle power in the injected than in the non-
injected leg, but this difference was not significant, while the other two groups had 
a significant drop in muscle power (≃90%,Figure 3-16). The N1 treated group 
retained a significantly bigger percentage of muscle force (43.5±10.5% SEM) 
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compared to the other two groups (2.4±0.9% SEM for TeNT+DMSO and 0.3±1.4% 
SEM for TeNT+N1AA).  
These experiments clearly demonstrated that the N1 peptide protects mice 
from tetanic paralysis. However, the mechanism of this protective action needed to 
be elucidated. Based on our predictions, the peptide is likely to bind to the ‘R’ site 
of TeNT, where sialic acid was shown to bind. The interruption of this interaction 
could lead to the blocking action of the N1 peptide. Alternatively, the peptide could 
block the binding of a protein receptor at the ‘R’ site, which could potentially be the 
actual protein it originates from; nidogen-1.  
The N1 peptide is a unique blocking agent of tetanus, since no other 
compound has been identified to date, which could inhibit tetanic paralysis with 
such efficiency.  
If the N1 peptide is able to compete with the receptor even after the binding 
of TeNT has occurred, it provides a very promising platform for drug development. 
When patients present with the first line of symptoms (lockjaw) (Centers for 
Disease, 2012), the agent based on the peptide could be administered 
systematically and this could prevent the further spread of TeNT to new NMJs. If 
the innervation circuits of vital muscles, such as the diaphragm can be protected 
from TeNT, the most common cause of death, respiratory failure can be avoided 
and this in turn would decrease the high mortality rate. Bone fractures (long bones 
and the spine) are the consequences of strong muscle spasms, which could also 
be prevented if the peptide-based new drug blocked TeNT from binding to the 
NMJs in big skeletal muscles (Centers for Disease, 2012). The second most 
common cause of death is secondary infection, which occurs during the prolonged 
hospitalisation. Provided that the novel therapeutic approach involves a compound, 
which is stable and can stay in the circulation for a long period of time, the hospital 
stay could be significantly reduced and the chances of contracting infections linked 
to immobility, cannulas and mechanical ventilation would decrease. 
Alternatively, this new approach could be integrated into the current medical 
intervention protocol (Table 18) and used in combination with Td vaccine (contains 
inactivated tetanus toxoid and pertussis vaccine) and tetanus immunoglobulin (TIG). 
This way the patients would not only survive tetanus, but be protected from 
contracting it again. 
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Table 18. The current medical protocol for tetanus intoxication (Centers for 
Disease, 2012) 
Vaccination History Clean, minor wounds All other wounds Td TIG Td TIG 
Unknown or less than 3 doses Yes No Yes Yes 
3 or more doses  
(last dose less than 5 y ago) 
No No No No 
 
 
6.3 Nidogens are extracellular matrix protein receptors for 
TeNT 
The N1 and N2 peptides originate from nidogen-1 and nidogen-2, 
respectively. Both nidogens are expressed in primary motor neurons, but nidogen-1 
is present in much higher quantities (Figure 4-3). In the initial proteomic analysis of 
endosomal carriers containing HCT, nidogen-1, but not -2 was found (Deinhardt et 
al., 2006b). However, the nidogen-1 antibody only worked for western blotting and 
not for immunofluorescence, so I relied on the nidogen-2 antibody to perform all 
immunocytochemistry and immunohistochemistry experiments. I observed cross-
reactivity between nidogen-1 and the anti-nidogen-2 antibody in Western blotting, 
which suggests that to a certain extent, both nidogen isoforms are recognised by 
this antibody. 
6.3.1 Nidogen-2 is taken up together with HCT in primary motor neurons 
By incubating primary motor neurons with HCT and the anti-nidogen-2 
antibody at the same time, I showed that nidogen-2 is taken up together with HCT in 
primary motor neurons (Mander’s coefficient 66.3±1.1%, Figure 4-4). Furthermore, 
the proteins interact with each other, since nidogen-2 is immunoprecipitated with 
HCT (Figure 4-5). To observe the interaction, the proteins had to be cross-linked 
prior to immunoprecipitation. Nidogens are heavily glycosylated and HCT binding to 
neurons is detergent sensitive. The detergents present in the lysis buffer are likely 
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to make the interaction between HCT and nidogens weaker and harder to detect 
and also disrupt the binding with polysialogangliosides. The cross-linking protocol 
prevents the disruptive effect of the lysis buffer, by stabilising the interaction. In 
addition, by allowing internalisation for 5 min, most of the HCT pool resided in early 
CCVs. The CCVs concentrate the HCT-nidogen complex, making them easier to 
stabilize. Partial hydrolysis of the adducts may occur during preparations of the 
samples for SDS-PAGE upon incubation at high temperature and alkaline pH, this 
might be the reason why the main bands on the blot were corresponding to the 
molecular weight of HCT (55 kDa) and a heavily glycosylated form of nidogen (250 
kDa). The nidogen-2 antibody is cross-reacting with nidogen-1 on western blots, so 
the observed band might contain nidogen-1 or -2. I looked for the presence of other 
known proteins, which reside within the signalling endosome (TrkB, sortilin, LAR), 
but did not detect their presence. However, the immunoprecipitation of HCT is very 
challenging, and the proteomic analysis of endosomal carriers has already 
confirmed the presence of TrkB and p75NTR, so I turned to other methods to 
investigate the identity of the transmembrane protein receptor(s).  
6.3.2 Nidogen-1 fits into the ‘R’ pocket of HCT 
Using biomolecular modelling, we showed that human nidogen-1 fits into the ‘R’ 
pocket of HCT; at the same site, where the N1 peptide binds (Figure 4-6). The 
residues important for the interaction are listed in Table 19. The common HCT 
interacting residues between the N1 peptide and nidogen-1 G2 domain are Q608 
and R610, which are conserved between mouse and human nidogen-1 
(IYTYQWRQT; Table 17). Y and W are not predicted to be directly involved in the 
binding, which is not surprising, given that they are hidden in the intact G2 domain 
(Figure 4-1 A) and this structure was used in the modelling. The first three residues 
of the N1 peptide (THI) make hydrogen bonds and polar interactions but these are 
not conserved between mouse and human. This difference might explain why the 
hN1 peptide binds HCT less than N1 (Figure 3-7). Since both the N1 peptide and 
nidogen-1 bind to the ‘R’ pocket, they might compete with each other for binding. In 
turn, this competition might largely contribute to the blocking potential of the N1 
peptide in vivo. 
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Unfortunately we could not model the possible interaction between a 
cleaved form of nidogen-1 (following plasmin cleavage) and HCT, because no 
crystal structure was available for the cleavage products of metalloproteases.  
The single alanine substitution of Q608 in the mouse peptide 
(THIYQWRQT) resulted in a significantly decreased binding to HCT (39.5±2.9% 
SEM; Figure 3-7), and the Y1229A mutant of HCT, (Y1229 interacts with Q608, 
S584 and T582) decreased the binding between HCT and N1 to a similar extent 
(40.6±12.2%; Figure 4-7).  
The R1226F substitution in HCT was proven to be the most effective in 
decreasing the HCT-N1 interaction (Figure 4-7), which was predicted to bind Q5 in 
the N1 peptide (corresponding to Q608 in nidogen-1) (Table 15). Furthermore, this 
HCT mutant has a much lower toxicity than wild type HCT (1.4±0.2% SEM) 
(Rummel, 2006), our data suggests a mechanistic explanation why this residue 
plays an important role in mediating the entry of HCT into motor neurons.  
To further prove the validity of this model, I showed that both nidogen-1 and 
-2 bind to HCT directly and that this binding is blocked when HCT is preincubated 
with the N1 and N2 peptides (Figure 4-8). 
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Table 19. Summary of HCT-Nidogen-1 or N1 interactions 
nidogen-­‐1	  (h-­‐G2)	   HCT	   N1	  (m)	  
521	   E	   N1216	   	  	  
	   	  
	  	   	  	  
523	   T	   G1215	   	  	  
	   	  
	  	  
	  530	   N	   A1217	   	  	  
	   	  
	  	  
	  575	   H	   N1144	   	  	  
	   	  
	  	  
	  580	   V	   N1144	   	  	  
	   	  
	  	  
	  582	   T	   I1145	   T1146	  
	   	  
	  	  
	  584	   S	   Y1229	   	  	  
	   	  
	  	  
	  586	   T	   K1213	   Y1229	  
	   	  
	  	  
	  604	   I	  
	  
	  	  
	  
D1214	   T	   1	  
605	   Y	  
	  
	  	  
	  
G1233	   H	   2	  
606	   T	  
	  
	  	  
	  
K1213	   I	   3	  
607	   Y	  
	  
	  	  
	   	  
Y	   4	  
608	   Q	   Y1229	   	  	   I1224	   R1226	   Q	   5	  
609	   W	  
	  
	  	  
	   	  
W	   6	  
610	   R	   D1214	   G1215	  
	   	  
R	   7	  
611	   Q	  
	  
	  	   D1278	   K1143	   Q	   8	  
612	   T	  
	  
	  	  
	   	  
T	   9	  
614	   T	   N1277	   	  	  
	   	  
	  	  
	   
The residues predicted to be involved in the interaction between the human nidogen-1 
G2 domain or mouse N1 peptide and HCT are shown. The amino acids within the G2 
domain and the N1 peptide are in bold and the experimentally tested point mutants of 
HCT are highlighted. Q608 and its corresponding amino acid in the N1 peptide, Q5 are 
highlighted in red, since these are the residues which are involved in binding both in 
the G2 domain and in the peptide. 
 
6.3.3 Recombinant nidogen-1 increases HCT binding and internalisation on 
primary motor neurons and this effect is blocked by the N1 peptide 
Nidogens are ECM proteins, and the observation that HCT entry is 
dependent on these proteins suggests that there are a certain number of 
accessible nidogen binding sites for HCT in the intact ECM. The addition of 
exogenous soluble nidogens lead to a significant increase in HCT binding and 
internalisation, which was completely blocked by the presence of the N1 peptide 
(Figure 4-9). This is in sharp contrast to the predicted outcome of a similar assay, 
where the receptor is a transmembrane protein: the soluble domain acts as a 
scavenger and sequesters the free ligand, leading to a decrease in binding and 
internalisation (Dong et al., 2006). Nidogen-1 had a dramatic effect (2-3 fold 
increase), whereas recombinant nidogen-2 only caused a minimal increase in HCT 
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binding and internalisation. Due to the unavailability of a nidogen-1 antibody for 
immunofluorescence, I stained the treated cells with anti-His antibody, which 
recognises the His-tag on the recombinant protein. It became clear that 
recombinant nidogen-1 binds to motor neurons (Figure 4-10). When HCT was 
preincubated with the N1 peptide, the increase observed in its binding in the 
presence of recombinant nidogen-1 was diminished, and HCT binding was still 
completely blocked (Figure 4-11). This experiment showed that HCT binding is 
dependent on the number of nidogen-1 binding sites available. The N1 peptide 
blocks the interaction between nidogen-1 and HCT in situ and completely abolishes 
HCT binding even in the presence of exogenous nidogen-1. However, we still 
cannot formally exclude the possibility that sialic acid, or another protein receptor 
bind at this site, and that the N1 peptide would block the interaction between these 
and HCT.  
6.3.4 Additional nidogen-1 increases TeNT toxicity in mice 
Based on the enhancing effect of nidogen-1 on HCT binding in primary motor 
neurons cultures, we hypothesised that co-injecting nidogen-1 with TeNT would 
lead to earlier onset, and/or more severe progression of tetanus. When mice were 
injected in the triceps surae muscle with the mixture of nidogen-1 and TeNT, the 
onset of tetanic paralysis occurred earlier and the mice progressed faster than the 
control groups in the early stages of the disease (Figure 4-12). The middle and final 
stages however, showed a similar timeline to the control groups (Figure 4-13 – the 
score points are equally spaced), which could be explained if nidogen-1 is required 
for the binding and subsequent internalisation of TeNT into retrogradely transported 
signalling endosomes, but cannot influence the speed of transport. Further 
experiments are required to investigate the mechanism by which exogenous 
nidogen-1 is facilitating clinical tetanus, but these fell beyond the scope of my PhD. 
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6.4 The absence of nidogens results in decreased HCT binding 
and partially protects mice from tetanus 
6.4.1 Nidogen content of the NMJ is the main determinant for HCT binding 
The observation that not all NMJs bind HCT led us to hypothesise that these 
junctions lacked a determinant, which was necessary for HCT binding. To exclude 
the possibility of lack of access to the site, we injected fluorescently labelled HCT in 
the tibialis anterior muscle of wild type mice, with this administration method, the 
probe spreads from the injection site and reaches all NMJs in the area. We took 
muscles at different time points to exclude the possibility of identifying false 
negative NMJs (due to their more efficient uptake and transport of HCT, these might 
appear negative at a later time point). However, even at the 30 min time point, 
about 30% of the NMJs were negative for HCT, in contrast to other NMJs in their 
vicinity. The muscles were counterstained for nidogen-2 and we observed that the 
staining intensity of the nidogen-2 antibody directly correlated to the HCT content on 
the NMJs (Figure 4-25). If nidogen-2 was absent, the HCT did not bind to the NMJ, 
indicating that nidogen-content is one of the main determinants for HCT binding. 
 
6.4.2 Nidogen-2 KO neurons bind less HCT 
If nidogens are crucial for TeNT binding at the NMJ and tetanic paralysis, 
their loss is expected to cause a decrease in HCT binding and protect mice from 
tetanus. However, it is not clear, which isoform is more important in these 
processes, since they have partially overlapping functions and they both bind to 
HCT directly, they can probably compensate for each others’ loss. Single nidogen 
KO primary motor neurons internalised HCT to a similar extent as their wild type 
counterparts (Figure 4-20, Figure 4-21), however, when the concentration of HCT 
was dropped from 40 nM to 10 nM, nidogen-2 KO neurons were less able to bind 
HCT than wild type neurons (Figure 4-22).  
6.4.3 Nidogen KO NMJs internalise less HCT  
When I tested HCT internalisation in single nidogen KO LAL muscles, I 
observed a similar phenomenon as in the primary motor neuron cultures. At a high 
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concentration (60 nM), HCT accumulated at the NMJ in all genotypes (Figure 4-26), 
but it was not capable to enter nidogen-1 and -2 KO NMJs when its concentration 
was dropped to 20 nM (Figure 4-27). This result is in agreement with our 
observation in wild type muscles, that nidogen-content is a major determinant for 
HCT binding, and it appears that the presence of both isoforms is important. 
However, the loss of HCT binding at the nidogen-1 and -2 KO NMJs might 
also be due to impairment in the general structure of the NMJ and problems with 
synaptic vesicle recycling/release. To exclude this possibility, I showed that the 
binding fragment of BoNT/A, which relies on SV2A for its entry into motor neurons, 
was internalised in both nidogen-1 and -2 KO NMJs in a similar extent than the wild 
type NMJ (Figure 4-28). The observed effect of nidogen-1 loss on HCT uptake at 
the NMJ was specifically due to the lack of extracellular nidogen-1, since the 
addition of recombinant nidogen-1 to the medium of LAL muscles restored HCT 
binding (Figure 4-29).  
6.4.4 Nidogen DKO hindbrains internalise less HCT 
To conclusively demonstrate the importance of nidogens in HCT binding and 
uptake, I wanted to test nidogen DKO primary motor neurons and NMJs in the 
same assays as before. Nidogen DKO mice were reported to be perinatally lethal 
(Bader et al., 2005), but in our hands, they never reached full gestation. I tried to 
obtain E13,5 embryos for primary motor neuron dissection, but the double mutants 
did not reach that age either. I decided to attempt to take hindbrains at E11,5 when 
nidogen DKO animals were still viable. It was clear that HCT was not taken up by 
nidogen DKO hindbrains, however, there was a small region in the developing 
mesencephalon, where I found HCT positive cells (Figure 4-30). These cells bind 
and internalise HCT in a nidogen-independent way and are positive for βIII tubulin, 
but their identity and the mechanism through which they internalised HCT remained 
unknown. 
6.4.5 Mice lacking nidogen-2 are partially protected from tetanus 
intoxication 
Nidogen-1 KO mice presented with severe epileptic seizures and early-
onset hindlimb paralysis. Due to these phenotypes, we could not investigate 
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tetanus intoxication in this strain (Figure 4-31). In contrast, nidogen-2 KO animals 
were viable and healthy; so we decided to assess their sensitivity to TeNT. 
Nidogen-2 KO mice were injected intraperitoneally with different doses of 
TeNT and the onset and progression of paralysis were closely monitored. When a 
low dose (1.5 ng/kg) of TeNT was injected into the peritoneal cavity, nidogen-2 KO 
mice were largely protected from paralysis, most of them survived beyond the 
humane endpoint of the experiment (Figure 4-32 A). However, when TeNT was 
injected in higher doses, there was no difference between the groups, although 
their symptoms were slightly different, and nidogen-2 KO mice appeared to have 
early breathing problems, which are more common in botulism than in tetanus. 
Furthermore, these mice developed a grey crescent in their eyes, which is a 
characteristic symptom of botulism, due to the dryness of the eye (Figure 4-32 B) 
(Suwan-apichon et al., 2006). 
6.5 LAR and TrkB might serve as co-receptors for TeNT 
Nidogens reside in the ECM and have no direct contact with the PM. 
Nidogen-1 was previously shown to interact with β-1 integrins and it serves as a 
promigratory factor for Schwann cells (Lee et al., 2007). In addition, the nidogen-
laminin complex was shown to bind to the protein tyrosine phosphatase receptor, 
LAR (O'Grady et al., 1998). LAR binds TrkB in a BDNF-dependent manner (Yang 
et al., 2006) and HCT binding is increased in the presence of BDNF. Furthermore, 
HCT is transported together with p75NTR and TrkB (Terenzio et al., 2014b). Both 
LAR and TrkB were present in the proteomic screens characterising HCT containing 
organelles previously performed in our laboratory (Deinhardt et al., 2006b) and I 
hypothesised that they might be part of the HCT binding complex on the PM. 
Nidogens may therefore serve as a link between HCT and these proteins (Figure 
6-2).  
Both LAR and TrkB colocalise with HCT in primary motor neurons (Figure 4-14, 
Figure 4-15), furthermore, the incubation of these cells with a polyclonal TrkB 
antibody inhibits HCT binding (Figure 4-16). Interestingly when HCT is pre-bound 
to the cells, the polyclonal TrkB antibody cannot recognise TrkB anymore. A 
possible explanation to this phenomenon is that a large protein complex is 
forming around TrkB during HCT binding ( 
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Figure 6-1), and this prevents the recognition of the epitope of the antibody. 
Conversely, when the antibody is already present, the complex cannot form around 
TrkB and HCT cannot bind to motor neurons. The possibility, that the TrkB antibody 
also blocks other HCT binding sites on the neuronal surface cannot be excluded, 
even though this is very unlikely, since the antibody is highly specific for TrkB 
(Figure 4-15 A) and the unbound antibodies were washed away before adding HCT 
to the medium. 
 
 
 
 
Figure 6-1. The proposed HCT binding complex 
Nidogens form a bridge between TeNT and LAR, which in turn can trigger the 
formation of TrkB-p75NTR heterodimers. This can happen either in the presence or 
absence of BDNF. 
 
I tested whether BDNF alone promotes the uptake of nidogen-2 (due to the 
antibody restrictions) and observed a slight increase in the amount of internalised 
nidogen-2 in neurons compared to resting conditions. When HCT is added, there is 
a similar increase in the level of nidogen-2 internalisation. Although the change in 
nidogen-2 uptake is lower than expected, this result shows that nidogen-2 uptake is 
affected by BDNF stimulation (Figure 4-17). 
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Figure 6-2. The suggested TeNT binding complex in signalling endosomes 
Based on the results presented in this thesis, nidogen could serve as a link between 
TeNT and LAR. LAR in turn binds to TrkB in a BDNF dependent manner, recruiting the 
TeNT-nidogen complex to signalling endosomes. 
 
 
When cells were starved in neurobasal medium, there was a robust uptake 
of nidogen-2 both in neurons and glial cells (Figure 4-17). This result might be due 
to stress; the cells take up the ECM components to cover their needs for protein 
synthesis, although this has never been shown before. The relationship between 
the ECM and starvation has been examined in the context of cancer; these cells 
rely on the interaction between integrins and the components of the ECM to aid 
their stress response (Jean et al., 2011). It would be interesting to see whether the 
robust uptake of nidogen-2 upon starvation has a signalling function, or if it is 
purely to cover the metabological needs of neurons and glial cells. If neurotrophins 
and growth factors are bound to ECM proteins, they might serve as a sink, and 
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upon starvation the mobilisation of the matrix might be required to obtain the 
trophic factors stored. Alternatively, this mechanism could serve to loosen up the 
ECM so the cells can detach and migrate. This is a very important triggering 
mechanism in metastasis formation in cancer cells (Lu et al., 2012), but it is unlikely 
to be the reason for the observed robust nidogen uptake in primary motor neuron 
cultures, since mature motor neurons and their glial support layer are not migratory. 
By studying this in more detail we could get a more comprehensive view on the role 
of ECM proteins in the homeostasis of the NMJ. Based on the data presented in 
this thesis, nidogens are taken up following different signals in an efficient manner, 
probably participating in neurotrophin signalling, but this aspect of their function has 
never been studied before. 
 
6.5.1 Recombinant nidogen-1 decreases the colocalisation between HCT and 
SV2A 
SV2 proteins were previously shown to serve as protein receptors for BoNTs 
(Dong et al., 2006, Baldwin and Barbieri, 2009, Rummel et al., 2009, Peng et al., 
2011) and SV2A was implicated in TeNT binding to central neurons (Yeh et al., 
2010). I observed a high colocalisation (45.8±4.7% SEM; Figure 4-19) between 
SV2A and HCT after internalisation, but not with SV2C (12±1.6% SEM; Figure 4-18). 
I hypothesised that the high colocalisation is due to the high concentration of HCT 
used in this assay. When mice were injected with a high dose of TeNT, they 
presented with symptoms of botulism, suggesting that TeNT enters motor neurons 
through a similar pathway used by BoNTs, and it subsequently blocks local 
synaptic transmission when applied at a high dose (Matsuda et al., 1982, 
Habermann et al., 1980). When recombinant nidogen-1 was added together with 
HCT to the motor neuron medium, the colocalisation between HCT and SV2A 
dropped to 22.2±1.4% (Figure 4-19), which suggests that HCT prefers to enter 
neurons via nidogens, if there are enough binding sites available. This is in 
agreement with the clinical representation of tetanus; at low doses (which are 
present after bacterial infection and autolysis) TeNT avoids the SV recycling 
pathway and enters the retrogradely transported signalling endosomes, the latter 
process is most probably mediated by nidogens. 
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6.6 HCT is transcytosed in primary motor neuron cultures 
To explain the clinical symptomology of tetanus intoxication, TeNT must be 
taken up by motor neurons, get retrogradely transported to the motor neuron soma 
in the spinal cord and get synaptically transferred to inhibitory interneurons. In this 
thesis, I showed that HCT is transcytosed in primary motor neuron cultures (Figure 
5-6). Furthermore, nidogen-2 is still present at the time of re-presentation on the 
somatic membrane (Figure 5-8). Before doing this experiment, I observed that 
nidogen-2 is present in the axonal compartment of microfluidic chambers (Figure 
5-7). This result suggests that nidogen-2 is produced and secreted by neurons. 
Alternatively the growing axon terminal could push its matrix along the 
microgrooves.  
The transcytosis assay on motor neurons was technically not possible 
before, due to the lack of reliable compartmentalised motor neuron cultures. I 
overcame this problem by designing microfluidic chambers with shorter, but 
shallower microgrooves (Figure 5-3). This still maintained the microfluidic isolation 
between the somatodendritic and axonal compartments, but the shorter distance 
was permissive for motor neuron axon crossing (Figure 5-1, Figure 5-4).  
Since HCT resides in signalling endosomes, it most probably exploits the 
transcytotic pathway used by neurotrophins and their receptors (Schwab and 
Thoenen, 1977, Ascano et al., 2009). The molecular mechanism, by which certain 
signalling endosomes are sorted to this route, is unknown. To investigate the 
identity of the molecule, which labels these organelles and targets them for 
transcytosis, a highly efficient method needs to be established to isolate them in 
high enough quantities for mass spectrometry analysis. Alternatively, a candidate-
based approach could be attempted. Specific Rab proteins might be involved; 
Rab5 and Rab 7 were shown to be crucial for the initial sorting and the subsequent 
long-range axonal transport of HCT containing signalling endosomes (Deinhardt et 
al., 2006b). Rab 11 might be an excellent candidate, as it was recently shown to 
regulate the transcytosis of beta-site amyloid precursor protein-cleaving enzyme 1 
(BACE1) in hippocampal neurons (Buggia-Prevot et al., 2014). To test whether Rab 
11 localises to the transcytotic pool of signalling endosomes, a labelled version of 
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Rab 11 needs to be expressed in neurons, or a high-affinity antibody needs to be 
purified. Dominant negative and constitutively active versions of the protein need to 
be overexpressed and their effect on the transcytosed pool of neurotrophin 
receptors and HCT should be established.  
 
6.7 The alternative entry hypothesis 
The concentration at which HCT, or TeNT was applied appeared to be 
crucial in all of the assays described in this thesis. When used at a high 
concentration, HCT colocalises with the synaptic vesicle protein, SV2A and enters 
nidogen-1 and -2 KO motor neurons and NMJs. Furthermore, nidogen-2 KO mice 
are only protected if TeNT is injected in doses close to the LD50 (Gill, 1982), but not 
higher. 
These observations combined with the decreased colocalisation between 
HCT and SV2A in the presence of recombinant nidogen-1 lead me to hypothesise 
that TeNT has two alternative entry routes: 
 
1. Nidogen-dependent entry into signalling endosomes.  
 
When TeNT is captured by nidogens localised at the BL of the NMJ, it is 
presented to the PM receptors, LAR and TrkB. Since the formation of the predicted 
binding complex is more efficient in the presence of BDNF, additional BDNF is 
increasing the amount of TeNT entering the neurons. Ligand-bound TrkB then 
facilitates the internalisation of the complex and the newly formed signalling 
endosomes recruit Rab5 and Rab7 sequentially, and are sorted to the retrograde 
axonal transport pathway (Figure 6-2) (Deinhardt et al., 2006b). Once in the motor 
neuron soma, the signalling endosome containing HCT is targeted to the 
transcytosis route and fuses with the PM in close vicinity to inhibitory terminals. The 
regulation of this process is currently unknown. Trk receptors are transported 
between the basolateral and apical membranes of neurons, but no specific 
targeting to inhibitory terminals has been shown to date (Butowt and von Bartheld, 
2001, Butowt and von Bartheld, 2003, Ascano et al., 2009). Alternatively, TeNT 
could be released at random sites on the motor neuron cell body and bind to SV2A 
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selectively on the PM of inhibitory terminals. It gets internalised into recycling SV, 
and once the pH in the lumen of these vesicles drops (while the neurotransmitters 
are reloaded), the L chain is released into the cytosol and cleaves synaptobrevin. 
This inhibits SV release and silences the inhibitory interneuron. The loss of 
inhibitory inputs on the motor neuron leads to its over-activation and this causes 
tetanus. 
 
2. SV2A dependent entry into synaptic vesicle recycling 
 
When nidogens are missing, or TeNT is present at high concentration and all 
nidogen-binding sites are occupied, it binds to SV2A at the motor neuron endplate. 
This targets TeNT to the SV recycling pathway (as explained above) and it cleaves 
synaptobrevin at the presynaptic site of the NMJ. This leads to the silencing of the 
motor neuron and flaccid paralysis, which are characteristic of botulism. 
 
The similarities between different CNT have been known for a long time, but 
due to the dramatically different clinical outcome, they were always thought to 
follow distinct intracellular routes. This study has clearly demonstrated that in the 
absence of sufficient nidogen-binding sites, or when all nidogen-binding sites are 
saturated, TeNT is capable of engaging with SV2A, and cause botulism-like 
symptoms. It was previously shown that TeNT enters synaptic vesicles via binding 
to SV2 in central neurons, but its colocalisation with SV2A was never investigated 
prior to this study (Matteoli et al., 1996, Yeh et al., 2010). On the other hand, 
BoNTA was shown to undergo retrograde axonal transport and retain its activity at 
distal sites (Antonucci et al., 2008, Restani et al., 2011). Furthermore, BoNT/A 
undergoes synaptic transfer in the CNS, just like TeNT (Restani et al., 2012b). It 
would be interesting to test whether BoNTs bind to nidogens and if blocking this 
interaction can prevent their transport and long-range effects (Figure 6-3). 
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Figure 6-3. Crosstalk between the entry pathway of TeNT and BoNTs in the NMJ 
Both TeNT and BoNTs accumulate in the synaptic space of the NMJ. This space is 
filled with the BL (light blue). In this study we showed that TeNT binds to nidogens and 
this pathway targets it to the retrograde axonal route. However, it also became clear 
that TeNT is able to engage with SV2A and can enter SV recycling at the NMJ if there 
is no nidogen available, or if TeNT is applied at a high dose. BoNT/A was previously 
shown to enter retrogradely transported carriers in motor neurons, reach the cell body 
and get transferred to other neurons. I hypothesise that both TeNT and BoNT/A can 
enter each-others’ entry route, and BoNT/A is probably using the same key proteins for 
its entry into signalling endosomes as TeNT. Reprinted with permission from Elsevier 
(Schmieg, 2015). 
 
 
6.8 The emerging importance of BL proteins in synaptic 
development, health and disease 
The ECM fills the extracellular space in our tissues. Despite its abundance 
and localisation, it was always thought to be a passive component in maintenance 
and homeostasis; a rigid structure, which keeps the cells in their place and shapes 
the organs. In the last decade, it became clear, that the ECM, especially its 
specialised form, the BL does much more than simply keeping the epithelial cells in 
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line and separating them from the other germ layers (Hughes et al., 2006). Our 
study is the first of its kind; it shows that a neurotropic virulence factor relies on an 
ECM protein for its high affinity and neuron specific entry. We have also shown that 
not all NMJs contain nidogen-2, even if they are in close vicinity (Figure 4-25). The 
physiological importance of the selective expression of nidogen-2 is unknown; the 
composition of the BL in individual NMJs has never been examined in detail. It has 
been documented however, that structural and physiological differences exist 
among NMJs within the same muscle, which are correlated to the twitch-type of the 
individual fibers. Fast-twitch fibers have higher quantal contents; the post-synaptic 
membrane contains more acetylcholine receptor (AChR) and display more folds 
than the slow-twitch fibers. Different fibers have distinct innervation timeline too; 
some muscles are ‘fast-synapsing’ (i.e. TA), while others are ‘delayed-synapsing’ 
(i.e. the lateral gastrocnemius). However, this has no correlation with the relative 
abundance of fast- and slow-twitch fibers within the muscle (Pun et al., 2002). 
 
6.8.1 BL in development 
6.8.1.1  Agrin 
During development, AChR are evenly distributed until the innervating axons 
reach the muscle. Once the overlying motor endplate is present, its BL gets in 
direct contact with the myofibril. The neuron secretes agrin (z8 splice isoform), 
which binds to laminin and accumulates in the synaptic BL (Table 16) (Denzer et al., 
1997). Agrin then acts on muscle cells to cluster AChR in the postsynaptic 
membrane (>10,000 AChR/µm2 compared to ∼10 AChR/µm2 outside of the 
postsynaptic site, (Cohen et al., 1997). If the z8 splice isoform of agrin is present, 
AChR is phosphorylated by transmembrane muscle-specific kinase (MuSK), a 
protein required for agrin action. However, agrin and MuSK do not bind directly 
(Glass et al., 1996). Low-density lipoprotein receptor-related protein (LRP4) 
emerged as a link between agrin and MuSK, which is essential for agrin signalling 
during post-synaptic differentiation (Kim et al., 2008, Zhang et al., 2008).  
 
Mice lacking agrin die at birth, the AChR clusters are greatly reduced, but 
not absent; a minority of nerve terminals are opposed to a specialised post-
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synaptic membrane, which is enriched in AChR and is still associated with 
cytoskeletal and BL components (Gautam et al., 1996). When MuSK or LRP-4 is 
absent, mice show no signs of post-synaptic differentiation (Gautam et al., 1999, 
Weatherbee et al., 2006).  
Furthermore, there is a cross-talk between the Wnt (Wingless-related 
intergration site) pathway and agrin. Dishevelled (Dvl), a cytosolic effector protein 
of the Wnt cascade was shown to directly bind to MuSK and regulate its activity 
(DeChiara et al., 1996, Glass et al., 1997, Luo et al., 2002). Furthermore, Wnt3 
collaborates with agrin to induce AChR cluster formation; it is required for the initial 
cluster formation, which are then enlarged by agrin (Henriquez et al., 2008). The 
most possible cross-talk between the two pathways is through Rac1, a small 
GTPase, which is required for the formation of AChR microclusters (Weston et al., 
2003, Weston et al., 2000). 
 
6.8.1.2  Rapsyn and Neuregulin 
Two further other proteins were implicated in AChR clustering. In rapsyn KO 
mice, MuSK accumulate at synaptic sites, but this is not followed by AChR 
clustering (Gautam et al., 1995). Rapsyn is a postsynaptic protein, which binds to 
AChR (Lin et al., 2001). 
Neuronally derived synaptic regulatory factor (neuregulin, NRG-1) is a 
presynaptic transmembrane protein. Its extracellular domain is released into the BL 
and is presented to the post-synaptic membrane, where it binds to ErbB tyrosine 
kinases. NRG-1 increases the amount of AChR at the synaptic site by promoting 
the expression of AChR genes in the synaptic myofibril nuclei (Won et al., 1999), 
however, its molecular regulation is still not fully understood (Falls, 2003). 
6.8.2 The importance of BL in disease 
It is the fine balance between the different components within the BL of the 
NMJ that are compromised in several diseases, which primarily present with 
decreased motor function. 
Human mutations in COLQ, LAMB2 and AGRN genes (coding for ColQ, 
laminin β2 and agrin, respectively) cause congenital myasthenic syndromes 
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(CMSs), which are characterised by muscle weakness and fatigue. Myasthenia 
gravis (MG) presents with similar symptoms to CMSs, but it is caused by 
autoantibodies targeting the AChR, MuSK or rapsyn cause the symptoms 
(Nicholson et al., 1983, Agius et al., 1998, Guptill et al., 2011). There are several 
different ultrastructure defects in the NMJ in CMSs and MG, such as the reduced 
size of motor neuron endplate, lower quantal content, encasement of the nerve 
endings by Schwann cells and shallow synaptic folds on the postsynaptic 
membrane (Maselli et al., 2012). The latter is more severe in cases, when rapsyn is 
deficient; this is not surprising, considering that rapsyn is an important regulator of 
AChR clustering (Burke et al., 2003, Losen et al., 2005, Martinez-Martinez et al., 
2007). The strong disruptive effect of the altered composition of synaptic BL on the 
ultrastructure of the NMJ and the subsequent symptoms of CMSs and MG clearly 
indicate the importance of this specialised structure in the development and 
maintenance of the NMJ. 
 
Figure 6-4. NMJ defects in MSCs 
Due to the deficiency (lower expression, mislocalisation) of specific synaptic BL 
components, the nerve terminals become small and fragmented; Schwann cell 
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processes invade the synaptic cleft, which is increased in diameter. Due to the lack of 
rapsyn, postsynaptic folds are simple and contain reduced levels of AChR. 
 
It was hypothesised that the NMJs remain immature in spastic quadriplegic 
cerebral palsy (CP), but it turned out that the only major defect was within the BL; 
laminin β2 was misplaced between the synaptic and extrasynaptic BL in patients, 
indicating the importance of this specialised ECM protein in NMJ function. Spastic 
CP is characterised by stiff muscles, weakness, and poor motor control and the 
patients have an altered sensitivity to drugs that target the NMJ, further enforcing 
how crucial the synaptic BL is for drug targeting (Robinson et al., 2013). 
The severe progressive paralytic phenotype of the nidogen-1 KO mice was 
not characterised in detail before, but the epileptic seizures and abnormal posture 
was reported (Dong et al., 2002). The mechanism by which loss of nidogen-1 
causes neuromuscular disruption in Mammals remains unknown, but based on the 
studies conducted in C. elegans and D. melanogaster it is most likely due to the 
disruption of the size of the active zones in the NMJs (Kaufmann et al., 2002, 
Ackley et al., 2005). 
6.8.3 The importance of BL in regeneration 
6.8.3.1  Central nervous system (CNS) 
The poor regenerating capacity of the CNS is well documented, however, if 
peripheral axons are injured, their potential to regenerate is relatively high. The 
ECM in the CNS changes upon direct injury, and these changes are detrimental for 
regeneration (Burnside and Bradbury, 2014). Several ECM components were 
targeted in an attempt to overcome the negative effect of the ECM after injury, such 
as Nogo-A (by using inhibiting antibodies, (Bandtlow and Schwab, 2000, Simonen 
et al., 2003, Zorner and Schwab, 2010, Schwab, 2010) and chondroitin sulphate 
proteoglycans (chondroitinase-ABC for digesting this ECM component; (Tom et al., 
2009). But while the former strategy proved to be highly successful, as it promoted 
plasticity and improved the motility of spinal cord-injured rats, the latter had no 
functional benefit despite the increased sprouting (Tom et al., 2009). It became 
clear, that combination therapy is the way forward, especially since the anti-Nogo-A 
treatment is time sensitive and is much less effective when started with a delay 
following injury (Gonzenbach et al., 2012). However, when combined with exercise, 
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which enhances neurotrophin signalling, especially through BDNF and TrkB 
(Weishaupt et al., 2012, Houle and Cote, 2013), anti-NogoA treatment can produce 
excellent results (Gonzenbach et al., 2010, Starkey and Schwab, 2012). Similarly, 
when combined with treadmill training and additional growth factors, chondroitinase 
ABC treatment caused functional locomotor improvement in rats (Alluin et al., 
2014). Increasing neurotrophin levels through exercise is preferred over 
administration of exogenous neurotrophins, since they cause many undesired side 
effects and are very expensive (Perez et al., 2013). By combining these and other 
strategies, we will be able to turn the ECM from non-permissive to facilitating in 
regards to axonal regeneration and to promote axonal growth and targeting; these 
should result in a better outlook for patients with spinal cord injury or stroke. 
6.8.3.2  Peripheral Nervous system (PNS) 
The ECM in the CNS is non-permissive for regeneration, however, if the 
synaptic BL of the NMJ remains intact after denervation or destruction of the 
muscle, it helps to dictate the topology of the NMJs on regenerating cell 
membranes (Letinsky et al., 1976, McMahan et al., 1978, Sanes et al., 1978). To 
be able to promote the complete restoration of the NMJ, the BL must not only mark 
the location, but also provide sufficient trophic support for the survival of the 
pre/postsynaptic site in absence of the synaptic partner. The best candidates to 
promote neurite outgrowth and synapse formation are fibroblast growth factor-2 
(FGF-2) and BDNF. 
BDNF is known to be essential for motor neuron survival, axonal 
regeneration and to regulate the distribution of postsynaptic AChR (Oppenheim et 
al., 1992, Yan et al., 1992, Henderson et al., 1993, Wells et al., 1999, Gordon, 
2009). When the vibrissal muscles are denervated, BDNF is essential to recover 
the presynaptic site of the NMJ. BDNF or TrkB heterozygous mice showed a 
decreased ability to reinnervate the vibrissal muscles, despite manual stimulation, 
showing that neurotrophin signalling is vital for the beneficial effect of training. The 
most likely explanation is that BDNF released by the muscle is captured within the 
ECM and any pro-BDNF present at the time of injury gets cleaved into its mature 
form upon exercise. Neurons sense the high concentration of BDNF within the 
empty NMJ and reinnervate it (Sohnchen et al., 2010). 
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Specialised ECM components at the NMJ might hold the key to explain why 
the PNS has a greater regenerating capacity, and any candidate ECM proteins, 
which accumulate neurotrophins, will serve as templates for novel strategies to 
improve the outlook of patients with CNS injury. Vice versa, engineering growth 
factors and neurotrophins to bind to ECM proteins with a high affinity, might 
increase their downstream signalling and lead to a better response to treatment, as 
it was recently shown in healing of chronic wounds and bone defects (Macri et al., 
2007, Martino et al., 2014). 
 
 
Chapter 7. Concluding remarks and future 
perspectives 
The discovery presented in this thesis, that the protein receptor of TeNT 
resides within the ECM, is the first of its kind (Bercsenyi et al., 2014). Before 
reaching the PM, extracellular ligands and neurotropic pathogens must make their 
way through the ECM, and during this journey, there is a high probability of 
interaction. By binding to ECM components, these factors could get stuck in the 
matrix. However, based on recent studies, it appears that the ECM acts as a 
facilitator of growth factor and neurotrophin signalling, by binding these factors and 
presenting them to the neural membrane. Although this process is not well studied 
at the molecular level, it must be tightly regulated and very robust. 
I showed in this thesis, that the ECM promotes TeNT binding and uptake 
into motor neurons (Bercsenyi et al., 2014). Since certain nidogen isoforms are 
exclusive to the synaptic BL, they do not only serve as an accumulating agent, but 
also mediate the motor neuron specificity of TeNT.  
By interfering with the first step in the capture mechanism of TeNT with a 
nidogen-specific peptide, N1, I demonstrated that the binding and uptake of TeNT 
can be blocked and tetanus intoxication can be prevented. This strategy might hold 
the promise for a long-awaited cure for tetanus in countries where vaccination is 
not available. To this end, the model of the HCT-nidogen-1 G2 complex needs to be 
experimentally verified using a co-crystallisation approach, which in turn might 
open the way to optimise novel blocking agents for the prevention of tetanus.  
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A pool of BoNT/A gets retrogradely transported and transcytosed. It is 
currently not known whether BoNT/A can bind to nidogens or other components of 
the ECM, and whether this interaction is responsible for its sorting to the 
transcytosis route. It would also be interesting to test if the N1 peptide can prevent 
the central effects of BoNT/A, or its interaction with FGFR3.  
On the other hand, nerve stimulation should increase the number of SV2A 
binding sites on the PM for TeNT and if this is the case, it should compensate the 
blocking effect of the N1 peptide, or the lack of nidogens and restore HCT binding in 
primary motor neurons and NMJs. 
Furthermore, the composition of the TeNT binding complex needs to be 
elucidated. LAR and TrkB are both great candidates, but it might be a bigger 
complex, and an immunoprecipitation followed by mass spectrometry analysis is 
required to shed light on its components. By obtaining LAR and TrkB deficient 
motor neurons, the importance of these proteins in the binding and uptake of TeNT 
could be studied and this might reveal further candidate sites for therapeutic 
intervention.
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